// Drug Database for MLA Quiz PWA
// Extracted from app.js for better organization

const drugDatabase = {
            'aciclovir': {
                name: 'Aciclovir',
                class: 'Antiviral drugs',
                mechanism: 'Nucleoside analogue - inhibits viral DNA polymerase after phosphorylation by viral thymidine kinase',
                dosing: 'Herpes simplex: 200mg 5x daily for 5 days. Shingles: 800mg 5x daily for 7 days. IV: 5-10mg/kg TDS',
                contraindications: 'Hypersensitivity. Caution in renal impairment, dehydration',
                interactions: 'Nephrotoxic drugs (↑ nephrotoxicity), probenecid (↑ levels), mycophenolate',
                monitoring: 'Renal function, hydration status, neurological symptoms (high doses)',
                pregnancy: 'Safe - no evidence of teratogenicity',
                sideEffects: 'GI upset, headache, dizziness, acute kidney injury (IV), neurological effects (high doses)',
                pharmacokinetics: 'Variable oral absorption (15-30%), half-life: 2-3h, mainly renal excretion',
                clinicalPearls: 'Most effective when started within 72h of rash onset. Maintain good hydration',
                indication: 'Herpes simplex, varicella zoster, prophylaxis in immunocompromised'
            },
            'adenosine': {
                name: 'Adenosine',
                class: 'Antiarrhythmic (Purine nucleoside)',
                mechanism: 'Blocks AV node conduction by activating adenosine A1 receptors',
                dosing: 'Adult: rapid IV bolus 6mg via a large vein (immediate saline flush), if ineffective give 12mg then 18mg as per Resuscitation Council (tachycardia) guidance. Pediatric: 0.1mg/kg (see paediatric guidance)',
                contraindications: 'Severe asthma (relative contraindication because of bronchospasm risk), COPD, 2nd/3rd degree heart block, sick sinus syndrome, WPW with AF',
                interactions: 'Dipyridamole (↑ effect), theophylline (↓ effect), carbamazepine (↑ heart block)',
                monitoring: 'Continuous ECG, blood pressure, respiratory status',
                pregnancy: 'Use only if maternal benefit outweighs fetal risk; severe maternal asthma increases risk of bronchospasm. Refer to UK resuscitation guidance and seek specialist advice in pregnancy',
                sideEffects: 'Chest pain, dyspnea, flushing, transient AV block, bronchospasm',
                pharmacokinetics: 'Very short half-life <10 seconds. Rapid cellular uptake and metabolism',
                clinicalPearls: 'Give fast IV push followed by saline flush. Warn patient of chest discomfort',
                indication: 'SVT termination, diagnostic test for broad complex tachycardia'
            },
            'adrenaline': {
                name: 'Adrenaline (Epinephrine)',
                class: 'Emergency drugs',
                mechanism: 'Non-selective α and β adrenergic agonist causing vasoconstriction and inotropy',
                dosing: 'Anaphylaxis: 500mcg IM (0.5ml of 1:1000). Cardiac arrest: 1mg IV (10ml of 1:10,000)',
                contraindications: 'None in life-threatening situations. Caution with severe hypertension',
                interactions: 'β-blockers (unopposed α effects), tricyclics (arrhythmias), MAOIs',
                monitoring: 'Heart rate, blood pressure, ECG, blood glucose',
                pregnancy: 'Safe in life-threatening situations',
                sideEffects: 'Tachycardia, hypertension, arrhythmias, tremor, anxiety, hyperglycaemia',
                pharmacokinetics: 'Rapid onset, short duration: 5-10min, metabolised by COMT/MAO',
                clinicalPearls: 'First-line for anaphylaxis. IM route for anaphylaxis, IV for cardiac arrest. Check expiry dates',
                indication: 'Anaphylaxis, cardiac arrest, severe asthma (nebulised), local anaesthetic adjunct'
            },
            'alendronic acid': {
                name: 'Alendronic Acid',
                class: 'Bisphosphonates',
                mechanism: 'Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite',
                dosing: 'Osteoporosis: 70mg weekly on empty stomach. Paget\'s disease: 40mg daily for 6 months',
                contraindications: 'Oesophageal abnormalities, hypocalcaemia, severe renal impairment',
                interactions: 'Calcium/iron/antacids (↓ absorption - separate by 2h), NSAIDs (↑ GI irritation)',
                monitoring: 'Calcium, phosphate, vitamin D levels. Dental health. Atypical fractures',
                pregnancy: 'Avoid - crosses placenta and may affect fetal bone development',
                sideEffects: 'Oesophageal irritation, osteonecrosis of jaw (rare), atypical fractures (rare)',
                pharmacokinetics: 'Poor oral absorption (<1%), long bone half-life (10+ years)',
                clinicalPearls: 'Take on empty stomach with full glass water. Stay upright 30min. Weekly dosing improves compliance',
                indication: 'Osteoporosis treatment/prevention, Paget\'s disease, steroid-induced osteoporosis'
            },
            'allopurinol': {
                name: 'Allopurinol',
                class: 'Xanthine oxidase inhibitor',
                mechanism: 'Inhibits xanthine oxidase, reducing uric acid production',
                dosing: 'Start 100mg daily, increase by 100mg every 2-4 weeks. Target <300 micromol/L. Max 900mg daily',
                contraindications: 'Acute gout attack, hypersensitivity, HLA-B*5801 positive (if known)',
                interactions: 'Azathioprine (↑ toxicity), warfarin (may ↑ INR), ACE inhibitors (hypersensitivity)',
                monitoring: 'Uric acid levels, LFTs, FBC, signs of hypersensitivity reaction',
                pregnancy: 'Avoid - limited safety data',
                sideEffects: 'Skin rashes, Stevens-Johnson syndrome, hepatotoxicity, blood dyscrasias',
                pharmacokinetics: 'Well absorbed, active metabolite oxypurinol, half-life: 18-30h',
                clinicalPearls: 'Never start during acute gout attack. Cover with colchicine/NSAID initially',
                indication: 'Gout prophylaxis, hyperuricaemia, tumour lysis syndrome prevention'
            },
            'amiodarone': {
                name: 'Amiodarone',
                class: 'Amiodarone',
                mechanism: 'Blocks potassium channels, prolongs action potential and refractory period',
                dosing: 'Loading: 200mg TDS for 1 week, then 200mg BD for 1 week. Maintenance: 200mg daily',
                contraindications: 'Sinus bradycardia, heart block, thyroid disease, iodine allergy',
                interactions: 'Warfarin (↑ INR), digoxin (↑ levels), β-blockers (bradycardia), many others',
                monitoring: 'TFTs, LFTs, CXR, ECG, visual symptoms. Pre-treatment: TFTs, LFTs, CXR',
                pregnancy: 'Avoid - neonatal hypo/hyperthyroidism, bradycardia',
                sideEffects: 'Pulmonary fibrosis, thyroid dysfunction, hepatotoxicity, corneal deposits, skin discolouration',
                pharmacokinetics: 'Very long half-life: 20-100 days, extensive tissue distribution',
                clinicalPearls: 'Many serious side effects. Regular monitoring essential. Sun protection (photosensitivity)',
                indication: 'Life-threatening arrhythmias, AF (when other drugs fail), VT/VF'
            },
            'amlodipine': {
                name: 'Amlodipine',
                class: 'Calcium channel blockers',
                mechanism: 'Blocks L-type calcium channels in vascular smooth muscle and myocardium, causing vasodilation',
                dosing: 'Hypertension: Start 5mg daily, max 10mg daily. Elderly/hepatic impairment: start 2.5mg daily',
                contraindications: 'Hypersensitivity, unstable angina, significant aortic stenosis',
                interactions: 'Simvastatin (limit simvastatin to 20mg), CYP3A4 inhibitors (monitor for hypotension)',
                monitoring: 'Blood pressure, heart rate, signs of fluid retention, ankle oedema',
                pregnancy: 'Avoid unless essential - limited safety data',
                sideEffects: 'Ankle oedema (dose-related), flushing, dizziness, fatigue, gingival hyperplasia (rare)',
                pharmacokinetics: 'Peak: 6-12h, Half-life: 35-50h, Hepatic metabolism via CYP3A4',
                clinicalPearls: 'Long half-life allows once daily dosing. Ankle oedema not due to fluid retention. Preferred CCB in UK',
                indication: 'Hypertension, stable angina. Often used as add-on therapy'
            },
            'amitriptyline': {
                name: 'Amitriptyline',
                class: 'Antidepressants, tricyclics and related drugs',
                mechanism: 'Inhibits reuptake of noradrenaline and serotonin, blocks multiple receptors',
                dosing: 'Depression: 50-75mg daily at night, max 150mg. Neuropathic pain: 10-25mg at night, max 75mg',
                contraindications: 'Recent MI, arrhythmias, severe liver disease, mania, MAOI use',
                interactions: 'MAOIs (dangerous), alcohol (↑ sedation), anticholinergics (↑ effects), tramadol',
                monitoring: 'ECG (elderly/cardiac disease), mood, suicide risk, anticholinergic effects',
                pregnancy: 'Use with caution - neonatal withdrawal possible',
                sideEffects: 'Sedation, dry mouth, constipation, weight gain, arrhythmias, anticholinergic effects',
                pharmacokinetics: 'Half-life: 10-28h, extensive hepatic metabolism, active metabolites',
                clinicalPearls: 'Take at night due to sedation. Start low for neuropathic pain. Cardiotoxic in overdose',
                indication: 'Depression, neuropathic pain, migraine prophylaxis, nocturnal enuresis'
            },
            'amoxicillin': {
                name: 'Amoxicillin',
                class: 'Penicillins, broad-spectrum',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'Adults: 500mg TDS or 1g BD. Severe infections: 1g TDS. Children: 40-90mg/kg daily in 2-3 divided doses',
                contraindications: 'Penicillin allergy, infectious mononucleosis (high rash risk)',
                interactions: 'Methotrexate (↑ toxicity), combined oral contraceptive (↓ efficacy), probenecid (↑ levels)',
                monitoring: 'Signs of allergic reaction, C. difficile-associated diarrhoea, renal function in severe illness',
                pregnancy: 'Safe - suitable for use in pregnancy',
                sideEffects: 'GI upset, diarrhoea, rash (especially with EBV), CDAD, hypersensitivity reactions',
                pharmacokinetics: 'Onset: 1h, Peak: 1-2h, Half-life: 1h, Excretion: mainly renal',
                clinicalPearls: 'Broad spectrum penicillin. Good oral bioavailability. Reduce dose in severe renal impairment (CrCl <30)',
                coverage: 'Gram-positive: Streptococci, some Staphylococci. Gram-negative: E. coli, H. influenzae. No MRSA/Pseudomonas cover'
            },
            'apixaban': {
                name: 'Apixaban',
                class: 'Direct oral anticoagulant (DOAC) - Factor Xa inhibitor',
                mechanism: 'Direct, selective inhibition of factor Xa in coagulation cascade',
                dosing: 'AF: 5mg BD. Reduce to 2.5mg BD if the patient meets ≥2 of the following: age ≥80 years, body weight ≤60 kg, serum creatinine ≥133 µmol/L (see SmPC). Note: patients with severe renal impairment (CrCl 15–29 mL/min) also commonly require 2.5mg BD — check the local formulary/SmPC for details. VTE: 10mg BD for 7 days, then 5mg BD',
                contraindications: 'Active bleeding, severe hepatic impairment, pregnancy, prosthetic valves',
                interactions: 'Strong CYP3A4 inhibitors (↓ dose), P-gp inducers (avoid), warfarin (↑ bleeding)',
                monitoring: 'Renal function, hepatic function, signs of bleeding. No routine coagulation monitoring',
                pregnancy: 'Contraindicated in pregnancy — refer to the SmPC/Medicines.org.uk for pregnancy guidance',
                sideEffects: 'Bleeding, anaemia, nausea, hypotension',
                pharmacokinetics: 'Peak: 3-4h, Half-life: 12h, multiple elimination pathways',
                clinicalPearls: 'Can be taken with or without food. Less renal clearance than rivaroxaban',
                indication: 'Atrial fibrillation stroke prevention, VTE treatment and prophylaxis'
            },
            'aspirin': {
                name: 'Aspirin',
                class: 'Antiplatelet drugs, aspirin',
                mechanism: 'Irreversibly inhibits COX-1, reducing TXA2 production and platelet aggregation',
                dosing: 'Cardioprotection: 75mg daily. Acute MI: 300mg STAT, then 75mg daily. Pain: 300-900mg QDS',
                contraindications: 'Active bleeding, severe heart failure, children <16 years (Reye\'s syndrome)',
                interactions: 'Warfarin (↑ bleeding), methotrexate (↑ toxicity), ACE inhibitors (↓ efficacy)',
                monitoring: 'Signs of bleeding, renal function, hearing (high doses)',
                pregnancy: 'Low-dose safe. Avoid high-dose in 3rd trimester (closure of ductus arteriosus)',
                sideEffects: 'GI bleeding, bronchospasm (asthma), tinnitus (high doses), Reye\'s syndrome (children)',
                pharmacokinetics: 'Rapidly absorbed, irreversible COX inhibition, platelet effect lasts 7-10 days',
                clinicalPearls: 'Dual antiplatelet therapy with clopidogrel post-ACS. Gastro-protection if high risk',
                indication: 'Secondary prevention of CVD, acute coronary syndromes, ischaemic stroke'
            },
            'atorvastatin': {
                name: 'Atorvastatin',
                class: 'Statins',
                mechanism: 'Competitively inhibits HMG-CoA reductase, rate-limiting enzyme in cholesterol synthesis',
                dosing: 'Adults: Start 20mg daily, usual dose 20-80mg daily. High-intensity: 40-80mg daily. Take any time of day',
                contraindications: 'Active liver disease, pregnancy, breastfeeding, unexplained persistent ↑ ALT/AST',
                interactions: 'Ciclosporin (↑ statin levels), warfarin (↑ INR), digoxin (↑ levels), grapefruit juice',
                monitoring: 'LFTs before treatment and at 3 months, lipids at 3 months, CK if muscle symptoms',
                pregnancy: 'Contraindicated - stop 3 months before conception',
                sideEffects: 'Myalgia (common), hepatotoxicity (rare), rhabdomyolysis (very rare), new-onset diabetes (slight ↑)',
                pharmacokinetics: 'Peak: 1-2h, Half-life: 14h, Metabolism: CYP3A4, active metabolites',
                clinicalPearls: 'High-intensity statin. NICE preferred high-intensity option. Can take any time due to long half-life',
                targets: 'Primary prevention: 20mg daily. Secondary prevention: 80mg daily. Target >40% LDL-C reduction'
            },
            'atropine': {
                name: 'Atropine',
                class: 'Antimuscarinic',
                mechanism: 'Competitive antagonist at muscarinic acetylcholine receptors',
                dosing: 'Bradycardia: 500mcg IV, repeat if necessary (max 3mg). Pre-med: 300-600mcg IM',
                contraindications: 'Narrow-angle glaucoma, prostatic enlargement, paralytic ileus',
                interactions: 'Tricyclics (↑ antimuscarinic effects), antihistamines (↑ sedation)',
                monitoring: 'Heart rate, blood pressure, pupil size, mental state',
                pregnancy: 'Safe - crosses placenta but no evidence of harm',
                sideEffects: 'Dry mouth, blurred vision, urinary retention, confusion, tachycardia',
                pharmacokinetics: 'Rapid onset: 1-2min IV, Duration: 30min-4h depending on dose',
                clinicalPearls: 'Antidote for organophosphate poisoning. May cause paradoxical bradycardia at low doses',
                indication: 'Symptomatic bradycardia, organophosphate poisoning, pre-medication'
            },
            'azithromycin': {
                name: 'Azithromycin',
                class: 'Antibiotic (Macrolide)',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 50S ribosomal subunit',
                dosing: 'Adult: 500mg daily for 3 days PO or 500mg daily IV. Pneumonia: 500mg x 5 days',
                contraindications: 'Macrolide allergy, severe liver disease, QT prolongation',
                interactions: 'Warfarin (↑ INR), digoxin (↑ levels), simvastatin (↑ myopathy), QT drugs',
                monitoring: 'QT interval, liver function, infection resolution, hearing (high dose)',
                pregnancy: 'Generally considered compatible in pregnancy; UKTIS advises azithromycin may be used if indicated (e.g., chlamydia), but avoid unnecessary use',
                sideEffects: 'GI upset, QT prolongation, hepatotoxicity, hearing loss (rare)',
                pharmacokinetics: 'Long tissue half-life 68h. Good intracellular penetration. Hepatic metabolism',
                clinicalPearls: 'Once daily dosing. Good atypical coverage. Short course therapy',
                indication: 'Atypical pneumonia, COPD exacerbations, chlamydia, URTI, skin infections'
            },
            'beclomethasone': {
                name: 'Beclomethasone',
                class: 'Inhaled corticosteroid',
                mechanism: 'Synthetic glucocorticoid with anti-inflammatory effects in airways',
                dosing: 'Adults: 200-800mcg daily in divided doses. Children: 100-400mcg daily. Use spacer device',
                contraindications: 'Hypersensitivity. Caution in active pulmonary TB',
                interactions: 'Few significant interactions due to low systemic absorption',
                monitoring: 'Growth in children, oral candidiasis, signs of systemic effects (high doses)',
                pregnancy: 'Safe - inhaled route minimises systemic exposure',
                sideEffects: 'Oral candidiasis, hoarse voice, growth retardation (children with high doses)',
                pharmacokinetics: 'Low systemic bioavailability (~20%), extensive first-pass metabolism',
                clinicalPearls: 'Brown/red preventer inhaler. Rinse mouth after use. Use spacer device. Regular use essential',
                indication: 'Asthma prophylaxis, COPD (in combination inhalers)'
            },
            'bendroflumethiazide': {
                name: 'Bendroflumethiazide',
                class: 'Diuretics, thiazide and thiazide-like',
                mechanism: 'Inhibits sodium-chloride cotransporter in distal convoluted tubule',
                dosing: 'Hypertension: 2.5mg daily (morning). Oedema: 5-10mg daily initially',
                contraindications: 'Anuria, severe renal/hepatic impairment, hypersensitivity to sulfonamides',
                interactions: 'Lithium (↑ toxicity), digoxin (hypokalaemia ↑ toxicity), NSAIDs (↓ effect)',
                monitoring: 'U&Es, glucose, uric acid, blood pressure',
                pregnancy: 'Avoid - may cause neonatal thrombocytopenia',
                sideEffects: 'Hyponatraemia, hypokalaemia, hyperuricaemia, glucose intolerance, impotence',
                pharmacokinetics: 'Onset: 2h, Peak: 4-6h, Duration: 12-18h',
                clinicalPearls: 'Historically commonly used, but NICE NG136 prefers thiazide-like diuretics (e.g., indapamide or chlortalidone) as first-line for hypertension; bendroflumethiazide is not considered first-line for HTN under current NICE guidance. Take in morning. 2.5mg often sufficient',
                indication: 'Hypertension, mild heart failure, oedema'
            },
            'benzylpenicillin': {
                name: 'Benzylpenicillin',
                class: 'Penicillins, narrow-spectrum',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'Adult: 0.6-2.4g QDS IV/IM. Meningitis: 2.4g 4-hourly. Severe infections: up to 14.4g/day',
                contraindications: 'Penicillin allergy, previous severe allergic reaction',
                interactions: 'Probenecid (↑ levels), methotrexate (↑ toxicity), oral contraceptives (↓ efficacy)',
                monitoring: 'Signs of infection resolution, allergic reactions, renal function if high dose',
                pregnancy: 'Generally considered compatible in pregnancy for indicated infections; consult local guidance or UKTIS for detailed advice',
                sideEffects: 'Allergic reactions (rash to anaphylaxis), diarrhea, injection site reactions',
                pharmacokinetics: 'Good tissue penetration. t½ 30min. Mainly renal excretion',
                clinicalPearls: 'First-line for streptococcal infections. Give IV for serious infections',
                indication: 'Meningitis, cellulitis, pneumonia, endocarditis, necrotizing fasciitis'
            },
            'bisoprolol': {
                name: 'Bisoprolol',
                class: 'Beta-blockers',
                mechanism: 'Selective antagonist of cardiac beta-1 adrenoreceptors',
                dosing: 'Heart failure: Start 1.25mg daily, titrate to 10mg daily. Hypertension: 5-10mg daily',
                contraindications: 'Asthma, severe COPD, cardiogenic shock, severe bradycardia, severe heart failure',
                interactions: 'Calcium channel blockers (↑ bradycardia), insulin (masks hypoglycemia), NSAIDs',
                monitoring: 'Heart rate, blood pressure, signs of heart failure, renal function, glucose',
                pregnancy: 'Use only if the potential maternal benefit outweighs fetal risk; consult UKTIS and specialist guidance',
                sideEffects: 'Bradycardia, hypotension, fatigue, cold extremities, bronchospasm',
                pharmacokinetics: 'Good oral bioavailability. t½ 10-12h. 50% hepatic, 50% renal elimination',
                clinicalPearls: 'Most cardioselective beta-blocker. Evidence-based for heart failure',
                indication: 'Heart failure, post-MI, hypertension, angina, atrial fibrillation'
            },
            'bumetanide': {
                name: 'Bumetanide',
                class: 'Loop diuretics',
                mechanism: 'Inhibits Na+-K+-2Cl- transporter in the thick ascending limb of the loop of Henle',
                dosing: 'IV/PO: 0.5-2mg once daily (usual IV bolus 1-2mg). Higher doses (up to 10mg) may be used in resistant oedema; titrate to effect',
                contraindications: 'Anuria, severe electrolyte depletion, hypersensitivity to sulfonamides',
                interactions: 'Aminoglycosides (↑ ototoxicity), ACE inhibitors/ARBs (↑ renal dysfunction), NSAIDs (↓ diuretic effect), digoxin (↑ arrhythmia risk with hypokalaemia)',
                monitoring: 'U&Es (especially K+, Na+, creatinine) 1–2 weeks after initiation/titration, blood pressure, weight, fluid balance. Monitor for hearing changes if high IV doses or rapid administration',
                pregnancy: 'Use with caution; consider specialist advice',
                sideEffects: 'Hypokalaemia, hyponatraemia, dehydration, hypotension, dizziness. Ototoxicity can occur with high or rapid IV doses and with concomitant aminoglycosides',
                pharmacokinetics: 'Rapid onset (IV), short half-life ~1-1.5h; hepatic metabolism and renal excretion',
                clinicalPearls: 'More potent than furosemide mg-for-mg. Useful when oral absorption of furosemide unreliable or in diuretic resistance. Monitor electrolytes closely. Beware ototoxicity with rapid/high-dose IV administration and when combined with aminoglycosides',
                indication: 'Acute pulmonary oedema, chronic heart failure with fluid overload, peripheral oedema'
            },
            'oxycodone': {
                name: 'Oxycodone',
                class: 'Opioid analgesic',
                mechanism: 'μ-opioid receptor agonist',
                dosing: 'Oral immediate-release: 5-10mg every 4-6 hours PRN. Modified-release: 10-20mg BD for chronic pain. Reduce dose in elderly/renal impairment',
                contraindications: 'Severe respiratory depression, acute or severe bronchial asthma, paralytic ileus, known hypersensitivity',
                interactions: 'CNS depressants (↑ sedation and respiratory depression), MAOIs (avoid), CYP3A4 inhibitors (↑ oxycodone levels)',
                monitoring: 'Respiratory rate, sedation, bowel function, pain control',
                pregnancy: 'Avoid near term; prolonged use may cause neonatal withdrawal',
                sideEffects: 'Nausea, constipation, sedation, pruritus, respiratory depression, dependence with long-term use',
                pharmacokinetics: 'Well absorbed orally, hepatic metabolism (CYP3A4/CYP2D6), half-life ~3-4h',
                clinicalPearls: 'Good oral alternative to morphine for moderate-severe pain. Always prescribe laxative when used regularly. Adjust for opioid-tolerant patients',
                indication: 'Moderate to severe acute or chronic pain, breakthrough pain in opioid-treated patients'
            },
            'lisinopril': {
                name: 'Lisinopril',
                class: 'ACE inhibitor',
                mechanism: 'Inhibits angiotensin-converting enzyme (ACE), reducing angiotensin II and aldosterone',
                dosing: 'Start 5-10mg once daily (usual maintenance 20-40mg daily). Lower starting doses in elderly or renal impairment',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, history of ACE inhibitor–induced angioedema',
                interactions: 'Potassium-sparing diuretics/ACEi/ARBs (↑ hyperkalaemia), NSAIDs (↓ antihypertensive effect), lithium (↑ toxicity)',
                monitoring: 'BP, serum creatinine and potassium 1-2 weeks after initiation or dose changes',
                pregnancy: 'Contraindicated — fetal toxicity',
                sideEffects: 'Dry cough, hyperkalaemia, hypotension, renal impairment, angioedema (rare)',
                pharmacokinetics: 'Not metabolised, excreted unchanged by kidneys; half-life ~12h',
                clinicalPearls: 'Start low and titrate; check renal function and K+ after initiation. Substitute with ARB if cough troublesome',
                indication: 'Hypertension, heart failure, post-MI, diabetic nephropathy'
            },
            'co-trimoxazole': {
                name: 'Co-trimoxazole (Trimethoprim + Sulfamethoxazole)',
                class: 'Antibacterial combination (folate synthesis inhibitors)',
                mechanism: 'Sequential blockade of folate synthesis pathway (trimethoprim inhibits dihydrofolate reductase; sulfamethoxazole inhibits dihydropteroate synthase)',
                dosing: 'Uncomplicated UTI (where susceptible): 160/800mg (one DS tablet) BD for 3 days. PCP prophylaxis: 160/800mg three times weekly or daily dosing as indicated',
                contraindications: 'Severe hepatic impairment, megaloblastic anaemia due to folate deficiency, sulfonamide allergy',
                interactions: 'Warfarin (↑ INR), methotrexate (↑ toxicity), ACEi/ARBs (↑ hyperkalaemia risk), trimethoprim may ↑ creatinine (functional)',
                monitoring: 'U&Es, FBC and LFTs for prolonged therapy; watch for rash and signs of bone marrow suppression',
                pregnancy: 'Avoid near term; caution in pregnancy due to folate antagonism',
                sideEffects: 'Rash (including SJS/TEN rare), GI upset, cytopenias, hyperkalaemia, photosensitivity',
                pharmacokinetics: 'Well absorbed orally; renal excretion of metabolites; half-lives differ between components',
                clinicalPearls: 'Check local resistance patterns for UTI use. Can potentiate warfarin — monitor INR closely',
                indication: 'UTI (where susceptible), PCP prophylaxis/treatment, certain systemic infections'
            }
            ,
            'calcium-gluconate': {
                name: 'Calcium Gluconate',
                class: 'Mineral replacement/Antidote',
                mechanism: 'Provides calcium ions essential for cardiac, skeletal muscle function and nerve transmission',
                dosing: 'Hypocalcemia: 10-20ml of 10% solution IV. Hyperkalemia: 10ml of 10% IV. Mg toxicity: 10-20ml IV',
                contraindications: 'Hypercalcemia, calcium kidney stones, digoxin toxicity',
                interactions: 'Digoxin (↑ toxicity), thiazides (↑ calcium), levothyroxine (↓ absorption)',
                monitoring: 'Serum calcium, phosphate, magnesium, ECG, signs of extravasation',
                pregnancy: 'Safe when clinically indicated. Essential mineral',
                sideEffects: 'Hypercalcemia, tissue necrosis (extravasation), bradycardia, hypotension',
                pharmacokinetics: 'IV: immediate effect. Calcium distributed to bones, excreted via kidneys',
                clinicalPearls: 'Preferred over calcium chloride peripherally. Give slowly to avoid arrhythmias',
                indication: 'Hypocalcemia, hyperkalemia, hypermagnesemia, calcium channel blocker overdose'
            },
            'carbamazepine': {
                name: 'Carbamazepine',
                class: 'Antiepileptic drug',
                mechanism: 'Blocks voltage-gated sodium channels, stabilizes neuronal membranes',
                dosing: 'Start 100-200mg BD, increase slowly to 800-1200mg daily in divided doses',
                contraindications: 'AV block, porphyria, bone marrow depression',
                interactions: 'Warfarin (↓ effect), contraceptives (↓ efficacy), numerous CYP450 interactions',
                monitoring: 'FBC, LFTs, sodium levels, carbamazepine levels (4-12mg/L)',
                pregnancy: 'Teratogenic - folate supplementation, specialist advice',
                sideEffects: 'Diplopia, ataxia, hyponatraemia, blood dyscrasias, Stevens-Johnson syndrome',
                pharmacokinetics: 'Induces own metabolism, half-life decreases with time',
                clinicalPearls: 'Start low, go slow. Monitor for hyponatraemia. Many drug interactions',
                indication: 'Epilepsy, trigeminal neuralgia, bipolar disorder (second-line)'
            },
            'cefalexin': {
                name: 'Cefalexin',
                class: 'Cephalosporins and carbapenems',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'Adults: 250-500mg QDS. Severe infections: 1-1.5g QDS. Children: 25mg/kg BD (max 1g BD)',
                contraindications: 'Cephalosporin hypersensitivity. Caution if penicillin allergy (cross-reactivity 1-3%)',
                interactions: 'Probenecid (↑ levels), warfarin (may ↑ INR), metformin (monitor)',
                monitoring: 'Signs of allergic reaction, C.difficile-associated diarrhoea, renal function',
                pregnancy: 'Safe - no increased risk of congenital abnormalities',
                sideEffects: 'GI upset, diarrhoea, allergic reactions, CDAD, transient rise in LFTs',
                pharmacokinetics: 'Well absorbed orally, Half-life: 1h, mainly renal excretion',
                clinicalPearls: 'Good oral bioavailability. First-line for cellulitis in UK. Take with food if GI upset',
                indication: 'Skin/soft tissue infections, UTI, respiratory tract infections, prophylaxis'
            },
            'ceftriaxone': {
                name: 'Ceftriaxone',
                class: 'Cephalosporins and carbapenems',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'Adult: 1-2g daily IV/IM. Severe infections: 2g BD. Meningitis: 2g BD. Max 4g/day',
                contraindications: 'Hypersensitivity to cephalosporins, premature neonates, hyperbilirubinemia',
                interactions: 'Calcium-containing solutions (precipitation), warfarin (↑ INR), probenecid (↑ levels)',
                monitoring: 'Signs of infection resolution, renal function, LFTs, FBC, C.diff surveillance',
                pregnancy: 'Generally considered compatible in pregnancy; consult UKTIS or SmPC for details',
                sideEffects: 'Diarrhea, rash, injection site reactions, gallbladder sludging, C.diff',
                pharmacokinetics: 'Good tissue penetration including CSF. t½ 6-9h. 50% renal excretion',
                clinicalPearls: 'Excellent CNS penetration. Once daily dosing. Avoid calcium solutions',
                indication: 'Pneumonia, meningitis, sepsis, gonorrhea, cellulitis, intra-abdominal infections'
            },
            'cetirizine': {
                name: 'Cetirizine',
                class: 'Second-generation antihistamine (H1 antagonist)',
                mechanism: 'Selective peripheral H1 receptor antagonist with minimal CNS penetration',
                dosing: 'Adults: 10mg daily. Children 6-12 years: 5mg daily or 2.5mg BD. Children 2-6 years: 2.5mg daily',
                contraindications: 'End-stage renal disease, hypersensitivity to cetirizine or hydroxyzine',
                interactions: 'Minimal interactions due to limited metabolism. Alcohol (↑ sedation)',
                monitoring: 'Sedation level (less than first-generation), renal function in elderly',
                pregnancy: 'Generally considered compatible in pregnancy; use when clinically indicated and consult UKTIS if concerned',
                sideEffects: 'Drowsiness (10%), dry mouth, headache, fatigue, GI upset',
                pharmacokinetics: 'Good oral absorption, Half-life: 8-11h, 60% renal excretion unchanged',
                clinicalPearls: 'Less sedating than chlorphenamine. Reduce dose in renal impairment. Available OTC',
                indication: 'Allergic rhinitis, chronic urticaria, allergic conjunctivitis, atopic dermatitis'
            },
            'chlorphenamine': {
                name: 'Chlorphenamine',
                class: 'First-generation antihistamine (H1-receptor antagonist)',
                mechanism: 'H1-receptor antagonist with anticholinergic and sedative properties',
                dosing: 'Adults: 4mg TDS-QDS. Children 1-2y: 1mg BD. Children 2-6y: 1mg QDS. IV: 10-20mg slowly',
                contraindications: 'MAOIs, severe liver disease, porphyria',
                interactions: 'Alcohol (↑ sedation), anticholinergics (↑ effects), MAOIs (avoid)',
                monitoring: 'Sedation level, anticholinergic effects, driving ability',
                pregnancy: 'Appears safe - no increased malformation risk',
                sideEffects: 'Sedation, dry mouth, blurred vision, urinary retention, confusion (elderly)',
                pharmacokinetics: 'Well absorbed, half-life: 12-15h, hepatic metabolism',
                clinicalPearls: 'Useful for acute allergic reactions. IM/IV route available for anaphylaxis adjunct',
                indication: 'Allergic reactions, urticaria, hay fever, insomnia (short-term)'
            },
            'ciprofloxacin': {
                name: 'Ciprofloxacin',
                class: 'Quinolones',
                mechanism: 'Inhibits bacterial DNA gyrase and topoisomerase IV',
                dosing: 'UTI: 250-500mg BD. Complicated infections: 400mg BD IV. Take 2h before/6h after dairy',
                contraindications: 'Epilepsy, G6PD deficiency, myasthenia gravis, children/pregnancy',
                interactions: 'Warfarin (↑ INR), theophylline (↑ levels), dairy products (↓ absorption)',
                monitoring: 'Tendon pain, CNS effects, QT interval, glucose (diabetics)',
                pregnancy: 'Avoid - arthropathy risk in developing cartilage',
                sideEffects: 'Tendon rupture, CNS effects, QT prolongation, photosensitivity, C.diff',
                pharmacokinetics: 'Good tissue penetration, half-life: 4h, renal/hepatic excretion',
                clinicalPearls: 'Broad spectrum but resistance increasing. Avoid dairy. Black box warning for tendons',
                indication: 'UTI, respiratory infections, GI infections, anthrax prophylaxis'
            },
            'citalopram': {
                name: 'Citalopram',
                class: 'Selective serotonin reuptake inhibitor (SSRI)',
                mechanism: 'Selective inhibition of serotonin reuptake with minimal effect on other neurotransmitters',
                dosing: 'Adults: Start 20mg daily, usual dose 20mg, max 40mg daily (20mg if >65 years or hepatic impairment)',
                contraindications: 'MAOIs, QT prolongation, recent MI, severe heart failure',
                interactions: 'MAOIs (serotonin syndrome), drugs prolonging QT interval, warfarin',
                monitoring: 'ECG if cardiac risk factors, electrolytes, mood, suicide risk',
                pregnancy: 'Use if benefit outweighs risk - potential pulmonary hypertension in neonate',
                sideEffects: 'Nausea, dry mouth, drowsiness, sexual dysfunction, QT prolongation (dose-related)',
                pharmacokinetics: 'Half-life: 35h, CYP2C19 and CYP3A4 metabolism',
                clinicalPearls: 'Lowest interaction profile of SSRIs. Dose reduction needed in elderly. ECG if >40mg or cardiac risk',
                indication: 'Depression, panic disorder (unlicensed but effective)'
            },
            'clarithromycin': {
                name: 'Clarithromycin',
                class: 'Macrolide antibiotic',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 50S ribosomal subunit',
                dosing: 'Adults: 250-500mg BD. Severe infections: 500mg BD. H.pylori: 500mg BD with PPI and amoxicillin',
                contraindications: 'Macrolide hypersensitivity, myasthenia gravis, severe hepatic impairment',
                interactions: 'Warfarin (↑ INR), simvastatin (rhabdomyolysis risk), digoxin (↑ levels)',
                monitoring: 'LFTs if prolonged use, signs of cardiac arrhythmias, drug interactions',
                pregnancy: 'Use only if essential - crosses placenta but no evidence of harm',
                sideEffects: 'GI upset, metallic taste, QT prolongation, hepatotoxicity (rare)',
                pharmacokinetics: 'Well absorbed, Half-life: 3-7h, hepatic metabolism (CYP3A4)',
                clinicalPearls: 'Part of triple therapy for H.pylori. Good tissue penetration. Many drug interactions via CYP3A4',
                indication: 'Respiratory tract infections, H.pylori eradication, skin infections, atypical pneumonia'
            },
            'clindamycin': {
                name: 'Clindamycin',
                class: 'Clindamycin',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 50S ribosomal subunit',
                dosing: 'Adult: 150-450mg QDS PO or 0.6-2.7g daily IV in divided doses. Max 4.8g/day IV',
                contraindications: 'Previous C.diff colitis, severe liver disease, lincomycin allergy',
                interactions: 'Neuromuscular blockers (↑ paralysis), warfarin (↑ INR), ciclosporin',
                monitoring: 'Diarrhea/C.diff symptoms, liver function, infection resolution',
                pregnancy: 'Generally considered compatible in pregnancy; seek UKTIS for specific scenarios',
                sideEffects: 'C.diff colitis, diarrhea, rash, metallic taste, liver dysfunction',
                pharmacokinetics: 'Good tissue/bone penetration. t½ 2-3h. Hepatic metabolism',
                clinicalPearls: 'Excellent bone penetration. High C.diff risk. Stop if diarrhea develops',
                indication: 'Bone/joint infections, anaerobic infections, skin/soft tissue, dental infections'
            },
            'clopidogrel': {
                name: 'Clopidogrel',
                class: 'Antiplatelet drugs, ADP-receptor antagonists',
                mechanism: 'Irreversibly inhibits P2Y12 ADP receptor on platelets',
                dosing: 'Acute coronary syndrome: 600mg loading dose, then 75mg daily. Stroke prevention: 75mg daily',
                contraindications: 'Active bleeding, severe hepatic impairment',
                interactions: 'Warfarin (↑ bleeding), PPIs (may ↓ efficacy), CYP2C19 inhibitors',
                monitoring: 'Signs of bleeding, FBC, hepatic function',
                pregnancy: 'Avoid - limited safety data, bleeding risk',
                sideEffects: 'Bleeding, dyspepsia, rash, thrombotic thrombocytopenic purpura (rare)',
                pharmacokinetics: 'Prodrug requiring CYP2C19 activation, irreversible platelet inhibition',
                clinicalPearls: 'Dual antiplatelet therapy with aspirin post-ACS. Genetic testing for CYP2C19 variants',
                indication: 'Acute coronary syndromes, stroke prevention, peripheral vascular disease'
            },
            'co-amoxiclav': {
                name: 'Co-amoxiclav',
                class: 'Penicillins, broad-spectrum',
                mechanism: 'Amoxicillin inhibits cell wall synthesis, clavulanic acid protects against beta-lactamases',
                dosing: 'Adults: 625mg TDS or 1g BD. Severe infections: 1.2g TDS IV. Available as 375mg, 625mg tablets',
                contraindications: 'Penicillin allergy, previous cholestatic jaundice with co-amoxiclav',
                interactions: 'Warfarin (↑ INR), methotrexate (↑ toxicity), probenecid (↑ levels)',
                monitoring: 'LFTs (risk of cholestatic jaundice), signs of C.difficile colitis',
                pregnancy: 'Safe - no increased risk of congenital abnormalities',
                sideEffects: 'GI upset, diarrhoea, cholestatic jaundice (rare), skin reactions',
                pharmacokinetics: 'Well absorbed, Half-life: 1h, mainly renal excretion',
                clinicalPearls: 'Broad spectrum including beta-lactamase producers. Take with food to ↓ GI upset. Monitor LFTs',
                indication: 'Respiratory tract infections, skin/soft tissue infections, dental infections, UTI'
            },
            'co-codamol': {
                name: 'Co-codamol',
                class: 'Opioid/paracetamol combination analgesic',
                mechanism: 'Codeine acts on μ-opioid receptors, paracetamol inhibits COX enzymes centrally',
                dosing: 'Adults: 8/500mg or 30/500mg, 1-2 tablets every 4-6 hours (max 8 tablets/24h). Children >12 years: 8/500mg only',
                contraindications: 'Children <12 years, acute respiratory depression, paralytic ileus, severe hepatic impairment',
                interactions: 'Alcohol (↑ sedation), MAOIs, other CNS depressants, warfarin (paracetamol component)',
                monitoring: 'Signs of respiratory depression, constipation, dependence with long-term use',
                pregnancy: 'Use with caution - potential neonatal withdrawal if used near term',
                sideEffects: 'Constipation, nausea, drowsiness, dizziness, dry mouth, potential for dependence',
                pharmacokinetics: 'Codeine: prodrug converted to morphine by CYP2D6. Half-life: 3-4h',
                clinicalPearls: 'Popular UK combination. 8/500mg available OTC. 30/500mg prescription only. Maximum 3 days OTC use',
                indication: 'Moderate pain where paracetamol alone insufficient. Post-operative pain, dental pain'
            },
            'codeine': {
                name: 'Codeine',
                class: 'Opioid analgesic',
                mechanism: 'Prodrug converted to morphine by CYP2D6, mu-opioid receptor agonist',
                dosing: 'Pain: 15-60mg QDS PRN. Cough: 15-30mg QDS. Diarrhoea: 30mg TDS-QDS',
                contraindications: 'Children <12 years, breastfeeding, severe respiratory disease, acute abdomen',
                interactions: 'Alcohol/sedatives (↑ sedation), MAOIs (avoid), CYP2D6 inhibitors (↓ efficacy)',
                monitoring: 'Respiratory rate, sedation level, bowel function, signs of dependence',
                pregnancy: 'Avoid near term - risk of neonatal respiratory depression',
                sideEffects: 'Constipation, nausea, sedation, respiratory depression, dependence',
                pharmacokinetics: 'Prodrug, 10% converted to morphine, half-life: 3-4h',
                clinicalPearls: 'Variable efficacy due to CYP2D6 polymorphisms. Always prescribe laxatives for regular use',
                indication: 'Mild to moderate pain, dry cough, diarrhoea'
            },
            'colecalciferol': {
                name: 'Colecalciferol (Vitamin D3)',
                class: 'Vitamin supplement',
                mechanism: 'Precursor to active vitamin D, essential for calcium absorption and bone health',
                dosing: 'Deficiency: 6000 units daily for 8 weeks. Maintenance: 800-2000 units daily',
                contraindications: 'Hypercalcaemia, severe renal impairment, sarcoidosis',
                interactions: 'Thiazides (↑ hypercalcaemia risk), digoxin (hypercalcaemia ↑ toxicity)',
                monitoring: 'Serum calcium, 25-OH vitamin D levels',
                pregnancy: 'Safe - 400 units daily recommended',
                sideEffects: 'Hypercalcaemia, hypercalciuria, nausea, constipation (overdose)',
                pharmacokinetics: 'Fat-soluble, stored in adipose tissue, half-life: 2-3 weeks',
                clinicalPearls: 'Increasingly prescribed due to widespread deficiency. Take with fatty meal for absorption',
                indication: 'Vitamin D deficiency, osteoporosis prevention, general health maintenance'
            },
            'cyclizine': {
                name: 'Cyclizine',
                class: 'Antihistamine antiemetic',
                mechanism: 'H1 receptor antagonist with anticholinergic properties, acts on vestibular system',
                dosing: 'Adults: 50mg TDS PO/IM/IV. Children 6-12 years: 25mg TDS. Motion sickness: 50mg 30min before travel',
                contraindications: 'Severe heart failure, porphyria, known hypersensitivity',
                interactions: 'CNS depressants (↑ sedation), anticholinergics (↑ effects), MAOIs',
                monitoring: 'Sedation level, anticholinergic effects, cardiac function in elderly',
                pregnancy: 'Generally considered compatible in pregnancy for short-term use; recommended by RCOG/UKTIS for nausea and vomiting in pregnancy when indicated (refer to UKTIS for detailed guidance)',
                sideEffects: 'Drowsiness, dry mouth, blurred vision, constipation, urinary retention',
                pharmacokinetics: 'Good oral absorption, Half-life: 20h, hepatic metabolism',
                clinicalPearls: 'Excellent for motion sickness and vertigo. Less sedating than promethazine',
                indication: 'Motion sickness, vertigo, nausea/vomiting, pregnancy sickness'
            },
            'dexamethasone': {
                name: 'Dexamethasone',
                class: 'Corticosteroid (glucocorticoid)',
                mechanism: 'Potent synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects',
                dosing: 'Cerebral oedema: 4mg QDS. COVID-19: 6mg daily for 10 days. Croup: 150mcg/kg single dose',
                contraindications: 'Systemic infection (unless covering antimicrobials), live vaccines',
                interactions: 'Similar to prednisolone - warfarin, NSAIDs, vaccines',
                monitoring: 'Blood glucose, blood pressure, mood changes, infection signs',
                pregnancy: 'Use if essential - crosses placenta more than prednisolone',
                sideEffects: 'Similar to prednisolone but more potent - hyperglycaemia, immunosuppression',
                pharmacokinetics: 'Long half-life: 36-72h, potency: 25x hydrocortisone',
                clinicalPearls: '4x more potent than prednisolone. Minimal mineralocorticoid activity. Used in COVID-19',
                indication: 'Cerebral oedema, severe COVID-19, croup, severe inflammatory conditions'
            },
            'diazepam': {
                name: 'Diazepam',
                class: 'Benzodiazepines',
                mechanism: 'Enhances GABA-A receptor activity, increasing chloride influx and neuronal inhibition',
                dosing: 'Anxiety: 2-5mg TDS. Status epilepticus: 10-20mg IV slowly. Muscle spasm: 2-15mg daily',
                contraindications: 'Respiratory depression, severe hepatic impairment, myasthenia gravis, sleep apnoea',
                interactions: 'Alcohol (↑ sedation), opioids (respiratory depression), phenytoin (variable)',
                monitoring: 'Respiratory function, level of sedation, signs of dependence',
                pregnancy: 'Avoid - risk of floppy baby syndrome and withdrawal in neonate',
                sideEffects: 'Sedation, ataxia, confusion (elderly), dependence, respiratory depression',
                pharmacokinetics: 'Long half-life: 20-100h (including active metabolites), hepatic metabolism',
                clinicalPearls: 'Long-acting benzodiazepine. High dependence potential. Flumazenil reverses effects',
                indication: 'Status epilepticus, severe anxiety, alcohol withdrawal, muscle spasm'
            },
            'diclofenac': {
                name: 'Diclofenac',
                class: 'Non-steroidal anti-inflammatory drug (NSAID)',
                mechanism: 'Potent non-selective COX inhibitor with good tissue penetration',
                dosing: 'Oral: 50mg TDS or 75mg BD with food. Topical: apply TDS-QDS. Injection: 75mg IM',
                contraindications: 'Active peptic ulceration, established ischaemic heart disease (IHD), peripheral arterial disease (PAD), cerebrovascular disease, or NYHA class II–IV heart failure — contraindicated. Avoid in uncontrolled hypertension and severe renal impairment',
                interactions: 'ACE inhibitors, warfarin, ciclosporin, lithium, methotrexate, other NSAIDs',
                monitoring: 'Cardiovascular risk assessment, renal function (check U&Es 1–2 weeks after initiation/titration), hepatic function, signs of GI bleeding',
                pregnancy: 'Avoid where possible; contraindicated in third trimester (risk of premature closure of the ductus arteriosus). Use only if benefit outweighs risk',
                sideEffects: 'Increased cardiovascular risk (myocardial infarction, stroke), GI bleeding, hepatotoxicity',
                pharmacokinetics: 'Good oral/topical absorption, Half-life: 1-2h, hepatic metabolism',
                clinicalPearls: 'Contraindicated in patients with established CVD (IHD, PAD, cerebrovascular disease) and in moderate–severe heart failure (NYHA II–IV). Consider alternative analgesics (topical NSAIDs, paracetamol) in patients with cardiovascular risk',
                indication: 'Acute musculoskeletal conditions, postoperative pain, topical for joint pain'
            },
            'digoxin': {
                name: 'Digoxin',
                class: 'Digoxin',
                mechanism: 'Inhibits Na+/K+-ATPase pump, increases intracellular Ca2+, ↑ contractility, ↓ AV conduction',
                dosing: 'Loading: 10-15 micrograms/kg IV or PO. Maintenance: 125-250 micrograms daily (reduce in elderly/renal impairment)',
                contraindications: 'Ventricular arrhythmias, heart block, hypertrophic cardiomyopathy with outflow obstruction',
                interactions: 'Amiodarone (↑ levels), diuretics (hypokalaemia ↑ toxicity), verapamil, quinidine',
                monitoring: 'Digoxin levels (6h post-dose), U&Es, heart rate, rhythm, signs of toxicity',
                pregnancy: 'Safe - no teratogenic effects, adjust dose due to increased clearance',
                sideEffects: 'Nausea, vomiting, visual disturbances, arrhythmias, confusion (toxicity)',
                pharmacokinetics: 'Half-life: 36h (longer in renal impairment), mainly renal excretion',
                clinicalPearls: 'Narrow therapeutic window. Target level 1.0-2.0 micrograms/L. Toxicity common in elderly',
                indication: 'AF (rate control), heart failure (symptom control). No mortality benefit'
            },
            'domperidone': {
                name: 'Domperidone',
                class: 'Antiemetic (Dopamine antagonist)',
                mechanism: 'Selective D2 receptor antagonist at CTZ, prokinetic effect on upper GI tract',
                dosing: 'Adults: 10mg TDS (max 10mg three times daily) before meals for up to 7 days (MHRA restriction). Not licensed for children <12 years or weight <35 kg',
                contraindications: 'Known cardiac conduction disorders, significant ventricular arrhythmia, moderate–severe hepatic impairment, prolactinoma, congenital or acquired QT prolongation',
                interactions: 'CYP3A4 inhibitors (↑ levels), other QT-prolonging drugs, anticholinergics',
                monitoring: 'Consider ECG in patients with cardiac risk factors or on concomitant QT-prolonging drugs. Check hepatic function if prolonged use. Monitor for extrapyramidal signs and signs of hyperprolactinaemia if used longer than recommended',
                pregnancy: 'Use only if essential and after specialist/UKTIS advice — limited safety data',
                sideEffects: 'QT prolongation and rare serious arrhythmias, galactorrhoea, gynaecomastia, extrapyramidal effects (rare)',
                pharmacokinetics: 'Poor oral bioavailability (~15%), Half-life: 7-9h, hepatic metabolism',
                clinicalPearls: 'MHRA guidance: restrict use to short-term symptomatic treatment of nausea and vomiting (max 7 days), avoid in patients with known cardiac disease or taking QT‑prolonging medicines. Not licensed for use in children <12 years or <35 kg. Consider alternative antiemetics in patients at cardiac risk',
                indication: 'Nausea and vomiting (short-term use only), selected gastroparesis after specialist advice'
            },
            'doxycycline': {
                name: 'Doxycycline',
                class: 'Tetracyclines and glycylcyclines',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 30S ribosomal subunit',
                dosing: 'Adults: 200mg on day 1, then 100mg daily. Acne: 40mg daily modified-release. Malaria prophylaxis: 100mg daily',
                contraindications: 'Pregnancy, breastfeeding, children <12 years, myasthenia gravis',
                interactions: 'Antacids/iron (↓ absorption), warfarin (↑ INR), penicillins (antagonistic)',
                monitoring: 'LFTs if prolonged use, signs of C.difficile colitis, photosensitivity',
                pregnancy: 'Contraindicated - risk of dental staining and bone growth inhibition in fetus',
                sideEffects: 'GI upset, photosensitivity, oesophageal irritation, vaginal thrush',
                pharmacokinetics: 'Well absorbed, Half-life: 18-22h, Hepatic metabolism and renal excretion',
                clinicalPearls: 'Take with food, avoid dairy 2h before/after. Stay upright 30min after dose. First-line for atypical pneumonia',
                indication: 'Respiratory tract infections, acne, chlamydia, malaria prophylaxis, Lyme disease'
            },
            'empagliflozin': {
                name: 'Empagliflozin',
                class: 'Sodium-glucose co-transporter 2 inhibitors',
                mechanism: 'Inhibits sodium-glucose co-transporter 2 in proximal renal tubules',
                dosing: 'Type 2 diabetes: 10mg daily, may increase to 25mg. Heart failure: 10mg daily',
                contraindications: 'Type 1 diabetes, ketoacidosis, severe renal impairment (eGFR <30)',
                interactions: 'Diuretics (↑ volume depletion), insulin (↑ hypoglycaemia risk)',
                monitoring: 'eGFR, ketones if unwell, genital infections, volume status',
                pregnancy: 'Avoid - limited safety data',
                sideEffects: 'Genital infections, UTI, volume depletion, diabetic ketoacidosis (rare)',
                pharmacokinetics: 'Long half-life: 12h, renal excretion, minimal drug interactions',
                clinicalPearls: 'Cardiovascular benefits in diabetes. Stop during illness (sick day rules). Monitor for DKA',
                indication: 'Type 2 diabetes, heart failure with reduced ejection fraction'
            },
            'enoxaparin': {
                name: 'Enoxaparin',
                class: 'Heparins and fondaparinux',
                mechanism: 'Enhances antithrombin III activity, preferentially inhibiting factor Xa',
                dosing: 'VTE prophylaxis: 40mg daily SC. VTE treatment: 1.5mg/kg daily or 1mg/kg BD SC',
                contraindications: 'Active bleeding, thrombocytopenia, severe renal impairment',
                interactions: 'Anticoagulants (↑ bleeding), NSAIDs (↑ bleeding), antiplatelets',
                monitoring: 'Anti-Xa levels (if required), platelet count, signs of bleeding',
                pregnancy: 'Safe - does not cross placenta. Preferred anticoagulant in pregnancy',
                sideEffects: 'Bleeding, thrombocytopenia (HIT), injection site reactions, osteoporosis',
                pharmacokinetics: 'Subcutaneous bioavailability 90%, half-life: 4-7h, renal excretion',
                clinicalPearls: 'More predictable than unfractionated heparin. Pregnancy anticoagulant of choice',
                indication: 'VTE prophylaxis/treatment, acute coronary syndromes, pregnancy anticoagulation'
            },
            'erythromycin': {
                name: 'Erythromycin',
                class: 'Macrolide antibiotic',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 50S ribosomal subunit',
                dosing: 'Adults: 250-500mg QDS. Children: 25-50mg/kg daily in divided doses. Take before food',
                contraindications: 'Hypersensitivity to macrolides, concurrent use with ergot alkaloids',
                interactions: 'Warfarin (↑ INR), theophylline (↑ levels), carbamazepine (↑ levels), QT-prolonging drugs',
                monitoring: 'LFTs with prolonged use, signs of C.difficile colitis, hearing (high doses)',
                pregnancy: 'Safe - drug of choice for chlamydia in pregnancy',
                sideEffects: 'GI upset, QT prolongation, cholestatic hepatitis, tinnitus',
                pharmacokinetics: 'Variable oral absorption, half-life: 1-4h, hepatic metabolism',
                clinicalPearls: 'Take before food to improve absorption. Many drug interactions via CYP3A4',
                indication: 'Respiratory tract infections, skin infections, chlamydia, legionella'
            },
            'ferrous sulfate': {
                name: 'Ferrous Sulfate',
                class: 'Iron',
                mechanism: 'Provides elemental iron for haemoglobin synthesis and correction of iron deficiency',
                dosing: 'Adults: 200mg (65mg elemental iron) BD-TDS on empty stomach. Prophylaxis: 200mg daily',
                contraindications: 'Haemochromatosis, haemosiderosis, non-iron deficiency anaemia',
                interactions: 'Tetracyclines (↓ absorption both), levothyroxine (separate by 4h), antacids (↓ absorption)',
                monitoring: 'FBC, iron studies, signs of iron overload with prolonged use',
                pregnancy: 'Safe and recommended - increased iron requirements',
                sideEffects: 'GI upset, constipation, diarrhoea, black stools, nausea',
                pharmacokinetics: 'Best absorbed on empty stomach, vitamin C enhances absorption',
                clinicalPearls: 'Take with orange juice (vitamin C). Black stools are normal. Continue 3 months after Hb normal',
                indication: 'Iron deficiency anaemia, prophylaxis in pregnancy/menorrhagia'
            },
            'fexofenadine': {
                name: 'Fexofenadine',
                class: 'Second-generation antihistamine (H1 antagonist)',
                mechanism: 'Selective peripheral H1 receptor antagonist with no CNS penetration',
                dosing: 'Adults: 120mg daily (seasonal rhinitis) or 180mg daily (urticaria). Children 6-12 years: 30mg BD',
                contraindications: 'Hypersensitivity to fexofenadine, severe renal impairment',
                interactions: 'Antacids (↓ absorption), fruit juices may ↓ absorption',
                monitoring: 'Effectiveness for allergic symptoms, minimal side effects',
                pregnancy: 'Use only if maternal benefit outweighs fetal risk; check UKTIS/SmPC for up-to-date evidence',
                sideEffects: 'Headache, drowsiness (2%), nausea, dyspepsia',
                pharmacokinetics: 'Good oral absorption, Half-life: 14h, minimal metabolism, renal/biliary excretion',
                clinicalPearls: 'Least sedating antihistamine. No cardiotoxicity. Take on empty stomach',
                indication: 'Seasonal allergic rhinitis, chronic idiopathic urticaria, allergic skin conditions'
            },
            'flucloxacillin': {
                name: 'Flucloxacillin',
                class: 'Penicillins, narrow-spectrum',
                mechanism: 'β-lactam antibiotic - inhibits cell wall synthesis, resistant to β-lactamases',
                dosing: 'Oral: 250-500mg QDS on empty stomach. IV: 0.25-2g QDS. Severe infections: up to 8g daily',
                contraindications: 'Penicillin allergy, previous flucloxacillin-induced hepatitis',
                interactions: 'Warfarin (may ↑ INR), methotrexate (↑ toxicity), probenecid (↑ levels)',
                monitoring: 'LFTs (risk of cholestatic hepatitis), signs of allergic reaction',
                pregnancy: 'Safe - no evidence of harm',
                sideEffects: 'GI upset, allergic reactions, cholestatic hepatitis (rare but serious), CDAD',
                pharmacokinetics: 'Variable oral absorption, half-life: 1h, mainly renal excretion',
                clinicalPearls: 'First-line for staphylococcal infections. Take on empty stomach. Monitor LFTs',
                indication: 'Staphylococcal infections (cellulitis, bone/joint infections), endocarditis prophylaxis'
            },
            'fluconazole': {
                name: 'Fluconazole',
                class: 'Triazole antifungal',
                mechanism: 'Inhibits fungal cytochrome P450 enzyme 14α-demethylase, disrupting ergosterol synthesis',
                dosing: 'Vaginal candidiasis: 150mg single dose. Oral candidiasis: 50mg daily for 7-14 days. Systemic: up to 400mg daily depending on indication',
                contraindications: 'Hypersensitivity to azoles, concurrent terfenadine/astemizole, significant hepatic impairment without specialist advice',
                interactions: 'Warfarin (↑ INR), phenytoin (↑ levels), rifampicin (↓ fluconazole levels), many CYP3A4 substrates/inhibitors',
                monitoring: 'LFTs with prolonged or high-dose therapy, signs of hepatotoxicity, review drug interactions',
                pregnancy: 'Avoid high or prolonged doses in pregnancy due to a malformation signal. A single 150mg dose for vaginal candidiasis is unlikely to increase risk but should be used only if clearly indicated — follow UKTIS guidance',
                sideEffects: 'GI upset, headache, skin rashes, hepatotoxicity (rare), QT prolongation',
                pharmacokinetics: 'Excellent oral bioavailability (~90%), CSF penetration, renal excretion',
                clinicalPearls: 'Single 150mg dose appropriate for uncomplicated vulvovaginal candidiasis; avoid prolonged or high-dose therapy in pregnancy. For systemic infections, specialist guidance and monitoring required',
                indication: 'Candidiasis (vaginal, oral, systemic), cryptococcal meningitis, fungal prophylaxis'
            },
            'fluoxetine': {
                name: 'Fluoxetine',
                class: 'Selective serotonin reuptake inhibitor (SSRI)',
                mechanism: 'Inhibits serotonin reuptake at synaptic cleft, increasing serotonin availability',
                dosing: 'Depression: Start 20mg daily, usual dose 20mg, max 60mg daily. Take in morning',
                contraindications: 'MAOIs (within 14 days), mania, severe hepatic impairment',
                interactions: 'MAOIs (serotonin syndrome), warfarin (↑ bleeding), tramadol (↑ seizure risk)',
                monitoring: 'Mood, suicide risk (especially <25 years), weight, sodium levels',
                pregnancy: 'Use if benefit outweighs risk - potential neonatal adaptation syndrome',
                sideEffects: 'Nausea, headache, insomnia, sexual dysfunction, weight loss, hyponatraemia',
                pharmacokinetics: 'Long half-life: 4-6 days (active metabolite: 4-16 days), CYP2D6 metabolism',
                clinicalPearls: 'Longest half-life SSRI - less withdrawal symptoms. May initially increase anxiety. Monitor under 25s weekly',
                indication: 'Depression, panic disorder, OCD, bulimia nervosa, premenstrual dysphoric disorder'
            },
            'folic acid': {
                name: 'Folic Acid',
                class: 'Vitamin supplement',
                mechanism: 'Synthetic form of folate, essential for DNA synthesis and red cell production',
                dosing: 'Deficiency: 5mg daily. Pregnancy: 400mcg daily (5mg if high risk). With methotrexate: 5mg weekly',
                contraindications: 'Megaloblastic anaemia until B12 deficiency excluded',
                interactions: 'Methotrexate (antagonistic - given on different days), phenytoin (↓ levels)',
                monitoring: 'FBC, B12 levels (must exclude B12 deficiency first)',
                pregnancy: 'Essential - prevents neural tube defects. Start pre-conception',
                sideEffects: 'Generally well tolerated. May mask B12 deficiency',
                pharmacokinetics: 'Well absorbed, stored in liver, renal excretion',
                clinicalPearls: 'Always check B12 before treating megaloblastic anaemia. Take with methotrexate day+1',
                indication: 'Folate deficiency, pregnancy/pre-conception, with methotrexate therapy'
            },
            'furosemide': {
                name: 'Furosemide',
                class: 'Diuretics, loop',
                mechanism: 'Inhibits Na+/K+/2Cl- co-transporter in ascending limb of loop of Henle',
                dosing: 'Heart failure: Start 20-40mg daily, titrate to response. Oedema: 20-80mg daily. IV dose = half oral dose',
                contraindications: 'Anuria, severe electrolyte imbalance, hepatic coma',
                interactions: 'Lithium (↑ toxicity), digoxin (hypokalaemia ↑ toxicity), NSAIDs (↓ effect)',
                monitoring: 'U&Es (check 1–2 weeks after initiation/titration), fluid balance, weight, hearing (especially after high IV doses), postural BP',
                pregnancy: 'Use with caution - may cause placental hypoperfusion',
                sideEffects: 'Hypokalaemia, hyponatraemia, dehydration, ototoxicity (especially with high IV doses or rapid administration), gout',
                pharmacokinetics: 'Oral onset: 1h, Peak: 1-2h, Duration: 6h. IV onset: 5min',
                clinicalPearls: 'Take in morning to avoid nocturia. Monitor K+ closely. Ototoxicity with high IV doses',
                indication: 'Heart failure, pulmonary oedema, hypertension (rarely used), ascites'
            },
            'gabapentin': {
                name: 'Gabapentin',
                class: 'Gabapentinoids',
                mechanism: 'Binds to voltage-gated calcium channel α2δ subunit, reducing neurotransmitter release',
                dosing: 'Neuropathic pain: Start 300mg daily, increase to 300mg TDS, max 3600mg daily in divided doses',
                contraindications: 'Hypersensitivity to gabapentin',
                interactions: 'Antacids (↓ absorption), opioids (↑ sedation), alcohol (↑ CNS depression)',
                monitoring: 'Pain scores, mood changes, renal function, signs of abuse/dependence',
                pregnancy: 'Use only if the maternal benefit outweighs fetal risk; consult UKTIS/SmPC',
                sideEffects: 'Drowsiness, dizziness, fatigue, peripheral oedema, weight gain, ataxia',
                pharmacokinetics: 'Dose-dependent absorption, Half-life: 5-7h, renal excretion unchanged',
                clinicalPearls: 'Gradual dose escalation needed. Reduce dose in renal impairment. Potential for abuse',
                indication: 'Neuropathic pain, epilepsy, restless leg syndrome (unlicensed)'
            },
            'gentamicin': {
                name: 'Gentamicin',
                class: 'Aminoglycoside',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 30S ribosomal subunit',
                dosing: 'Adult: 5-7mg/kg daily IV/IM. Adjust for renal function. Monitor levels - trough <2mg/L',
                contraindications: 'Myasthenia gravis, previous 8th nerve damage, severe renal impairment',
                interactions: 'Loop diuretics (↑ ototoxicity), vancomycin (↑ nephrotoxicity), muscle relaxants',
                monitoring: 'Renal function, hearing, balance, drug levels (peak/trough), urine output',
                pregnancy: 'Avoid in pregnancy due to fetal risk (see SmPC/UKTIS); specialist advice required if exposure occurs',
                sideEffects: 'Nephrotoxicity, ototoxicity (vestibular/auditory), neuromuscular blockade',
                pharmacokinetics: 'Poor oral absorption. Good tissue penetration. t½ 2-3h. 95% renal excretion',
                clinicalPearls: 'Once daily dosing preferred. Synergistic with beta-lactams. Monitor levels',
                indication: 'Serious gram-negative infections, endocarditis, sepsis, UTI, pneumonia'
            },
            'gliclazide': {
                name: 'Gliclazide',
                class: 'Sulfonylurea',
                mechanism: 'Stimulates insulin release from pancreatic β-cells by blocking K-ATP channels',
                dosing: 'Standard release: 40-80mg daily with breakfast, max 320mg daily. MR: 30-120mg daily',
                contraindications: 'Type 1 diabetes, ketoacidosis, severe renal/hepatic impairment',
                interactions: 'Alcohol (↑ hypoglycaemia), β-blockers (mask hypoglycaemia), steroids (↑ glucose)',
                monitoring: 'Blood glucose, HbA1c, weight, signs of hypoglycaemia',
                pregnancy: 'Switch to insulin - crosses placenta',
                sideEffects: 'Hypoglycaemia, weight gain, GI upset, skin reactions',
                pharmacokinetics: 'Half-life: 10-20h, hepatic metabolism, renal excretion',
                clinicalPearls: 'Second-line after metformin. Take with food. Lower hypoglycaemia risk than glibenclamide',
                indication: 'Type 2 diabetes (when metformin contraindicated/not tolerated or as add-on)'
            },
            'glyceryl-trinitrate': {
                name: 'Glyceryl Trinitrate (GTN)',
                class: 'Nitrates',
                mechanism: 'Releases nitric oxide causing smooth muscle relaxation and vasodilation',
                dosing: 'Angina: 400-800mcg SL PRN. IV: 10-200mcg/min. Topical: 2.5-5mg patches daily',
                contraindications: 'Severe aortic stenosis, hypertrophic cardiomyopathy, PDE5 inhibitor use',
                interactions: 'Sildenafil/PDE5 inhibitors (severe hypotension), alcohol (↑ hypotension)',
                monitoring: 'Blood pressure, heart rate, headache severity, nitrate tolerance',
                pregnancy: 'Use if benefits outweigh risks. Limited data but generally considered safe',
                sideEffects: 'Headache, hypotension, flushing, dizziness, nitrate tolerance',
                pharmacokinetics: 'SL: onset 2-5min, duration 30min. Patches: onset 30min, duration 12-14h',
                clinicalPearls: 'Nitrate-free period needed to prevent tolerance. Keep tablets in original container',
                indication: 'Angina, heart failure, hypertensive emergency, anal fissure'
            },
            'haloperidol': {
                name: 'Haloperidol',
                class: 'Antipsychotics, first-generation (typical)',
                mechanism: 'Dopamine D2 receptor antagonist, primarily in mesolimbic pathway',
                dosing: 'Psychosis: 1.5-3mg BD-TDS. Acute agitation: 5-10mg IM. Elderly: start 0.5mg BD',
                contraindications: 'Comatose states, severe CNS depression, Parkinson\'s disease',
                interactions: 'Alcohol (↑ sedation), anticholinergics (↑ side effects), carbamazepine (↓ levels)',
                monitoring: 'Extrapyramidal side effects, prolactin levels, ECG (QT interval), FBC',
                pregnancy: 'Use only if essential - limited safety data',
                sideEffects: 'Extrapyramidal effects, tardive dyskinesia, sedation, hyperprolactinaemia, QT prolongation',
                pharmacokinetics: 'Half-life: 12-38h, hepatic metabolism, high first-pass effect',
                clinicalPearls: 'High risk of extrapyramidal effects. Consider anticholinergic for acute dystonia',
                indication: 'Schizophrenia, acute psychosis, severe agitation, nausea/vomiting (low dose)'
            },
            'heparin': {
                name: 'Heparin',
                class: 'Heparins and fondaparinux',
                mechanism: 'Binds to antithrombin III, enhancing inactivation of thrombin and factor Xa',
                dosing: 'DVT/PE: Loading 80 units/kg IV, then 18 units/kg/h. Monitor APTT. Prophylaxis: 5000 units SC BD-TDS',
                contraindications: 'Active bleeding, severe thrombocytopenia, previous HIT, severe liver disease',
                interactions: 'Aspirin, warfarin (↑ bleeding risk), NSAIDS (↑ bleeding risk)',
                monitoring: 'APTT (target 1.5-2.5x control), platelet count (HIT screening), signs of bleeding',
                pregnancy: 'Safe - does not cross placenta. First-line anticoagulant in pregnancy',
                sideEffects: 'Bleeding, HIT, osteoporosis (long-term), alopecia, skin necrosis',
                pharmacokinetics: 'IV: immediate onset, t½ 1-2h. SC: onset 1-2h. Metabolism hepatic',
                clinicalPearls: 'Monitor for HIT. Reverse with protamine. Use anti-Xa levels if APTT unreliable',
                indication: 'DVT/PE treatment, ACS, AF, cardiac surgery, dialysis, stroke prevention'
            },
            'hydrocortisone': {
                name: 'Hydrocortisone',
                class: 'Corticosteroids, topical',
                mechanism: 'Anti-inflammatory glucocorticoid effects via cytoplasmic receptors',
                dosing: 'Topical: Apply thinly BD-QDS. Oral: 20-30mg daily in divided doses',
                contraindications: 'Viral skin infections, rosacea, perioral dermatitis (topical)',
                interactions: 'Minimal with topical use. Oral form: similar to prednisolone',
                monitoring: 'Skin atrophy with prolonged topical use, HPA axis suppression',
                pregnancy: 'Safe topically. Oral use: similar precautions to prednisolone',
                sideEffects: 'Topical: skin atrophy, striae. Oral: similar to other corticosteroids',
                pharmacokinetics: 'Topical absorption varies by site. Oral: short half-life 8-12h',
                clinicalPearls: 'Mildest topical steroid. Available OTC in low concentrations. Safe for face/children',
                indication: 'Eczema, dermatitis, insect bites, adrenal insufficiency (oral)'
            },
            'hyoscine': {
                name: 'Hyoscine (Scopolamine)',
                class: 'Anticholinergic/Antimuscarinic',
                mechanism: 'Competitive antagonist of muscarinic acetylcholine receptors',
                dosing: 'Motion sickness: 0.3mg patch behind ear. Palliative care: 0.4-0.6mg SC/IV TDS-QDS',
                contraindications: 'Narrow-angle glaucoma, prostatic enlargement, myasthenia gravis, intestinal obstruction',
                interactions: 'Anticholinergic drugs (↑ effects), phenothiazines, tricyclics',
                monitoring: 'Anticholinergic effects, confusion in elderly, respiratory secretions',
                pregnancy: 'Generally considered compatible for short-term use in pregnancy for nausea; consult UKTIS for guidance',
                sideEffects: 'Dry mouth, drowsiness, blurred vision, confusion, hallucinations',
                pharmacokinetics: 'Crosses blood-brain barrier, Half-life: 4-8h, hepatic metabolism',
                clinicalPearls: 'Patches for motion sickness. Excellent for respiratory secretions in palliative care',
                indication: 'Motion sickness, excessive respiratory secretions, smooth muscle spasm'
            },
            'ibuprofen': {
                name: 'Ibuprofen',
                class: 'Non-steroidal anti-inflammatory drug (NSAID)',
                mechanism: 'Non-selective cyclooxygenase (COX) inhibitor, reducing prostaglandin synthesis',
                dosing: 'Adults: 400mg TDS-QDS with food (max 2.4g daily). Children >6 months: 20-30mg/kg daily in 3-4 divided doses',
                contraindications: 'Active peptic ulceration, severe heart failure, severe renal impairment, pregnancy (3rd trimester)',
                interactions: 'ACE inhibitors (↓ antihypertensive effect), warfarin (↑ bleeding risk), lithium (↑ toxicity), methotrexate (↑ toxicity)',
                monitoring: 'Renal function, blood pressure, signs of GI bleeding, fluid retention',
                pregnancy: 'Avoid in 3rd trimester - risk of oligohydramnios and premature closure of ductus arteriosus',
                sideEffects: 'GI bleeding/perforation, acute kidney injury, fluid retention, hypertension, bronchospasm (aspirin-sensitive asthma)',
                pharmacokinetics: 'Onset: 30min, Peak: 1-2h, Half-life: 2-4h, Hepatic metabolism',
                clinicalPearls: 'Most widely used NSAID in UK. Always take with food. Use lowest effective dose for shortest time',
                indication: 'Pain and inflammation, particularly musculoskeletal conditions, fever, dysmenorrhoea'
            },
            'insulin': {
                name: 'Insulin (Human)',
                class: 'Insulin',
                mechanism: 'Replaces endogenous insulin, promoting glucose uptake and protein synthesis',
                dosing: 'Variable - basal: 0.2-0.4 units/kg/day. Bolus: carbohydrate counting. Sliding scale for acute illness',
                contraindications: 'Hypoglycaemia. Caution in renal/hepatic impairment',
                interactions: 'β-blockers (mask hypoglycaemia), steroids (↑ requirements), alcohol (↑ hypoglycaemia)',
                monitoring: 'Blood glucose, HbA1c, injection sites, weight, hypoglycaemia awareness',
                pregnancy: 'Safe - insulin of choice in pregnancy. Requirements increase',
                sideEffects: 'Hypoglycaemia, lipodystrophy, weight gain, local reactions',
                pharmacokinetics: 'Rapid-acting: onset 15min. Long-acting: 1-2h onset, 24h duration',
                clinicalPearls: 'Rotate injection sites. Store in fridge. Multiple types: rapid, short, intermediate, long-acting',
                indication: 'Type 1 diabetes, type 2 diabetes (various indications), diabetic ketoacidosis'
            },
            'ipratropium': {
                name: 'Ipratropium',
                class: 'Short-acting muscarinic antagonist (SAMA)',
                mechanism: 'Competitive antagonist of muscarinic receptors in bronchial smooth muscle',
                dosing: 'MDI: 40mcg QDS. Nebuliser: 250-500mcg QDS. Acute exacerbation: 500mcg nebulised',
                contraindications: 'Hypersensitivity to atropine or derivatives',
                interactions: 'Other anticholinergics (↑ anticholinergic effects)',
                monitoring: 'Bronchodilator response, anticholinergic side effects, eye symptoms',
                pregnancy: 'Safe - minimal systemic absorption',
                sideEffects: 'Dry mouth, cough, headache, paradoxical bronchospasm (rare)',
                pharmacokinetics: 'Minimal systemic absorption, onset: 15min, duration: 3-6h',
                clinicalPearls: 'Additive effect with beta-2 agonists. Avoid contact with eyes (glaucoma risk)',
                indication: 'COPD, severe asthma (add-on therapy), acute exacerbations'
            },
            'ketamine': {
                name: 'Ketamine',
                class: 'Dissociative Anaesthetic/Analgesic',
                mechanism: 'NMDA receptor antagonist causing dissociative anaesthesia and analgesia',
                dosing: 'Anaesthesia: 1-2mg/kg IV, 4-6mg/kg IM. Analgesia: 0.1-0.3mg/kg IV. Depression: 0.5mg/kg',
                contraindications: 'Severe hypertension, raised ICP, psychotic disorders, porphyria',
                interactions: 'CNS depressants, sympathomimetics (↑ hypertension), theophylline',
                monitoring: 'Blood pressure, heart rate, respiratory rate, emergence reactions',
                pregnancy: 'Use only if benefit outweighs risk; consult UKTIS or SmPC as needed',
                sideEffects: 'Emergence reactions, hallucinations, hypertension, tachycardia, laryngospasm',
                pharmacokinetics: 'Rapid onset 1-2min IV. t½ 2-3h. Hepatic metabolism to active metabolites',
                clinicalPearls: 'Maintains airway reflexes. Good for unstable patients. Pre-treat with benzodiazepine',
                indication: 'Emergency anaesthesia, procedural sedation, severe asthma, treatment-resistant depression'
            },
            'lactulose': {
                name: 'Lactulose',
                class: 'Osmotic laxative',
                mechanism: 'Non-absorbable disaccharide, osmotically active, acidifies colon reducing ammonia absorption',
                dosing: 'Adults: 15ml BD initially, adjust to 1-2 soft stools daily. Hepatic encephalopathy: 30-50ml TDS',
                contraindications: 'Galactosaemia, intestinal obstruction, fructose intolerance',
                interactions: 'No significant drug interactions',
                monitoring: 'Stool frequency/consistency, electrolyte balance, dehydration risk',
                pregnancy: 'Generally considered compatible in pregnancy; minimal systemic absorption',
                sideEffects: 'Flatulence, abdominal cramps, nausea, electrolyte disturbance (overdose)',
                pharmacokinetics: 'Not absorbed in small intestine, fermented by colonic bacteria',
                clinicalPearls: 'Safe in pregnancy and elderly. Takes 2-3 days for full effect. Sweet taste',
                indication: 'Constipation, hepatic encephalopathy, preparation for procedures'
            },
            'lansoprazole': {
                name: 'Lansoprazole',
                class: 'Proton pump inhibitor (PPI)',
                mechanism: 'Irreversibly inhibits gastric H+/K+-ATPase (proton pump)',
                dosing: 'GORD: 30mg daily. Peptic ulcer: 30mg daily for 4-8 weeks. H.pylori: 30mg BD with antibiotics',
                contraindications: 'Hypersensitivity to PPIs',
                interactions: 'Similar to omeprazole - clopidogrel, warfarin, digoxin',
                monitoring: 'Similar to omeprazole - B12, magnesium with long-term use',
                pregnancy: 'Generally safe - no increased malformation risk',
                sideEffects: 'Similar to omeprazole - headache, GI upset, long-term risks',
                pharmacokinetics: 'Enteric-coated, acid-labile, hepatic metabolism',
                clinicalPearls: 'Alternative to omeprazole. Take before food. Orodispersible tablets available',
                indication: 'GORD, peptic ulcer disease, H.pylori eradication, Zollinger-Ellison syndrome'
            },
            'levodopa': {
                name: 'Levodopa/Carbidopa (Co-careldopa)',
                class: 'Dopaminergic drug for Parkinson\'s disease',
                mechanism: 'Levodopa converted to dopamine in brain; carbidopa prevents peripheral conversion',
                dosing: 'Start 62.5mg (50mg levodopa + 12.5mg carbidopa) TDS, increase gradually',
                contraindications: 'Narrow-angle glaucoma, melanoma, MAOIs',
                interactions: 'MAOIs (hypertensive crisis), antipsychotics (antagonism), iron (↓ absorption)',
                monitoring: 'Motor symptoms, dyskinesias, psychiatric symptoms, blood pressure',
                pregnancy: 'Use only if essential - limited safety data',
                sideEffects: 'Nausea, dyskinesias, psychiatric symptoms, postural hypotension',
                pharmacokinetics: 'Short half-life: 1-3h, extensive first-pass metabolism',
                clinicalPearls: 'Take 30min before food. Wearing-off effects develop over time. Protein meals reduce absorption',
                indication: 'Parkinson\'s disease, restless legs syndrome'
            },
            'levonorgestrel': {
                name: 'Levonorgestrel',
                class: 'Synthetic progestogen',
                mechanism: 'Progesterone receptor agonist, prevents/delays ovulation and affects endometrium',
                dosing: 'Emergency contraception: 1.5mg STAT (within 72h). IUS: 52mg over 5 years',
                contraindications: 'Pregnancy, severe liver disease, undiagnosed vaginal bleeding',
                interactions: 'Enzyme inducers (↓ efficacy - may need higher dose), ritonavir',
                monitoring: 'Pregnancy test if period late, BP with IUS, bleeding patterns',
                pregnancy: 'Contraindicated - stop if pregnancy occurs',
                sideEffects: 'Nausea, headache, breast tenderness, irregular bleeding, mood changes',
                pharmacokinetics: 'Rapid absorption, half-life: 24-32h, hepatic metabolism',
                clinicalPearls: 'Most effective within 12h of unprotected intercourse. Available OTC as emergency contraception',
                indication: 'Emergency contraception, long-term contraception (IUS), menorrhagia'
            },
            'levothyroxine': {
                name: 'Levothyroxine',
                class: 'Thyroid hormones',
                mechanism: 'Synthetic L-thyroxine (T4) hormone, converted to active T3 in peripheral tissues',
                dosing: 'Adults <50yrs: 1.6micrograms/kg daily. >50yrs or cardiac disease: 25-50micrograms daily, increase by 25-50micrograms every 3-4 weeks',
                contraindications: 'Untreated adrenal insufficiency, acute myocardial infarction, thyrotoxicosis',
                interactions: 'Iron/calcium (take 4h apart), warfarin (↑ anticoagulant effect), carbamazepine (↑ metabolism)',
                monitoring: 'TSH every 6-8 weeks until stable, then annually. Free T4 if pituitary disease suspected',
                pregnancy: 'Safe - essential in pregnancy. Increase dose by 25-50micrograms. Monitor TSH each trimester',
                sideEffects: 'Over-replacement: palpitations, insomnia, tremor, weight loss, heat intolerance, AF, osteoporosis',
                pharmacokinetics: 'Peak: 2-4h, Half-life: 7 days, Steady state: 6-8 weeks',
                clinicalPearls: 'Take on empty stomach 30-60min before breakfast. Consistent brand/timing. TSH target 0.5-2.5mU/L',
                indication: 'Primary hypothyroidism, secondary hypothyroidism, thyroid cancer (TSH suppression)'
            },
            'lidocaine': {
                name: 'Lidocaine',
                class: 'Local anaesthetic (amide type)',
                mechanism: 'Blocks voltage-gated sodium channels, preventing nerve conduction',
                dosing: 'Local infiltration: max 4.5mg/kg (7mg/kg with adrenaline). Topical: 2-5% preparations',
                contraindications: 'Heart block, severe cardiac failure, hypersensitivity to amides',
                interactions: 'Beta-blockers (↑ toxicity), cimetidine (↑ levels), class I antiarrhythmics',
                monitoring: 'Signs of systemic toxicity, cardiac rhythm (IV use)',
                pregnancy: 'Safe for local use - does not cross placenta significantly',
                sideEffects: 'Local: burning, swelling. Systemic: CNS toxicity, cardiac arrhythmias',
                pharmacokinetics: 'Rapid onset: 2-5min, duration: 1-3h, hepatic metabolism',
                clinicalPearls: 'Most common local anaesthetic. Adrenaline prolongs duration. IV form for arrhythmias',
                indication: 'Local anaesthesia, topical anaesthesia, ventricular arrhythmias (IV)'
            },
            'lithium': {
                name: 'Lithium carbonate',
                class: 'Mood stabiliser',
                mechanism: 'Unclear - affects neurotransmitter function and cellular signalling',
                dosing: 'Start 200-400mg daily, target level 0.6-1.0mmol/L for maintenance, 0.8-1.2mmol/L acute',
                contraindications: 'Severe renal/cardiac disease, Addison\'s disease, dehydration, pregnancy (1st trimester)',
                interactions: 'Diuretics (↑ toxicity), ACE inhibitors (↑ levels), NSAIDs (↑ levels), theophylline (↓ levels)',
                monitoring: 'Lithium levels weekly until stable, then 3-monthly. TFTs, U&Es, weight',
                pregnancy: 'Avoid 1st trimester (Ebstein\'s anomaly). Use with caution thereafter',
                sideEffects: 'Tremor, polyuria, weight gain, hypothyroidism, nephrotoxicity, teratogenicity',
                pharmacokinetics: 'Narrow therapeutic window, renal excretion, half-life: 12-27h',
                clinicalPearls: 'Regular level monitoring essential. Toxicity >1.5mmol/L. Maintain good hydration',
                indication: 'Bipolar disorder (acute treatment and prophylaxis), treatment-resistant depression'
            },
            'loperamide': {
                name: 'Loperamide',
                class: 'Opioid antidiarrhoeal agent',
                mechanism: 'Mu-opioid receptor agonist in GI tract, slows intestinal motility',
                dosing: 'Adults: 4mg initially, then 2mg after each loose stool (max 16mg daily). Children >4 years: weight-based dosing',
                contraindications: 'Acute dysentery, acute ulcerative colitis, bacterial enterocolitis, children <4 years',
                interactions: 'P-glycoprotein inhibitors (↑ CNS effects), quinidine, ritonavir',
                monitoring: 'Stool frequency, abdominal pain, signs of toxic megacolon',
                pregnancy: 'Safe - limited systemic absorption, no increased malformation risk',
                sideEffects: 'Constipation, abdominal cramps, drowsiness, dry mouth, nausea',
                pharmacokinetics: 'Poor oral absorption, minimal CNS penetration, Half-life: 10-14h',
                clinicalPearls: 'Available OTC (max 2 days). Does not cross blood-brain barrier at therapeutic doses',
                indication: 'Acute diarrhoea, chronic diarrhoea, IBS with diarrhoea'
            },
            'loratadine': {
                name: 'Loratadine',
                class: 'Second-generation antihistamine (H1 antagonist)',
                mechanism: 'Selective peripheral H1 receptor antagonist, minimal CNS and anticholinergic effects',
                dosing: 'Adults: 10mg daily. Children 2-12 years: 5mg daily (<30kg) or 10mg daily (>30kg)',
                contraindications: 'Hypersensitivity to loratadine, severe hepatic impairment',
                interactions: 'CYP3A4 inhibitors (ketoconazole, erythromycin) may ↑ levels but no clinical significance',
                monitoring: 'Sedation level, effectiveness for allergic symptoms',
                pregnancy: 'Generally considered compatible in pregnancy; preferred antihistamine in many cases, see UKTIS',
                sideEffects: 'Headache, drowsiness (3%), dry mouth, fatigue, nervousness',
                pharmacokinetics: 'Rapidly absorbed, Half-life: 8h (active metabolite 28h), hepatic metabolism',
                clinicalPearls: 'Non-sedating antihistamine. Once daily dosing. Available OTC. No dose adjustment in renal disease',
                indication: 'Allergic rhinitis, chronic idiopathic urticaria, allergic skin conditions'
            },
            'lorazepam': {
                name: 'Lorazepam',
                class: 'Short-acting benzodiazepine',
                mechanism: 'Enhances GABA-A receptor activity, increasing neuronal inhibition',
                dosing: 'Anxiety: 1-4mg daily in divided doses. Status epilepticus: 4mg IV slowly',
                contraindications: 'Respiratory depression, severe hepatic impairment, myasthenia gravis',
                interactions: 'Alcohol (↑ sedation), opioids (respiratory depression), phenytoin',
                monitoring: 'Respiratory function, sedation level, signs of dependence',
                pregnancy: 'Avoid - risk of floppy baby syndrome, neonatal withdrawal',
                sideEffects: 'Sedation, confusion (elderly), dependence, respiratory depression',
                pharmacokinetics: 'Intermediate half-life: 10-20h, conjugated (safer in elderly)',
                clinicalPearls: 'Shorter-acting than diazepam. Less affected by hepatic impairment. High dependence risk',
                indication: 'Short-term anxiety, status epilepticus, premedication'
            },
            'losartan': {
                name: 'Losartan',
                class: 'Angiotensin receptor blockers',
                mechanism: 'Selective antagonist of angiotensin II at AT1 receptors',
                dosing: 'Hypertension: Start 50mg daily, max 100mg daily. Heart failure: Start 12.5mg daily, target 150mg daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, severe renal impairment',
                interactions: 'NSAIDs (↓ efficacy), potassium supplements (hyperkalemia), lithium (↑ levels)',
                monitoring: 'eGFR, potassium, blood pressure. Check 1-2 weeks after starting',
                pregnancy: 'Contraindicated - teratogenic in 2nd/3rd trimester',
                sideEffects: 'Dizziness, hyperkalemia, dry cough (less than ACE-I), angioedema (rare)',
                pharmacokinetics: 'Prodrug, active metabolite half-life: 6-9h, hepatic metabolism',
                clinicalPearls: 'Alternative to ACE inhibitor if cough. Less cough than ACE-I but more expensive',
                indication: 'Hypertension, heart failure, diabetic nephropathy, post-MI (ACE-I intolerant)'
            },
            'magnesium-sulfate': {
                name: 'Magnesium Sulfate',
                class: 'Mineral supplement/Antiarrhythmic',
                mechanism: 'Essential cofactor for enzymes, membrane stabilizer, calcium channel blocker',
                dosing: 'Hypomagnesemia: 8mmol IV over 24h. Torsades: 8mmol IV over 10-15min. Eclampsia: 4g IV then 1g/h',
                contraindications: 'Severe renal impairment, myasthenia gravis, heart block',
                interactions: 'Digoxin (↓ efficacy), neuromuscular blockers (↑ paralysis), calcium channel blockers',
                monitoring: 'Serum magnesium, reflexes, respiratory rate, urine output, renal function',
                pregnancy: 'Safe and indicated for eclampsia/pre-eclampsia. Standard treatment',
                sideEffects: 'Hypotension, respiratory depression, areflexia, cardiac arrest (overdose)',
                pharmacokinetics: 'Onset 1-5min IV. Excreted unchanged by kidneys. t½ 3-4h',
                clinicalPearls: 'Check reflexes before each dose. Have calcium gluconate ready as antidote',
                indication: 'Eclampsia, torsades de pointes, hypomagnesemia, severe asthma'
            },
            'meropenem': {
                name: 'Meropenem',
                class: 'Antibiotic (Carbapenem)',
                mechanism: 'Inhibits bacterial cell wall synthesis, stable to most beta-lactamases',
                dosing: 'Adult: 0.5-1g TDS IV. Severe infections/meningitis: 2g TDS. Infuse over 15-30min',
                contraindications: 'Carbapenem allergy, severe penicillin allergy (cross-reactivity)',
                interactions: 'Probenecid (↑ levels), valproate (↓ seizure threshold), ganciclovir',
                monitoring: 'Renal function, seizure activity, infection resolution, C.diff surveillance',
                pregnancy: 'Generally considered compatible where benefits outweigh risks; consult UKTIS/SmPC',
                sideEffects: 'Diarrhea, nausea, headache, seizures (high dose/renal impairment), C.diff',
                pharmacokinetics: 'Excellent tissue penetration including CSF. t½ 1h. 70% renal excretion',
                clinicalPearls: 'Broad spectrum including ESBL producers. Lower seizure risk than imipenem',
                indication: 'Severe sepsis, complicated UTI, intra-abdominal infections, meningitis'
            },
            'metformin': {
                name: 'Metformin',
                class: 'Metformin',
                mechanism: 'Decreases hepatic glucose production, improves peripheral insulin sensitivity, ↓ intestinal glucose absorption',
                dosing: 'Standard-release: Start 500mg BD with meals, increase weekly. Max 1g BD. Modified-release: Start 500mg OD, max 2g OD',
                contraindications: 'eGFR <30, acute conditions with tissue hypoxia, severe heart failure, alcohol dependence',
                interactions: 'Iodinated contrast media (stop 48h before), alcohol (↑ lactic acidosis risk), diuretics (dehydration risk)',
                monitoring: 'HbA1c every 3-6 months, eGFR annually (6-monthly if ≥45), vitamin B12 annually',
                pregnancy: 'Safe - may be used in gestational diabetes and PCOS',
                sideEffects: 'GI upset (30%), diarrhoea, metallic taste, vitamin B12 deficiency, lactic acidosis (very rare)',
                pharmacokinetics: 'Peak: 2-3h, Half-life: 6h, No metabolism, Excretion: renal unchanged',
                clinicalPearls: 'First-line T2DM in UK. Weight neutral/modest loss. Cardiovascular benefits. Take with food to ↓ GI effects',
                efficacy: 'HbA1c reduction: 11-22mmol/mol (1-2%). Does not cause hypoglycaemia as monotherapy'
            },
            'methotrexate': {
                name: 'Methotrexate',
                class: 'Methotrexate',
                mechanism: 'Inhibits dihydrofolate reductase, interfering with folate metabolism',
                dosing: 'Rheumatoid arthritis: 7.5-25mg weekly. Always prescribe folic acid 5mg weekly (day after MTX)',
                contraindications: 'Pregnancy, breastfeeding, severe renal/hepatic impairment, immunodeficiency',
                interactions: 'NSAIDs (↑ toxicity), trimethoprim (↑ toxicity), PPIs (↑ levels)',
                monitoring: 'FBC, LFTs, U&Es weekly initially, then monthly. CXR annually',
                pregnancy: 'Contraindicated - teratogenic and abortifacient',
                sideEffects: 'Bone marrow suppression, hepatotoxicity, pulmonary fibrosis, mucositis',
                pharmacokinetics: 'Variable absorption, renal excretion, polyglutamate forms accumulate',
                clinicalPearls: 'Always prescribe with folic acid. Stop if infection/illness. DMARD monitoring essential',
                indication: 'Rheumatoid arthritis, psoriasis, cancer (various), ectopic pregnancy'
            },
            'metoclopramide': {
                name: 'Metoclopramide',
                class: 'Antiemetic/Prokinetic (Dopamine antagonist)',
                mechanism: 'Blocks dopamine D2 receptors in CTZ and enhances GI motility',
                dosing: 'Adult: 10mg TDS PO/IV/IM. Max 5 days treatment. Reduce dose in elderly/renal impairment',
                contraindications: 'GI obstruction, perforation, pheochromocytoma, prolactinoma, Parkinson\'s disease',
                interactions: 'Dopamine agonists (antagonism), CNS depressants, digoxin (↑ absorption)',
                monitoring: 'Neurological symptoms (tardive dyskinesia), cardiac conduction, renal function',
                pregnancy: 'Generally considered compatible and commonly used for hyperemesis gravidarum; consult UKTIS as required',
                sideEffects: 'Extrapyramidal effects, tardive dyskinesia, drowsiness, depression, galactorrhea',
                pharmacokinetics: 'Onset 30min PO, 10min IV. t½ 4-6h. Hepatic metabolism, renal excretion',
                clinicalPearls: 'Limit to 5 days to reduce tardive dyskinesia risk. Give procyclidine for dystonia',
                indication: 'Nausea/vomiting, gastroparesis, migraine-associated nausea, postoperative nausea'
            },
            'metronidazole': {
                name: 'Metronidazole',
                class: 'Metronidazole',
                mechanism: 'Disrupts DNA synthesis in anaerobic bacteria and protozoa',
                dosing: 'Oral: 400mg TDS for 5-7 days. IV: 500mg TDS. C.diff: 400mg TDS for 10-14 days',
                contraindications: 'Hypersensitivity, first trimester pregnancy, disulfiram reaction with alcohol',
                interactions: 'Warfarin (↑ INR), alcohol (disulfiram-like reaction), lithium (↑ levels)',
                monitoring: 'Signs of peripheral neuropathy with prolonged use, avoid alcohol',
                pregnancy: 'Avoid in first trimester. Use with caution thereafter',
                sideEffects: 'Metallic taste, nausea, disulfiram reaction with alcohol, peripheral neuropathy (prolonged use)',
                pharmacokinetics: 'Well absorbed orally, CSF penetration, hepatic metabolism',
                clinicalPearls: 'Excellent anaerobic cover. Avoid alcohol during and 48h after treatment. Turns urine dark',
                indication: 'Anaerobic infections, C.difficile colitis, H.pylori eradication, bacterial vaginosis'
            },
            'midazolam': {
                name: 'Midazolam',
                class: 'Benzodiazepine/Sedative',
                mechanism: 'GABA-A receptor agonist causing CNS depression and amnesia',
                dosing: 'Conscious sedation: 1-2.5mg IV slowly. Anaesthesia: 0.15-0.3mg/kg IV. Seizures: 0.2mg/kg IV/IM',
                contraindications: 'Severe respiratory depression, acute narrow-angle glaucoma, myasthenia gravis',
                interactions: 'CNS depressants (↑ sedation), CYP3A4 inhibitors (↑ levels), alcohol',
                monitoring: 'Respiratory rate, oxygen saturation, blood pressure, level of consciousness',
                pregnancy: 'Avoid in pregnancy where possible; if exposure occurs seek specialist/UKTIS advice regarding neonatal withdrawal and risks',
                sideEffects: 'Respiratory depression, hypotension, amnesia, paradoxical agitation',
                pharmacokinetics: 'Rapid onset 2-5min IV. t½ 1-4h. Hepatic metabolism (CYP3A4)',
                clinicalPearls: 'Flumazenil antidote available. Titrate slowly. Have airway management ready',
                indication: 'Conscious sedation, premedication, status epilepticus, ICU sedation'
            },
            'mirtazapine': {
                name: 'Mirtazapine',
                class: 'Noradrenergic and specific serotonergic antidepressant (NaSSA)',
                mechanism: 'Blocks α2-adrenergic autoreceptors and 5-HT2/5-HT3 receptors, enhancing noradrenaline and serotonin',
                dosing: 'Adults: Start 15mg at night, increase after 1-2 weeks to 30mg, max 45mg daily',
                contraindications: 'MAOIs, mania, severe hepatic impairment',
                interactions: 'MAOIs, warfarin, alcohol (↑ sedation), tramadol',
                monitoring: 'FBC (especially first few months), weight, mood, sedation level',
                pregnancy: 'Use if benefit outweighs risk - limited safety data',
                sideEffects: 'Sedation (dose-related), weight gain, dry mouth, constipation, blood dyscrasias (rare)',
                pharmacokinetics: 'Half-life: 20-40h, hepatic metabolism',
                clinicalPearls: 'Paradoxical effect: more sedating at lower doses. Good for depression with insomnia/weight loss',
                indication: 'Depression (especially with anxiety, insomnia, or weight loss)'
            },
            'montelukast': {
                name: 'Montelukast',
                class: 'Leukotriene receptor antagonist',
                mechanism: 'Selective antagonist of cysteinyl leukotriene (CysLT1) receptors',
                dosing: 'Adults: 10mg daily at bedtime. Children 6-14 years: 5mg daily. Children 2-5 years: 4mg daily',
                contraindications: 'Hypersensitivity to montelukast, acute asthma attacks',
                interactions: 'CYP2C8 inducers (rifampicin) may ↓ levels. CYP2C8/2C9 interactions possible',
                monitoring: 'Asthma control, mood changes, neuropsychiatric symptoms, liver function',
                pregnancy: 'Generally considered compatible; continue if clinically required and consult UKTIS for specific drug guidance',
                sideEffects: 'Headache, GI upset, neuropsychiatric effects (mood changes, sleep disturbances)',
                pharmacokinetics: 'Rapid absorption, Half-life: 3-6h, extensive hepatic metabolism',
                clinicalPearls: 'Add-on therapy in asthma step 3. Take at bedtime. Monitor for mood changes',
                indication: 'Asthma prophylaxis, allergic rhinitis, exercise-induced bronchospasm'
            },
            'morphine': {
                name: 'Morphine',
                class: 'Opioid analgesic',
                mechanism: 'Mu-opioid receptor agonist in CNS and peripheral tissues',
                dosing: 'Oral: 5-10mg 4-hourly PRN. IV: 2.5-10mg slowly. MST: 10-30mg BD (opioid-naive)',
                contraindications: 'Respiratory depression, acute abdomen, severe asthma, raised ICP',
                interactions: 'Alcohol/sedatives (↑ sedation), MAOIs (avoid), gabapentinoids (↑ sedation)',
                monitoring: 'Respiratory rate, sedation level, bowel function, pain scores',
                pregnancy: 'Use with caution - neonatal withdrawal syndrome possible',
                sideEffects: 'Respiratory depression, sedation, nausea, constipation, euphoria, dependence',
                pharmacokinetics: 'Oral bioavailability: 30%, Half-life: 2-4h, hepatic metabolism',
                clinicalPearls: 'Always prescribe laxatives. Start low in elderly/renal impairment. Naloxone reverses effects',
                indication: 'Severe pain, acute MI, acute pulmonary oedema, palliative care'
            },
            'naloxone': {
                name: 'Naloxone',
                class: 'Opioid antagonist',
                mechanism: 'Competitive antagonist at mu-opioid receptors, reversing opioid effects',
                dosing: 'IV: 400mcg-2mg, repeat every 2-3min. IM: 400mcg. Infusion: 4mcg/kg/h',
                contraindications: 'Hypersensitivity. Caution in opioid-dependent patients (withdrawal)',
                interactions: 'Reverses all opioid effects including analgesia',
                monitoring: 'Respiratory rate, consciousness level, blood pressure, pain levels',
                pregnancy: 'Safe - no evidence of harm',
                sideEffects: 'Opioid withdrawal syndrome, hypertension, arrhythmias, pulmonary oedema',
                pharmacokinetics: 'Rapid onset: 1-2min IV, Duration: 30-60min (shorter than many opioids)',
                clinicalPearls: 'Shorter duration than most opioids - may need repeat doses. Titrate to respiratory rate',
                indication: 'Opioid overdose, reversal of opioid-induced respiratory depression'
            },
            'naproxen': {
                name: 'Naproxen',
                class: 'Non-steroidal anti-inflammatory drug (NSAID)',
                mechanism: 'Non-selective COX inhibitor with longer half-life than other NSAIDs',
                dosing: 'Adults: 250-500mg BD with food. Acute pain: 500mg initially, then 250mg TDS',
                contraindications: 'Active peptic ulceration, severe heart failure, severe renal/hepatic impairment',
                interactions: 'ACE inhibitors (↓ effect), warfarin (↑ bleeding), lithium (↑ toxicity)',
                monitoring: 'Renal function, blood pressure, signs of GI bleeding, cardiovascular events',
                pregnancy: 'Avoid in 3rd trimester. Use lowest dose for shortest time if essential',
                sideEffects: 'GI bleeding, cardiovascular events, renal impairment, fluid retention',
                pharmacokinetics: 'Good oral absorption, Half-life: 12-15h, hepatic metabolism',
                clinicalPearls: 'Longer half-life allows BD dosing. Lower GI toxicity than some NSAIDs',
                indication: 'Inflammatory conditions, musculoskeletal pain, dysmenorrhoea, acute gout'
            },
            'nitrofurantoin': {
                name: 'Nitrofurantoin',
                class: 'Nitrofurantoin',
                mechanism: 'Inhibits bacterial enzymes involved in carbohydrate metabolism',
                dosing: 'UTI treatment: 100mg BD for 3 days (women) or 7 days (men). Prophylaxis: 50-100mg at night',
                contraindications: 'eGFR <45ml/min/1.73mÂ², pregnancy at term, G6PD deficiency, acute porphyria',
                interactions: 'Magnesium salts (↓ absorption), probenecid (↑ toxicity)',
                monitoring: 'Renal function, LFTs, signs of pulmonary toxicity (chronic use)',
                pregnancy: 'Safe except at term (risk of neonatal haemolysis)',
                sideEffects: 'GI upset, pulmonary toxicity (chronic use), peripheral neuropathy, hepatotoxicity',
                pharmacokinetics: 'Rapidly absorbed, concentrated in urine, Half-life: 20min',
                clinicalPearls: 'Excellent for uncomplicated UTI. Take with food. Avoid if eGFR <45. Urine may turn brown',
                indication: 'UTI treatment and prophylaxis. Not effective for pyelonephritis'
            },
            'noradrenaline': {
                name: 'Noradrenaline',
                class: 'Sympathomimetic (Alpha/Beta agonist)',
                mechanism: 'Potent α1 and moderate β1 agonist causing vasoconstriction and increased contractility',
                dosing: 'IV infusion: 0.01-3mcg/kg/min via central line. Titrate to MAP >65mmHg',
                contraindications: 'Hypovolemia (relative), pregnancy (unless life-threatening), peripheral vascular disease',
                interactions: 'TCAs (↑ pressor response), MAOIs (↑ hypertensive crisis), halothane (arrhythmias)',
                monitoring: 'Blood pressure, heart rate, urine output, peripheral perfusion, ECG',
                pregnancy: 'Avoid unless life-threatening. May reduce uterine blood flow',
                sideEffects: 'Hypertension, arrhythmias, peripheral ischemia, tissue necrosis (extravasation)',
                pharmacokinetics: 'IV only. Onset immediate, duration 1-2min after stopping. Metabolized by COMT/MAO',
                clinicalPearls: 'First-line vasopressor in septic shock. Give via central line. Have phentolamine ready',
                indication: 'Septic shock, cardiogenic shock, severe hypotension, cardiac arrest'
            },
            'olanzapine': {
                name: 'Olanzapine',
                class: 'Antipsychotics, second-generation (atypical)',
                mechanism: 'Dopamine D2, serotonin 5-HT2A receptor antagonist with multiple receptor activity',
                dosing: 'Schizophrenia: Start 10mg daily, range 5-20mg. Bipolar: 15mg daily, adjust 5-20mg',
                contraindications: 'Comatose states, severe CNS depression',
                interactions: 'Alcohol (↑ sedation), carbamazepine (↓ olanzapine levels), smoking (↓ levels)',
                monitoring: 'Weight, glucose, lipids, prolactin, FBC, LFTs, movement disorders',
                pregnancy: 'Use only if essential - risk of extrapyramidal symptoms in neonate',
                sideEffects: 'Weight gain, diabetes, dyslipidaemia, sedation, extrapyramidal effects (less than typical)',
                pharmacokinetics: 'Half-life: 30h, hepatic metabolism, smoking increases clearance',
                clinicalPearls: 'Lower EPS risk than haloperidol but significant metabolic effects. Regular monitoring essential',
                indication: 'Schizophrenia, bipolar disorder (acute mania), treatment-resistant depression'
            },
            'omeprazole': {
                name: 'Omeprazole',
                class: 'Proton pump inhibitor (PPI)',
                mechanism: 'Irreversibly inhibits gastric H+/K+-ATPase (proton pump)',
                dosing: 'GORD: 20mg daily. Peptic ulcer: 20-40mg daily. H.pylori: 20mg BD with antibiotics',
                contraindications: 'Hypersensitivity to PPIs',
                interactions: 'Clopidogrel (↓ efficacy), warfarin (↑ INR), digoxin (↑ levels)',
                monitoring: 'Vitamin B12, magnesium with long-term use. Review need regularly',
                pregnancy: 'Generally safe - limited human data',
                sideEffects: 'Headache, GI upset, increased infection risk, hypomagnesaemia (long-term)',
                pharmacokinetics: 'Onset: 1h, Peak: 2h, Duration: 72h, CYP2C19 metabolism',
                clinicalPearls: 'First PPI available OTC in UK. Take 30min before food',
                indication: 'GORD, peptic ulcer disease, H.pylori eradication'
            },
            'ondansetron': {
                name: 'Ondansetron',
                class: 'Antiemetic (5-HT3 antagonist)',
                mechanism: 'Selective antagonist of 5-HT3 receptors in CTZ and vagal afferents',
                dosing: 'Adult: 4-8mg TDS PO/IV/IM. Chemotherapy: 8mg pre-chemo then 8mg BD. Max 32mg/day',
                contraindications: 'Congenital long QT syndrome, severe hepatic impairment',
                interactions: 'QT-prolonging drugs, apomorphine (severe hypotension), rifampicin (↓ efficacy)',
                monitoring: 'QT interval (especially IV), constipation, liver function',
                pregnancy: 'Generally considered compatible where benefits outweigh risks; check UKTIS/SmPC as needed',
                sideEffects: 'Constipation, headache, QT prolongation, hypersensitivity reactions',
                pharmacokinetics: 'Good oral bioavailability. t½ 3-6h. Hepatic metabolism (CYP3A4)',
                clinicalPearls: 'Most effective for chemotherapy-induced nausea. Check QT with IV use',
                indication: 'Chemotherapy-induced nausea, postoperative nausea, radiotherapy nausea'
            },
            'pantoprazole': {
                name: 'Pantoprazole',
                class: 'Proton Pump Inhibitor',
                mechanism: 'Irreversibly inhibits gastric H+/K+-ATPase (proton pump)',
                dosing: 'Adult: 40mg daily PO/IV. Severe GORD: 40mg BD. Zollinger-Ellison: up to 240mg daily',
                contraindications: 'Hypersensitivity to PPIs, severe liver disease',
                interactions: 'Clopidogrel (↓ efficacy), digoxin (↑ levels), ketoconazole (↓ absorption)',
                monitoring: 'Magnesium levels (long-term), B12 levels, bone density, C.diff risk',
                pregnancy: 'Generally considered compatible where clinically necessary; consult UKTIS',
                sideEffects: 'Headache, diarrhea, hypomagnesemia, increased fracture risk, C.diff',
                pharmacokinetics: 'Onset 2-3 days for full effect. t½ 1h. Hepatic metabolism (CYP2C19)',
                clinicalPearls: 'IV formulation available. Less drug interactions than omeprazole',
                indication: 'GORD, peptic ulcer disease, H.pylori eradication, stress ulcer prophylaxis'
            },
            'paracetamol': {
                name: 'Paracetamol',
                class: 'Paracetamol',
                mechanism: 'Inhibits COX enzymes centrally, affects prostaglandin synthesis in hypothalamus',
                dosing: 'Adults: 500mg-1g every 4-6 hours (max 4g/24h). Children: 15mg/kg every 4-6 hours (max 60mg/kg/24h)',
                contraindications: 'Severe hepatic impairment, hypersensitivity to paracetamol',
                interactions: 'Warfarin (↑ INR with regular use), carbamazepine (↑ hepatotoxicity risk), chronic alcohol (↑ hepatotoxicity)',
                monitoring: 'Liver function with prolonged use, paracetamol levels in overdose',
                pregnancy: 'Safe - preferred analgesic and antipyretic in pregnancy',
                sideEffects: 'Hepatotoxicity (overdose), very rarely serious skin reactions (SJS/TEN)',
                pharmacokinetics: 'Onset: 30min, Peak: 1h, Half-life: 2h, Metabolism: hepatic conjugation',
                clinicalPearls: 'First-line analgesic in UK. No anti-inflammatory effect. Overdose antidote: N-acetylcysteine. Safe in asthma',
                indication: 'Pain relief, fever reduction. Safe alternative to NSAIDs'
            },
            'phenytoin': {
                name: 'Phenytoin',
                class: 'Antiepileptic drug',
                mechanism: 'Blocks voltage-gated sodium channels, stabilizing neuronal membranes',
                dosing: 'Loading: 15-20mg/kg IV slowly. Maintenance: 300-400mg daily (adjust to levels)',
                contraindications: 'Heart block, sinus bradycardia, porphyria',
                interactions: 'Warfarin (variable), carbamazepine (↓ levels), numerous others',
                monitoring: 'Phenytoin levels (10-20mg/L), LFTs, FBC, folate, gum hyperplasia',
                pregnancy: 'Teratogenic - folate supplementation essential',
                sideEffects: 'Gum hyperplasia, hirsutism, acne, ataxia, nystagmus, confusion',
                pharmacokinetics: 'Zero-order kinetics at therapeutic doses, highly protein-bound',
                clinicalPearls: 'Narrow therapeutic window. Many drug interactions. IV administration requires cardiac monitoring',
                indication: 'Epilepsy, status epilepticus, trigeminal neuralgia'
            },
            'piperacillin-tazobactam': {
                name: 'Piperacillin-Tazobactam',
                class: 'Antibiotic (Penicillin/Beta-lactamase inhibitor)',
                mechanism: 'Piperacillin inhibits cell wall synthesis; tazobactam inhibits beta-lactamases',
                dosing: 'Adult: 4.5g TDS IV over 30min. Severe infections: 4.5g QDS. Adjust for renal function',
                contraindications: 'Penicillin allergy, severe beta-lactam allergy',
                interactions: 'Probenecid (↑ levels), aminoglycosides (inactivation), warfarin (↑ INR)',
                monitoring: 'Renal function, infection resolution, allergic reactions, C.diff surveillance',
                pregnancy: 'Generally considered compatible when clinically indicated; consult UKTIS/SmPC',
                sideEffects: 'Diarrhea, rash, phlebitis, electrolyte disturbances, C.diff colitis',
                pharmacokinetics: 'Good tissue penetration. t½ 1h. 80% renal excretion unchanged',
                clinicalPearls: 'Broad spectrum anti-pseudomonal. Common empirical choice for sepsis',
                indication: 'Hospital-acquired pneumonia, complicated UTI, sepsis, neutropenic fever'
            },
            'prednisolone': {
                name: 'Prednisolone',
                class: 'Corticosteroid (glucocorticoid)',
                mechanism: 'Synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects',
                dosing: 'Acute: 30-60mg daily, then taper. Maintenance: 5-15mg daily. Always taper gradually',
                contraindications: 'Systemic infection (unless life-threatening), live vaccines',
                interactions: 'Warfarin (variable effect), NSAIDs (↑ GI bleeding), vaccines (↓ response)',
                monitoring: 'Blood glucose, blood pressure, bone density, growth (children)',
                pregnancy: 'Use if essential - may cause cleft palate (first trimester)',
                sideEffects: 'Weight gain, mood changes, osteoporosis, diabetes, increased infection risk',
                pharmacokinetics: 'Half-life: 12-36h, oral bioavailability: 70%',
                clinicalPearls: 'Never stop abruptly. Take with food. Consider bone protection',
                indication: 'Asthma, COPD exacerbation, inflammatory conditions'
            },
            'pregabalin': {
                name: 'Pregabalin',
                class: 'Gabapentinoids',
                mechanism: 'Binds to voltage-gated calcium channels reducing excitatory neurotransmitter release',
                dosing: 'Neuropathic pain: Start 75mg BD, titrate to 150-300mg BD. Epilepsy: 150-600mg daily',
                contraindications: 'Hypersensitivity to pregabalin, galactose intolerance',
                interactions: 'CNS depressants (↑ sedation), ACE inhibitors (↑ angioedema risk)',
                monitoring: 'Renal function, weight gain, mood changes, visual disturbances',
                pregnancy: 'Avoid in pregnancy unless specialist advice indicates otherwise; check UKTIS/SmPC for details',
                sideEffects: 'Sedation, dizziness, weight gain, peripheral edema, blurred vision',
                pharmacokinetics: 'Good oral absorption. t½ 6h. 90% renal excretion unchanged',
                clinicalPearls: 'Effective for neuropathic pain. Controlled drug. Gradual withdrawal needed',
                indication: 'Neuropathic pain, epilepsy, generalized anxiety disorder, fibromyalgia'
            },
            'prochlorperazine': {
                name: 'Prochlorperazine',
                class: 'Antiemetic/Antipsychotic (Phenothiazine)',
                mechanism: 'Blocks dopamine D2 receptors in CTZ and has anticholinergic effects',
                dosing: 'Adult: 5-10mg TDS PO, 12.5mg IM, 25mg PR. Vertigo: 5mg TDS for 2 days then 5mg BD',
                contraindications: 'CNS depression, bone marrow depression, pheochromocytoma, young children',
                interactions: 'CNS depressants, anticholinergics, lithium (↑ extrapyramidal effects)',
                monitoring: 'Extrapyramidal symptoms, blood counts, hepatic function, cardiac conduction',
                pregnancy: 'Use only if maternal benefit outweighs fetal risk; consider specialist/UKTIS advice due to potential neonatal extrapyramidal effects',
                sideEffects: 'Extrapyramidal effects, sedation, anticholinergic effects, tardive dyskinesia',
                pharmacokinetics: 'Good oral absorption. t½ 23h. Extensive hepatic metabolism',
                clinicalPearls: 'Effective for vertigo and labyrinthitis. Avoid in Parkinson\'s disease',
                indication: 'Nausea/vomiting, vertigo, migraine, schizophrenia (higher doses)'
            },
            'propofol': {
                name: 'Propofol',
                class: 'General Anaesthetic (Phenolic compound)',
                mechanism: 'GABA-A receptor agonist causing rapid onset anaesthesia',
                dosing: 'Induction: 1.5-2.5mg/kg IV. Maintenance: 4-12mg/kg/h IV. ICU sedation: 0.3-4mg/kg/h',
                contraindications: 'Egg/soy allergy, children <16 years (prolonged use), severe cardiac failure',
                interactions: 'CNS depressants (↑ effect), NO drug interactions metabolically',
                monitoring: 'Blood pressure, respiratory rate, depth of anaesthesia, lipid levels (prolonged use)',
                pregnancy: 'Use in pregnancy only if essential and after considering maternal and fetal risks; consult obstetric/anesthetic guidance',
                sideEffects: 'Hypotension, respiratory depression, injection pain, propofol infusion syndrome',
                pharmacokinetics: 'Rapid onset 40s, offset 5-10min. t½ 1-3h. Hepatic and extrahepatic metabolism',
                clinicalPearls: 'Painful injection - use lidocaine. Quick recovery. Risk of PRIS with prolonged use',
                indication: 'General anaesthesia induction/maintenance, ICU sedation, procedural sedation'
            },
            'quinine': {
                name: 'Quinine',
                class: 'Quinine',
                mechanism: 'Interferes with parasitic DNA replication, affects calcium distribution in muscle',
                dosing: 'Malaria: 600mg TDS for 7 days. Cramps: 200-300mg at bedtime (unlicensed)',
                contraindications: 'Optic neuritis, tinnitus, myasthenia gravis, G6PD deficiency',
                interactions: 'Warfarin (↑ INR), digoxin (↑ levels), mefloquine (↑ seizure risk)',
                monitoring: 'Hearing, vision, blood glucose, cardiac rhythm, signs of cinchonism',
                pregnancy: 'Use with caution - may cause thrombocytopenia in neonate',
                sideEffects: 'Cinchonism (tinnitus, headache, nausea), hypoglycaemia, arrhythmias',
                pharmacokinetics: 'Half-life: 18h in malaria (shorter in healthy), hepatic metabolism',
                clinicalPearls: 'Unlicensed use for nocturnal cramps. Monitor for cinchonism. Resistance common',
                indication: 'Complicated malaria, nocturnal leg cramps (second-line)'
            },
            'ramipril': {
                name: 'Ramipril',
                class: 'Angiotensin-converting enzyme (ACE) inhibitors',
                mechanism: 'Inhibits ACE, preventing conversion of angiotensin I to II, reducing aldosterone secretion',
                dosing: 'Hypertension: Start 1.25-2.5mg daily, usual 2.5-5mg daily, max 10mg daily. Heart failure: Start 1.25mg daily, target 10mg daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, angioedema history, hyperkalaemia >5.5mmol/L',
                interactions: 'NSAIDs (↓ antihypertensive effect, ↑ nephrotoxicity), potassium supplements (hyperkalaemia), lithium (↑ levels)',
                monitoring: 'eGFR and potassium baseline, 1-2 weeks after starting/dose change, then annually',
                pregnancy: 'Contraindicated - teratogenic (oligohydramnios, IUGR, renal dysgenesis)',
                sideEffects: 'Dry cough (10-15%), hyperkalaemia, acute kidney injury, angioedema (rare), hypotension',
                pharmacokinetics: 'Prodrug activated hepatically, Half-life: 13-17h, Excretion: renal and biliary',
                clinicalPearls: 'Most commonly prescribed ACE inhibitor in UK. Renoprotective in diabetes. Stop immediately if pregnant',
                indication: 'Hypertension, heart failure, post-MI, diabetic nephropathy, primary prevention in high CV risk'
            },
            'ranitidine': {
                name: 'Ranitidine',
                class: 'H2-receptor antagonist',
                mechanism: 'Competitive antagonist of histamine H2-receptors in gastric parietal cells',
                dosing: 'GORD: 150mg BD or 300mg at night. Peptic ulcer: 300mg at night. Acute: 50mg IV TDS',
                contraindications: 'Hypersensitivity, porphyria',
                interactions: 'Warfarin (may ↑ INR), ketoconazole (↓ absorption), atazanavir',
                monitoring: 'Symptom relief, signs of gastric malignancy (prolonged use)',
                pregnancy: 'Safe - no evidence of harm',
                sideEffects: 'Generally well tolerated, headache, dizziness, GI upset, confusion (elderly)',
                pharmacokinetics: 'Well absorbed, half-life: 2-3h, renal and hepatic elimination',
                clinicalPearls: 'Less effective than PPIs. Withdrawn in many countries due to NDMA contamination concerns',
                indication: 'GORD, peptic ulcer disease, stress ulcer prophylaxis'
            },
            'rivaroxaban': {
                name: 'Rivaroxaban',
                class: 'Direct oral anticoagulant (DOAC) - Factor Xa inhibitor',
                mechanism: 'Direct, selective inhibition of factor Xa in coagulation cascade',
                dosing: 'AF: 20mg daily with food. PE/DVT: 15mg BD for 3 weeks, then 20mg daily',
                contraindications: 'Active bleeding, severe renal impairment (CrCl <15ml/min), pregnancy',
                interactions: 'Strong CYP3A4 inhibitors (↑ levels), warfarin (↑ bleeding), NSAIDs (↑ bleeding)',
                monitoring: 'Renal function, signs of bleeding. No routine INR monitoring needed',
                pregnancy: 'Contraindicated - crosses placenta',
                sideEffects: 'Bleeding (major/minor), anaemia, nausea, elevated LFTs',
                pharmacokinetics: 'Peak: 2-4h, Half-life: 5-9h (longer in elderly), renal excretion 66%',
                clinicalPearls: 'Take with food to improve absorption. No antidote available (andexanet alfa limited availability)',
                indication: 'Atrial fibrillation, VTE treatment/prophylaxis, post-orthopedic surgery prophylaxis'
            },
            'salbutamol': {
                name: 'Salbutamol',
                class: 'Short-acting β2-agonist (SABA)',
                mechanism: 'Selective β2-adrenoreceptor agonist causing bronchodilation',
                dosing: 'Inhaler: 100-200mcg PRN, max 800mcg daily. Nebuliser: 2.5-5mg QDS',
                contraindications: 'Hypersensitivity. Caution in cardiovascular disease',
                interactions: 'β-blockers (antagonistic), digoxin (hypokalaemia), diuretics',
                monitoring: 'Peak flow, symptoms, heart rate, potassium (high doses)',
                pregnancy: 'Safe - drug of choice in pregnancy',
                sideEffects: 'Tremor, palpitations, headache, hypokalaemia (high doses)',
                pharmacokinetics: 'Inhaled onset: 5min, Duration: 3-5h',
                clinicalPearls: 'Blue inhaler. If using >3x/week, need preventer. Use spacer',
                indication: 'Asthma, COPD, hyperkalaemia (nebulised)'
            },
            'salmeterol': {
                name: 'Salmeterol',
                class: 'Long-acting β2-agonist (LABA)',
                mechanism: 'Selective β2-adrenoreceptor agonist with 12-hour duration of action',
                dosing: 'Adults: 25-50mcg BD via inhaler. Always used with inhaled corticosteroid',
                contraindications: 'Hypersensitivity. Never use as monotherapy in asthma',
                interactions: 'β-blockers (antagonism), diuretics (hypokalaemia), theophylline',
                monitoring: 'Peak flow, asthma control, signs of paradoxical bronchospasm',
                pregnancy: 'Safe - no evidence of harm',
                sideEffects: 'Tremor, palpitations, headache, paradoxical bronchospasm',
                pharmacokinetics: 'Onset: 10-20min, Peak: 3-4h, Duration: 12h',
                clinicalPearls: 'Always combined with ICS. Not for acute relief. Green accuhaler common in UK',
                indication: 'Asthma (step 3+ therapy with ICS), COPD (combination inhalers)'
            },
            'senna': {
                name: 'Senna',
                class: 'Stimulant laxative',
                mechanism: 'Anthraquinone glycosides stimulate colonic peristalsis and inhibit water/electrolyte absorption',
                dosing: 'Adults: 7.5-15mg at bedtime (sennosides). Children >6 years: 3.75-7.5mg at bedtime',
                contraindications: 'Intestinal obstruction, inflammatory bowel disease, severe dehydration, appendicitis',
                interactions: 'Cardiac glycosides (hypokalaemia ↑ toxicity), thiazide diuretics',
                monitoring: 'Bowel movements, electrolyte balance with prolonged use, dependency',
                pregnancy: 'Generally considered compatible in pregnancy; consult UKTIS if exposure occurs',
                sideEffects: 'Abdominal cramps, hypokalaemia, melanosis coli (prolonged use), dependency',
                pharmacokinetics: 'Prodrug activated by colonic bacteria, onset 8-12h',
                clinicalPearls: 'Most widely used stimulant laxative in UK. Avoid prolonged use >1 week',
                indication: 'Constipation, bowel preparation, opioid-induced constipation'
            },
            'sertraline': {
                name: 'Sertraline',
                class: 'Selective serotonin reuptake inhibitor (SSRI)',
                mechanism: 'Potent and selective inhibition of serotonin reuptake',
                dosing: 'Adults: Start 50mg daily, can increase by 50mg increments weekly, max 200mg daily. Take with food',
                contraindications: 'MAOIs, unstable epilepsy, mania',
                interactions: 'MAOIs, warfarin (↑ bleeding risk), NSAIDs, tramadol',
                monitoring: 'Mood, suicide risk (especially <25 years), bleeding if on anticoagulants',
                pregnancy: 'Preferred SSRI in pregnancy - lowest risk profile',
                sideEffects: 'Nausea, diarrhoea, insomnia, sexual dysfunction, tremor, dry mouth',
                pharmacokinetics: 'Half-life: 26h, extensive first-pass metabolism',
                clinicalPearls: 'NICE first-line SSRI choice. Take with food to ↓ GI upset. Lower drug interaction potential',
                indication: 'Depression, panic disorder, OCD, PTSD, social anxiety disorder'
            },
            'sildenafil': {
                name: 'Sildenafil',
                class: 'Phosphodiesterase type 5 inhibitor',
                mechanism: 'Inhibits PDE5, increasing cGMP levels and causing smooth muscle relaxation',
                dosing: 'Erectile dysfunction: 50mg 1h before sexual activity. Pulmonary hypertension: 20mg TDS',
                contraindications: 'Nitrates, recent MI/stroke, severe hypotension, hereditary retinal disorders',
                interactions: 'Nitrates (severe hypotension), alpha-blockers (hypotension), CYP3A4 inhibitors',
                monitoring: 'Blood pressure, vision changes, priapism, cardiovascular status',
                pregnancy: 'Not applicable for ED indication. Limited data for pulmonary hypertension',
                sideEffects: 'Headache, flushing, dyspepsia, visual disturbances, priapism (rare)',
                pharmacokinetics: 'Rapid absorption, peak: 1h, half-life: 4h, hepatic metabolism',
                clinicalPearls: 'Never with nitrates. High-fat meals delay absorption. Seek help if erection >4h',
                indication: 'Erectile dysfunction, pulmonary arterial hypertension'
            },
            'simvastatin': {
                name: 'Simvastatin',
                class: 'Statins',
                mechanism: 'Competitively inhibits HMG-CoA reductase, rate-limiting enzyme in cholesterol synthesis',
                dosing: 'Start 20mg at night, max 80mg daily. Usual maintenance: 20-40mg daily',
                contraindications: 'Active liver disease, pregnancy, breastfeeding',
                interactions: 'Amlodipine (max simvastatin 20mg), clarithromycin (rhabdomyolysis risk), grapefruit juice',
                monitoring: 'LFTs at baseline and 3 months, CK if muscle symptoms, lipid profile',
                pregnancy: 'Contraindicated - cholesterol essential for fetal development',
                sideEffects: 'Myalgia, rhabdomyolysis (rare), hepatotoxicity, diabetes risk',
                pharmacokinetics: 'Extensive first-pass metabolism, active metabolites, CYP3A4 substrate',
                clinicalPearls: 'Take at night (cholesterol synthesis peaks). Many drug interactions. Generic statin',
                indication: 'Hypercholesterolaemia, cardiovascular disease prevention'
            },
            'spironolactone': {
                name: 'Spironolactone',
                class: 'Aldosterone antagonists',
                mechanism: 'Competitive antagonist of aldosterone at mineralocorticoid receptors',
                dosing: 'Heart failure: Start 25mg daily, max 50mg daily. Ascites: 100-400mg daily. Monitor K+ closely',
                contraindications: 'Hyperkalaemia (>5.0mmol/L), severe renal impairment, Addison\'s disease',
                interactions: 'ACE inhibitors/ARBs (↑ hyperkalaemia), potassium supplements, trimethoprim',
                monitoring: 'U&Es within 1 week, then monthly for 3 months, then 3-monthly. Gynaecomastia',
                pregnancy: 'Avoid - feminisation of male fetus',
                sideEffects: 'Hyperkalaemia, gynaecomastia, menstrual irregularities, GI upset',
                pharmacokinetics: 'Half-life: 1-2 days (active metabolites), onset of action: 2-3 days',
                clinicalPearls: 'K+-sparing effect. Check K+ before starting and monitor closely. Mortality benefit in heart failure',
                indication: 'Heart failure (with ACE-I + β-blocker), primary hyperaldosteronism, ascites'
            },
            'sumatriptan': {
                name: 'Sumatriptan',
                class: 'Serotonin 5-HT1-receptor agonists (triptans)',
                mechanism: 'Selective 5-HT1B/1D receptor agonist causing vasoconstriction and neuronal inhibition',
                dosing: 'Subcutaneous: 6mg, may repeat after 1h. Oral: 50-100mg, may repeat after 2h. Max 300mg/24h',
                contraindications: 'Ischaemic heart disease, cerebrovascular disease, uncontrolled hypertension',
                interactions: 'MAOIs (avoid), SSRIs (serotonin syndrome risk), ergot alkaloids',
                monitoring: 'Cardiovascular status, blood pressure, frequency of use (medication overuse headache)',
                pregnancy: 'Avoid - limited safety data',
                sideEffects: 'Injection site reactions, chest tightness, dizziness, fatigue, medication overuse headache',
                pharmacokinetics: 'Rapid onset SC: 10-15min, Oral: 30min, half-life: 2h',
                clinicalPearls: 'Most effective when taken early in attack. Limit to 2 days/week to avoid medication overuse',
                indication: 'Acute migraine treatment, cluster headache (subcutaneous)'
            },
            'theophylline': {
                name: 'Theophylline',
                class: 'Methylxanthine bronchodilator',
                mechanism: 'Phosphodiesterase inhibition and adenosine receptor antagonism',
                dosing: 'MR preparation: 200-300mg BD. Adjust to therapeutic levels (10-20mg/L)',
                contraindications: 'Hypersensitivity, porphyria. Caution in cardiovascular disease',
                interactions: 'Ciprofloxacin (↑ levels), carbamazepine (↓ levels), smoking (↓ levels)',
                monitoring: 'Theophylline levels, signs of toxicity, heart rate, seizures',
                pregnancy: 'Use with caution - crosses placenta but appears safe',
                sideEffects: 'Nausea, headache, insomnia, arrhythmias, seizures (toxicity)',
                pharmacokinetics: 'Narrow therapeutic window, hepatic metabolism, wide individual variation',
                clinicalPearls: 'Narrow therapeutic window. Many factors affect levels (smoking, infections, drugs)',
                indication: 'Asthma/COPD (when other treatments inadequate), acute severe asthma'
            },
            'tramadol': {
                name: 'Tramadol',
                class: 'Opioids',
                mechanism: 'Weak mu-opioid agonist + inhibits serotonin/noradrenaline reuptake',
                dosing: 'Immediate release: 50-100mg QDS PRN (max 400mg daily). MR: 100-400mg daily',
                contraindications: 'Epilepsy, head injury, concurrent MAOIs, severe respiratory depression',
                interactions: 'MAOIs (serotonin syndrome), SSRIs (↑ seizure risk), carbamazepine (↓ efficacy)',
                monitoring: 'Seizure risk, respiratory depression, signs of dependence',
                pregnancy: 'Avoid - risk of neonatal withdrawal syndrome',
                sideEffects: 'Nausea, dizziness, seizures, constipation, serotonin syndrome, dependence',
                pharmacokinetics: 'Active metabolite via CYP2D6, half-life: 5-7h',
                clinicalPearls: 'Lower respiratory depression than other opioids. Seizure risk especially with SSRIs',
                indication: 'Moderate pain when paracetamol/NSAIDs insufficient'
            },
            'tranexamic-acid': {
                name: 'Tranexamic Acid',
                class: 'Antifibrinolytic',
                mechanism: 'Lysine analog that inhibits plasminogen activation and plasmin activity',
                dosing: 'Major bleeding: 1g IV over 10min, then 1g over 8h. Trauma: 1g IV then 1g over 8h within 3h',
                contraindications: 'Active thromboembolic disease, history of seizures, subarachnoid hemorrhage',
                interactions: 'Hormonal contraceptives (↑ thrombosis risk), factor IX complex concentrates',
                monitoring: 'Signs of thrombosis, renal function, visual disturbances',
                pregnancy: 'Generally considered compatible and widely used in postpartum haemorrhage; follow local guidance',
                sideEffects: 'Nausea, diarrhea, thrombosis (rare), seizures (high dose), visual disturbances',
                pharmacokinetics: 'Peak 3h PO, 1h IV. 90% excreted unchanged in urine. t½ 2-3h',
                clinicalPearls: 'Most effective within 3h of trauma. Reduces mortality in major bleeding',
                indication: 'Major bleeding, trauma, menorrhagia, hereditary angioedema'
            },
            'trimethoprim': {
                name: 'Trimethoprim',
                class: 'Folate synthesis inhibitor antibiotic',
                mechanism: 'Inhibits bacterial dihydrofolate reductase, preventing folate synthesis',
                dosing: 'UTI: 200mg BD for 3 days (uncomplicated) or 7 days (men/complicated). Prophylaxis: 100mg at night',
                contraindications: 'Folate deficiency, severe renal impairment, blood dyscrasias',
                interactions: 'Warfarin (↑ INR), methotrexate (↑ toxicity), ACE inhibitors (hyperkalaemia)',
                monitoring: 'FBC if prolonged use, U&Es (can cause hyperkalaemia), signs of folate deficiency',
                pregnancy: 'Avoid in first trimester (folate antagonist). Folate supplementation if essential',
                sideEffects: 'GI upset, skin rashes, hyperkalaemia, blood dyscrasias (rare)',
                pharmacokinetics: 'Well absorbed, Half-life: 10h, mainly renal excretion',
                clinicalPearls: 'First-line for uncomplicated UTI in women. Can cause hyperkalaemia especially with ACE-I',
                indication: 'UTI treatment and prophylaxis, pneumocystis pneumonia prophylaxis'
            },
            'vancomycin': {
                name: 'Vancomycin',
                class: 'Glycopeptide antibiotic',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to D-alanyl-D-alanine terminals',
                dosing: 'IV: 15-20mg/kg BD (adjust to levels). Oral: 125mg QDS for C.diff. Target trough 15-20mg/L',
                contraindications: 'Hypersensitivity to glycopeptides',
                interactions: 'Aminoglycosides (↑ nephrotoxicity), loop diuretics (↑ ototoxicity)',
                monitoring: 'Trough levels, renal function, hearing, signs of red man syndrome',
                pregnancy: 'Use if essential - crosses placenta but appears safe',
                sideEffects: 'Red man syndrome, nephrotoxicity, ototoxicity, thrombophlebitis',
                pharmacokinetics: 'Poor oral absorption (for systemic use), renal excretion, half-life: 6h',
                clinicalPearls: 'MRSA first-line. Slow IV infusion to prevent red man syndrome. TDM essential',
                indication: 'MRSA infections, serious Gram-positive infections, C.difficile colitis (oral)'
            },
            'warfarin': {
                name: 'Warfarin',
                class: 'Warfarin',
                mechanism: 'Inhibits vitamin K epoxide reductase, preventing synthesis of factors II, VII, IX, X',
                dosing: 'Start 5-10mg daily (3mg if elderly/liver disease). Adjust based on INR. Target INR 2.0-3.0 (2.5-3.5 for mechanical valves)',
                contraindications: 'Active bleeding, pregnancy (except mechanical heart valves), severe hepatic disease',
                interactions: 'Numerous: antibiotics, NSAIDs, amiodarone, alcohol. Check BNF interaction checker',
                monitoring: 'INR: daily until stable, then weekly, then up to 12-weekly when stable',
                pregnancy: 'Teratogenic - avoid except mechanical valves (use LMWH periconception)',
                sideEffects: 'Bleeding (major risk), skin necrosis (rare), purple toe syndrome (rare)',
                pharmacokinetics: 'Onset: 36-72h, Half-life: 36-42h, CYP2C9 metabolism',
                clinicalPearls: 'Take same time daily. Avoid vitamin K-rich foods in large amounts. Reversal: vitamin K ± PCC',
                indication: 'AF, VTE, mechanical heart valves. Being replaced by DOACs where appropriate'
            },
            'zopiclone': {
                name: 'Zopiclone',
                class: 'Z-drug (non-benzodiazepine hypnotic)',
                mechanism: 'Selective GABA-A receptor modulator at benzodiazepine binding site',
                dosing: 'Adults: 7.5mg at bedtime. Elderly: 3.75mg. Max 4 weeks treatment',
                contraindications: 'Severe respiratory insufficiency, myasthenia gravis, severe hepatic impairment',
                interactions: 'Alcohol (↑ sedation), opioids (respiratory depression), CYP3A4 inhibitors',
                monitoring: 'Sleep quality, daytime drowsiness, signs of dependence, memory problems',
                pregnancy: 'Avoid - risk of withdrawal symptoms in neonate',
                sideEffects: 'Metallic taste, daytime drowsiness, dependence, rebound insomnia, amnesia',
                pharmacokinetics: 'Rapid absorption, half-life: 5h, hepatic metabolism',
                clinicalPearls: 'Shorter course than benzodiazepines but still dependence risk. Distinctive metallic taste',
                indication: 'Short-term insomnia (max 4 weeks). Second-line to sleep hygiene measures'
            },
            'sitagliptin': {
                name: 'Sitagliptin',
                class: 'Dipeptidylpeptidase-4 inhibitors',
                mechanism: 'Inhibits DPP-4 enzyme, increasing incretin hormone levels (GLP-1 and GIP)',
                dosing: 'Type 2 diabetes: 100mg daily. Renal impairment: 50mg daily (eGFR 30-50), 25mg daily (eGFR <30)',
                contraindications: 'Type 1 diabetes, diabetic ketoacidosis, hypersensitivity',
                interactions: 'Minimal drug interactions. Digoxin (↑ levels slightly)',
                monitoring: 'HbA1c, renal function, signs of pancreatitis, hypoglycaemia (with other drugs)',
                pregnancy: 'Avoid - limited safety data, insulin preferred',
                sideEffects: 'Headache, URTI, pancreatitis (rare), hypoglycaemia (with insulin/sulfonylureas)',
                pharmacokinetics: 'Good oral absorption, half-life: 12h, mainly renal excretion',
                clinicalPearls: 'Weight neutral. Low hypoglycaemia risk as monotherapy. Good add-on to metformin',
                indication: 'Type 2 diabetes as monotherapy or combination therapy'
            },
            'venlafaxine': {
                name: 'Venlafaxine',
                class: 'Antidepressants, tetracyclic and serotonin-noradrenaline reuptake inhibitors',
                mechanism: 'Inhibits reuptake of serotonin and noradrenaline (SNRI)',
                dosing: 'Depression: Start 75mg daily, usual 150mg daily, max 375mg daily. XL formulation preferred',
                contraindications: 'MAOIs, uncontrolled hypertension, severe hepatic/renal impairment',
                interactions: 'MAOIs (serotonin syndrome), warfarin (↑ bleeding), tramadol (↑ seizure risk)',
                monitoring: 'Blood pressure (dose-related ↑), mood, suicide risk, withdrawal symptoms',
                pregnancy: 'Use if benefit outweighs risk - neonatal complications possible',
                sideEffects: 'Nausea, headache, hypertension (dose-related), withdrawal syndrome, sexual dysfunction',
                pharmacokinetics: 'Half-life: 5h (active metabolite 11h), hepatic metabolism',
                clinicalPearls: 'Monitor BP regularly. Severe withdrawal syndrome - taper slowly. Effective for anxiety',
                indication: 'Depression, generalized anxiety disorder, social anxiety disorder, panic disorder'
            },
            'quetiapine': {
                name: 'Quetiapine',
                class: 'Antipsychotics, second-generation (atypical)',
                mechanism: 'Dopamine D2 and serotonin 5-HT2A receptor antagonist',
                dosing: 'Schizophrenia: Start 25mg BD, increase to 300-450mg daily. Bipolar: 300-800mg daily',
                contraindications: 'Comatose states, severe CNS depression',
                interactions: 'Alcohol (↑ sedation), CYP3A4 inhibitors (↑ levels), phenytoin (↓ levels)',
                monitoring: 'Blood glucose, lipids, weight, prolactin, ECG, movement disorders',
                pregnancy: 'Use only if essential - extrapyramidal symptoms in neonate possible',
                sideEffects: 'Sedation, weight gain, diabetes, postural hypotension, dry mouth, constipation',
                pharmacokinetics: 'Half-life: 6h (XR: 7h), extensive hepatic metabolism',
                clinicalPearls: 'Lower EPS risk than typical antipsychotics. Significant metabolic effects. Take with food',
                indication: 'Schizophrenia, bipolar disorder, adjunctive treatment in depression'
            },
            'glucagon': {
                name: 'Glucagon',
                class: 'Emergency drugs',
                mechanism: 'Hormone that stimulates hepatic glucose production and glycogenolysis',
                dosing: 'Severe hypoglycaemia: 1mg IM/SC/IV. Children <25kg: 0.5mg. May repeat after 10min',
                contraindications: 'Phaeochromocytoma (may cause hypertensive crisis)',
                interactions: 'Warfarin (may ↑ anticoagulant effect)',
                monitoring: 'Blood glucose, consciousness level, blood pressure',
                pregnancy: 'Safe when clinically indicated',
                sideEffects: 'Nausea, vomiting, hypokalaemia, hypotension, allergic reactions',
                pharmacokinetics: 'Onset: 8-10min IM, Duration: 1-2h, hepatic metabolism',
                clinicalPearls: 'Give glucose orally when conscious. Ineffective if glycogen stores depleted. Train family/carers',
                indication: 'Severe hypoglycaemia when IV glucose not possible, diagnostic use'
            },
            'diltiazem': {
                name: 'Diltiazem',
                class: 'Calcium channel blockers',
                mechanism: 'Non-dihydropyridine CCB - blocks L-type calcium channels in heart and vessels',
                dosing: 'Hypertension: 60mg BD or 120mg XL daily. Angina: 60mg TDS or 120-300mg XL daily',
                contraindications: 'Heart block, sick sinus syndrome, severe bradycardia, severe heart failure',
                interactions: 'Beta-blockers (↑ bradycardia), digoxin (↑ levels), simvastatin (↑ levels)',
                monitoring: 'Heart rate, blood pressure, signs of heart failure, liver function',
                pregnancy: 'Avoid unless essential - limited safety data',
                sideEffects: 'Bradycardia, heart block, ankle oedema, constipation, gingival hyperplasia',
                pharmacokinetics: 'Half-life: 3-4h (XL: 6-8h), extensive hepatic metabolism',
                clinicalPearls: 'Rate-limiting CCB. Good for AF rate control. Avoid with beta-blockers',
                indication: 'Hypertension, angina, atrial fibrillation (rate control)'
            },
            'glimepiride': {
                name: 'Glimepiride',
                class: 'Sulfonylureas',
                mechanism: 'Stimulates insulin release from pancreatic β-cells by blocking K-ATP channels',
                dosing: 'Start 1mg daily with breakfast, usual 1-4mg daily, max 6mg daily',
                contraindications: 'Type 1 diabetes, ketoacidosis, severe renal/hepatic impairment',
                interactions: 'Alcohol (↑ hypoglycaemia), β-blockers (mask hypoglycaemia), steroids (↑ glucose)',
                monitoring: 'Blood glucose, HbA1c, weight, signs of hypoglycaemia',
                pregnancy: 'Switch to insulin - crosses placenta',
                sideEffects: 'Hypoglycaemia, weight gain, GI upset, skin reactions, hyponatraemia',
                pharmacokinetics: 'Half-life: 5-8h, hepatic metabolism, renal excretion',
                clinicalPearls: 'Longer acting than gliclazide. Take with breakfast. Lower hypoglycaemia risk than glibenclamide',
                indication: 'Type 2 diabetes (when metformin contraindicated/not tolerated or as add-on)'
            },
            'pioglitazone': {
                name: 'Pioglitazone',
                class: 'Thiazolidinediones',
                mechanism: 'PPAR-γ agonist, improves insulin sensitivity in muscle and adipose tissue',
                dosing: 'Start 15-30mg daily, max 45mg daily. Take with or without food',
                contraindications: 'Heart failure, bladder cancer history, severe hepatic impairment',
                interactions: 'Insulin (↑ hypoglycaemia, fluid retention), gemfibrozil (↑ levels)',
                monitoring: 'Weight, signs of heart failure, liver function, bone density, bladder symptoms',
                pregnancy: 'Avoid - limited safety data, insulin preferred',
                sideEffects: 'Weight gain, fluid retention, heart failure, bone fractures, bladder cancer risk',
                pharmacokinetics: 'Half-life: 3-7h (active metabolites 16-24h), hepatic metabolism',
                clinicalPearls: 'May take 2-3 months for full effect. Monitor for heart failure. Avoid in osteoporosis',
                indication: 'Type 2 diabetes as monotherapy or combination therapy'
            },
            'escitalopram': {
                name: 'Escitalopram',
                class: 'Antidepressants, selective serotonin reuptake inhibitors',
                mechanism: 'Selective inhibition of serotonin reuptake with high selectivity',
                dosing: 'Adults: Start 10mg daily, usual dose 10-20mg daily. Elderly: max 10mg daily',
                contraindications: 'MAOIs, QT prolongation, recent MI',
                interactions: 'MAOIs (serotonin syndrome), drugs prolonging QT interval, warfarin',
                monitoring: 'ECG if cardiac risk factors, mood, suicide risk, sexual function',
                pregnancy: 'Use if benefit outweighs risk - potential neonatal complications',
                sideEffects: 'Nausea, headache, sexual dysfunction, insomnia, QT prolongation',
                pharmacokinetics: 'Half-life: 27-32h, hepatic metabolism via CYP2C19',
                clinicalPearls: 'S-enantiomer of citalopram. Often better tolerated than citalopram. Take any time of day',
                indication: 'Depression, generalized anxiety disorder, panic disorder, social anxiety'
            },
            'tiotropium': {
                name: 'Tiotropium',
                class: 'Antimuscarinics, bronchodilators',
                mechanism: 'Long-acting muscarinic antagonist (LAMA) - blocks M3 receptors in airways',
                dosing: 'COPD: 18mcg daily via HandiHaler or 5mcg daily via Respimat. Take same time each day',
                contraindications: 'Hypersensitivity to atropine derivatives',
                interactions: 'Other anticholinergics (↑ anticholinergic effects)',
                monitoring: 'Lung function, symptoms, anticholinergic side effects, narrow-angle glaucoma',
                pregnancy: 'Use only if benefit outweighs risk - limited safety data',
                sideEffects: 'Dry mouth, constipation, urinary retention, narrow-angle glaucoma, paradoxical bronchospasm',
                pharmacokinetics: 'Long duration of action (24h), minimal systemic absorption',
                clinicalPearls: 'Once daily LAMA for COPD. Different devices deliver different doses. Avoid contact with eyes',
                indication: 'COPD maintenance therapy, add-on to bronchodilators'
            },
            'mesalazine': {
                name: 'Mesalazine',
                class: 'Aminosalicylates',
                mechanism: 'Anti-inflammatory action in gut mucosa, exact mechanism unknown',
                dosing: 'Ulcerative colitis: 1.2-2.4g daily in divided doses. Maintenance: 1.2-1.6g daily',
                contraindications: 'Severe renal impairment, salicylate hypersensitivity',
                interactions: 'Lactulose (↓ release), azathioprine (theoretical ↑ leucopenia)',
                monitoring: 'FBC, U&Es, LFTs before and during treatment. Annual monitoring',
                pregnancy: 'Safe - continue treatment. Folic acid supplementation recommended',
                sideEffects: 'Headache, nausea, rash, blood dyscrasias, nephrotoxicity (rare)',
                pharmacokinetics: 'Topical action in gut, minimal systemic absorption',
                clinicalPearls: 'Take with food. Multiple formulations with different release characteristics',
                indication: 'Ulcerative colitis treatment and maintenance, Crohn\'s disease (limited efficacy)'
            },
            'loperamide': {
                name: 'Loperamide',
                class: 'Antidiarrhoeal drugs',
                mechanism: 'Mu-opioid receptor agonist in GI tract, slows intestinal motility',
                dosing: 'Adults: 4mg initially, then 2mg after each loose stool (max 16mg daily). Children >4 years: weight-based',
                contraindications: 'Acute dysentery, acute ulcerative colitis, bacterial enterocolitis, children <4 years',
                interactions: 'P-glycoprotein inhibitors (↑ CNS effects), quinidine, ritonavir',
                monitoring: 'Stool frequency, abdominal pain, signs of toxic megacolon',
                pregnancy: 'Safe - limited systemic absorption, no increased malformation risk',
                sideEffects: 'Constipation, abdominal cramps, drowsiness, dry mouth, nausea',
                pharmacokinetics: 'Poor oral absorption, minimal CNS penetration, Half-life: 10-14h',
                clinicalPearls: 'Available OTC (max 2 days). Does not cross blood-brain barrier at therapeutic doses',
                indication: 'Acute diarrhoea, chronic diarrhoea, IBS with diarrhoea'
            },
            'topiramate': {
                name: 'Topiramate',
                class: 'Antiepileptic drugs',
                mechanism: 'Multiple mechanisms: blocks sodium channels, enhances GABA, blocks glutamate receptors',
                dosing: 'Epilepsy: Start 25mg BD, increase weekly to 200-400mg daily. Migraine: 25mg daily, increase to 100mg daily',
                contraindications: 'Hypersensitivity, acute narrow-angle glaucoma',
                interactions: 'Carbamazepine (↓ topiramate), oral contraceptives (↓ efficacy), lithium (↑ levels)',
                monitoring: 'Weight, kidney stones, mood changes, cognitive function, visual disturbances',
                pregnancy: 'Avoid - teratogenic risk including cleft palate. Effective contraception essential',
                sideEffects: 'Weight loss, cognitive impairment, kidney stones, acute glaucoma, metabolic acidosis',
                pharmacokinetics: 'Half-life: 20-30h, 80% renal excretion unchanged',
                clinicalPearls: 'Weight loss common (beneficial in some). Cognitive effects dose-related. Slow titration essential',
                indication: 'Epilepsy, migraine prophylaxis, bipolar disorder (unlicensed)'
            },
            'candesartan': {
                name: 'Candesartan',
                class: 'Angiotensin receptor blockers',
                mechanism: 'Selective antagonist of angiotensin II at AT1 receptors',
                dosing: 'Hypertension: Start 8mg daily, usual 8-16mg daily, max 32mg daily. Heart failure: Start 4mg daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, severe renal/hepatic impairment',
                interactions: 'NSAIDs (↓ efficacy), potassium supplements (hyperkalemia), lithium (↑ levels)',
                monitoring: 'eGFR, potassium, blood pressure. Check 1-2 weeks after starting',
                pregnancy: 'Contraindicated - teratogenic in 2nd/3rd trimester',
                sideEffects: 'Dizziness, hyperkalemia, acute kidney injury, angioedema (rare)',
                pharmacokinetics: 'Prodrug, active metabolite half-life: 9h, renal and biliary excretion',
                clinicalPearls: 'Alternative to ACE inhibitor if cough. Often better tolerated than other ARBs',
                indication: 'Hypertension, heart failure, diabetic nephropathy, post-MI'
            },
            'formoterol': {
                name: 'Formoterol',
                class: 'Beta2-agonists',
                mechanism: 'Selective β2-adrenoreceptor agonist with rapid onset and long duration',
                dosing: 'Adults: 12mcg BD via dry powder inhaler. Max 48mcg daily. Always with ICS in asthma',
                contraindications: 'Hypersensitivity. Never use as monotherapy in asthma',
                interactions: 'β-blockers (antagonism), diuretics (hypokalemia), theophylline',
                monitoring: 'Peak flow, asthma control, heart rate, potassium (high doses)',
                pregnancy: 'Safe - no evidence of harm',
                sideEffects: 'Tremor, palpitations, headache, muscle cramps, hypokalemia',
                pharmacokinetics: 'Onset: 1-3min, Duration: 12h, hepatic metabolism',
                clinicalPearls: 'Rapid onset unlike salmeterol. Always combined with ICS. Available in combination inhalers',
                indication: 'Asthma (step 3+ with ICS), COPD (combination inhalers)'
            },
            'budesonide': {
                name: 'Budesonide',
                class: 'Corticosteroids, inhaled',
                mechanism: 'Synthetic glucocorticoid with potent anti-inflammatory effects in airways',
                dosing: 'Adults: 200-800mcg BD inhaled. Children: 100-400mcg BD. Use spacer device',
                contraindications: 'Hypersensitivity. Caution in active pulmonary TB',
                interactions: 'CYP3A4 inhibitors (↑ systemic exposure), minimal with inhaled use',
                monitoring: 'Growth in children, oral candidiasis, signs of systemic effects',
                pregnancy: 'Safe - preferred ICS in pregnancy',
                sideEffects: 'Oral candidiasis, hoarse voice, growth suppression (children, high doses)',
                pharmacokinetics: 'High first-pass metabolism, low systemic bioavailability',
                clinicalPearls: 'High potency ICS. Good safety profile. Rinse mouth after use',
                indication: 'Asthma prophylaxis, COPD (in combination inhalers), Crohn\'s disease (oral)'
            },
            'norethisterone': {
                name: 'Norethisterone',
                class: 'Oestrogens and progestogens',
                mechanism: 'Synthetic progestogen with weak androgenic and estrogenic activity',
                dosing: 'Menorrhagia: 5mg TDS for 10 days. Contraception: 350mcg daily. Endometriosis: 10-15mg daily',
                contraindications: 'Pregnancy, severe liver disease, thromboembolism, breast cancer',
                interactions: 'Enzyme inducers (↓ efficacy), lamotrigine (may ↓ levels)',
                monitoring: 'Breakthrough bleeding, weight, mood, thrombotic risk factors',
                pregnancy: 'Contraindicated - may masculinize female fetus',
                sideEffects: 'Weight gain, mood changes, breakthrough bleeding, acne, androgenic effects',
                pharmacokinetics: 'Well absorbed, hepatic metabolism, half-life: 5-13h',
                clinicalPearls: 'Multiple indications and doses. Weak androgenic effects. Can delay menstruation',
                indication: 'Menorrhagia, endometriosis, contraception (POP), HRT, delayed menstruation'
            },
            'hydroxychloroquine': {
                name: 'Hydroxychloroquine',
                class: 'Disease-modifying antirheumatic drugs',
                mechanism: 'Antimalarial with immunomodulatory effects, exact mechanism in rheumatic disease unknown',
                dosing: 'Rheumatoid arthritis: 200-400mg daily with food. Max 5mg/kg/day based on ideal body weight',
                contraindications: 'Retinal/visual field changes, severe liver disease, porphyria',
                interactions: 'Digoxin (↑ levels), antiepileptics (↓ seizure threshold), QT-prolonging drugs',
                monitoring: 'Annual ophthalmology screening, FBC, liver function, symptoms',
                pregnancy: 'Safe in established rheumatic disease - continue treatment',
                sideEffects: 'Retinopathy (dose/time related), GI upset, skin reactions, cardiomyopathy (rare)',
                pharmacokinetics: 'Long half-life: 1-2 months, extensive tissue distribution',
                clinicalPearls: 'Takes 2-3 months for effect. Retinopathy related to cumulative dose. Generally well tolerated',
                indication: 'Rheumatoid arthritis, SLE, malaria prophylaxis and treatment'
            },
            'phenoxymethylpenicillin': {
                name: 'Phenoxymethylpenicillin (Penicillin V)',
                class: 'Penicillins, narrow-spectrum',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'Adults: 500mg QDS on empty stomach. Children: 62.5-125mg QDS (<1yr), 125-250mg QDS (1-5yrs), 250mg QDS (6-12yrs)',
                contraindications: 'Penicillin allergy, severe renal impairment',
                interactions: 'Methotrexate (↑ toxicity), probenecid (↑ levels), oral contraceptives (↓ efficacy)',
                monitoring: 'Signs of allergic reaction, C. difficile-associated diarrhoea',
                pregnancy: 'Safe - suitable for use in pregnancy',
                sideEffects: 'GI upset, diarrhoea, allergic reactions, CDAD, oral thrush',
                pharmacokinetics: 'Variable oral absorption, best on empty stomach, half-life: 0.5-1h',
                clinicalPearls: 'Oral alternative to benzylpenicillin. Take 1h before or 2h after food. First-line for streptococcal infections',
                coverage: 'Gram-positive: Streptococci, pneumococci. Limited gram-negative cover. No staphylococcal cover',
                indication: 'Streptococcal pharyngitis, pneumococcal infections, rheumatic fever prophylaxis, endocarditis prophylaxis'
            },
            'dihydrocodeine': {
                name: 'Dihydrocodeine',
                class: 'Opioid analgesic',
                mechanism: 'Mu-opioid receptor agonist, weaker than morphine but stronger than codeine',
                dosing: 'Adults: 30mg every 4-6 hours PRN (max 240mg daily). Modified release: 60-120mg BD',
                contraindications: 'Respiratory depression, acute abdomen, severe asthma, paralytic ileus',
                interactions: 'CNS depressants (↑ sedation), MAOIs (avoid), rifampicin (↓ efficacy)',
                monitoring: 'Respiratory rate, sedation level, bowel function, pain scores, signs of dependence',
                pregnancy: 'Use with caution - neonatal withdrawal syndrome possible',
                sideEffects: 'Sedation, constipation, nausea, respiratory depression, dependence, tolerance',
                pharmacokinetics: 'Good oral bioavailability, half-life: 3-4h, hepatic metabolism',
                clinicalPearls: 'Step 2 analgesic (WHO ladder). Always prescribe laxatives. Less euphoric than morphine',
                indication: 'Moderate to severe pain, persistent cough (unlicensed)'
            },
            'flumazenil': {
                name: 'Flumazenil',
                class: 'Benzodiazepine antagonist',
                mechanism: 'Competitive antagonist at benzodiazepine binding site on GABA-A receptor',
                dosing: 'IV: 200mcg over 15 seconds, then 100mcg at 60-second intervals (max 1mg). Infusion: 100-400mcg/h',
                contraindications: 'Mixed overdose with tricyclics, epilepsy on benzodiazepines, chronic benzodiazepine use',
                interactions: 'Can precipitate withdrawal seizures in chronic benzodiazepine users',
                monitoring: 'Consciousness level, respiratory rate, blood pressure, seizure activity, re-sedation',
                pregnancy: 'Use only if clearly indicated - limited safety data',
                sideEffects: 'Anxiety, agitation, seizures (especially in mixed overdose), re-sedation, withdrawal syndrome',
                pharmacokinetics: 'Rapid onset: 1-2min, short duration: 20-50min, hepatic metabolism',
                clinicalPearls: 'Short half-life - may need repeated doses. Risk of seizures in mixed overdose. Monitor for re-sedation',
                indication: 'Benzodiazepine overdose reversal, procedural sedation reversal, hepatic encephalopathy (unlicensed)'
            },
            'atenolol': {
                name: 'Atenolol',
                class: 'Beta-blockers',
                mechanism: 'Selective beta-1 adrenergic receptor antagonist',
                dosing: 'Hypertension: 25-50mg daily. Angina: 50-100mg daily. Post-MI: 50mg BD. Elderly: start 25mg daily',
                contraindications: 'Asthma, severe COPD, cardiogenic shock, severe bradycardia, heart block',
                interactions: 'Calcium channel blockers (↑ bradycardia), insulin (masks hypoglycaemia), NSAIDs (↓ antihypertensive effect)',
                monitoring: 'Heart rate, blood pressure, signs of heart failure, renal function, glucose (diabetics)',
                pregnancy: 'Use with caution - risk of IUGR and neonatal complications',
                sideEffects: 'Bradycardia, hypotension, fatigue, cold extremities, bronchospasm, vivid dreams',
                pharmacokinetics: 'Low lipophilicity, mainly renal excretion, half-life: 6-7h',
                clinicalPearls: 'Less CNS side effects than lipophilic beta-blockers. Reduce dose in renal impairment. Water-soluble',
                indication: 'Hypertension, angina, post-MI, arrhythmias, anxiety (short-term)'
            },
            'carbimazole': {
                name: 'Carbimazole',
                class: 'Antithyroid drugs',
                mechanism: 'Inhibits thyroid peroxidase, blocking iodine organification and thyroid hormone synthesis',
                dosing: 'Initial: 15-40mg daily in divided doses. Maintenance: 5-15mg daily. Titrate according to TFTs',
                contraindications: 'Severe blood disorders, severe liver disease, breast-feeding',
                interactions: 'Warfarin (↓ anticoagulation as thyroid status normalises), digoxin (↓ levels)',
                monitoring: 'TFTs every 4-6 weeks initially, then 2-3 monthly. FBC (especially first 3 months), LFTs',
                pregnancy: 'Use propylthiouracil in first trimester - carbimazole teratogenic',
                sideEffects: 'Rash, arthralgia, agranulocytosis (rare but serious), hepatitis, vasculitis',
                pharmacokinetics: 'Prodrug converted to methimazole, half-life: 4-6h, crosses placenta',
                clinicalPearls: 'Monitor for sore throat/fever (agranulocytosis). Switch to propylthiouracil in pregnancy. Block-and-replace regimen option',
                indication: 'Hyperthyroidism (Graves disease, toxic multinodular goitre), pre-operative preparation'
            },
            'paroxetine': {
                name: 'Paroxetine',
                class: 'Selective serotonin reuptake inhibitors',
                mechanism: 'Selective inhibition of serotonin reuptake, minimal effect on noradrenaline and dopamine',
                dosing: 'Depression: 20mg daily, max 50mg daily. Panic disorder: 10mg daily initially, usual 40mg daily',
                contraindications: 'MAOIs (within 14 days), pregnancy/breastfeeding, unstable epilepsy',
                interactions: 'MAOIs (serotonin syndrome), warfarin (↑ bleeding), tramadol (serotonin syndrome), tamoxifen (↓ efficacy)',
                monitoring: 'Mood, suicidal ideation (especially <25yrs), weight, sexual function, withdrawal symptoms',
                pregnancy: 'Avoid - increased malformation risk, especially cardiac defects',
                sideEffects: 'Nausea, sexual dysfunction, weight gain, withdrawal syndrome, sweating, tremor',
                pharmacokinetics: 'Short half-life: 24h, extensive hepatic metabolism, highly protein-bound',
                clinicalPearls: 'Most sedating SSRI. Worst withdrawal syndrome - taper slowly. Strong CYP2D6 inhibitor',
                indication: 'Depression, panic disorder, OCD, social anxiety disorder, PTSD'
            },
            'risperidone': {
                name: 'Risperidone',
                class: 'Atypical antipsychotics',
                mechanism: 'Dopamine D2 and serotonin 5-HT2A receptor antagonist',
                dosing: 'Schizophrenia: 2mg daily initially, usual 4-6mg daily. Elderly: 0.5mg BD initially',
                contraindications: 'Coma, CNS depression, phaeochromocytoma, prolactinoma',
                interactions: 'CNS depressants (↑ sedation), carbamazepine (↓ levels), fluoxetine (↑ levels)',
                monitoring: 'Weight, glucose, lipids, prolactin, movement disorders, LFTs, FBC, ECG',
                pregnancy: 'Use only if benefit outweighs risk - risk of extrapyramidal symptoms in neonate',
                sideEffects: 'Extrapyramidal symptoms, hyperprolactinaemia, weight gain, sedation, postural hypotension',
                pharmacokinetics: 'Good oral bioavailability, half-life: 3h (parent), 24h (active metabolite)',
                clinicalPearls: 'Lower risk of metabolic effects than olanzapine. Monitor for tardive dyskinesia. Depot formulation available',
                indication: 'Schizophrenia, bipolar mania, behavioural disturbance in dementia (short-term)'
            },
            'nifedipine': {
                name: 'Nifedipine',
                class: 'Calcium channel blockers',
                mechanism: 'Blocks L-type calcium channels, causing vasodilation and reduced peripheral resistance',
                dosing: 'Hypertension: Modified release 10mg BD or 30mg daily. Max 90mg daily. Angina: 5-20mg TDS (immediate release)',
                contraindications: 'Cardiogenic shock, unstable angina, acute MI, aortic stenosis',
                interactions: 'Beta-blockers (↑ hypotension), digoxin (↑ levels), grapefruit juice (↑ levels)',
                monitoring: 'Blood pressure, heart rate, ankle oedema, signs of heart failure',
                pregnancy: 'Use with caution - may inhibit labour',
                sideEffects: 'Flushing, headache, ankle oedema, gingival hyperplasia, palpitations',
                pharmacokinetics: 'Rapid absorption, extensive first-pass metabolism, half-life: 2-5h (immediate), 7-12h (modified release)',
                clinicalPearls: 'Use modified-release preparations only. Sublingual immediate-release can cause stroke. Peripheral oedema dose-related',
                indication: 'Hypertension, angina, Raynaud phenomenon'
            },
            'sulfasalazine': {
                name: 'Sulfasalazine',
                class: 'Disease-modifying antirheumatic drugs',
                mechanism: 'Cleaved in colon to 5-aminosalicylic acid and sulfapyridine, anti-inflammatory action',
                dosing: 'Rheumatoid arthritis: 500mg daily initially, increase weekly to 2-3g daily in divided doses',
                contraindications: 'Sulfonamide allergy, severe renal/hepatic impairment, porphyria',
                interactions: 'Folate antagonists (↑ toxicity), digoxin (↓ absorption), warfarin (↑ anticoagulation)',
                monitoring: 'FBC (especially first 3 months), LFTs, U&Es, folate levels',
                pregnancy: 'Generally safe - supplement with folate 5mg daily',
                sideEffects: 'GI upset, rash, blood disorders, male infertility (reversible), orange discoloration of urine',
                pharmacokinetics: 'Prodrug, cleaved by colonic bacteria, active metabolites have different kinetics',
                clinicalPearls: 'DMARD with dual action (RA and IBD). Take with food. Supplement folate. Check G6PD deficiency',
                indication: 'Rheumatoid arthritis, ulcerative colitis, Crohn disease'
            },
            'bisacodyl': {
                name: 'Bisacodyl',
                class: 'Stimulant laxatives',
                mechanism: 'Stimulates colonic nerve plexus, increasing peristalsis and secretion',
                dosing: 'Oral: 5-10mg at night. Rectal: 10mg suppository. Max 3 consecutive days',
                contraindications: 'Intestinal obstruction, acute abdomen, severe dehydration, ileus',
                interactions: 'Milk/antacids (enteric coating dissolution), diuretics (↑ electrolyte loss)',
                monitoring: 'Bowel movements, electrolytes (with prolonged use), signs of dependency',
                pregnancy: 'Safe for short-term use',
                sideEffects: 'Abdominal cramps, diarrhoea, electrolyte imbalance, dependency with long-term use',
                pharmacokinetics: 'Enteric-coated tablets, activated in alkaline environment of small intestine',
                clinicalPearls: 'Take tablets whole, avoid milk within 1h. Suppositories work within 30min. Short-term use only',
                indication: 'Constipation, bowel preparation for procedures'
            }
            ,
            'enalapril': {
                name: 'Enalapril',
                class: 'ACE inhibitor',
                mechanism: 'Inhibits angiotensin-converting enzyme, lowering angiotensin II production',
                dosing: 'Start 2.5-5mg once daily in elderly; usual maintenance 5-20mg once daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, history of ACE inhibitor–induced angioedema',
                interactions: 'Potassium supplements/ACEi/ARBs (↑ hyperkalaemia), NSAIDs (↓ effect), lithium (↑ toxicity)',
                monitoring: 'BP, renal function and K+ 1-2 weeks after starting or dose changes',
                pregnancy: 'Contraindicated - fetal toxicity',
                sideEffects: 'Cough, hyperkalaemia, hypotension, dizziness, renal impairment, angioedema',
                pharmacokinetics: 'Prodrug converted to enalaprilat; excreted renally; half-life variable',
                clinicalPearls: 'Start low and titrate, check renal function after initiation. Substitute with ARB if cough occurs',
                indication: 'Hypertension, heart failure, post-MI'
            },
            'levetiracetam': {
                name: 'Levetiracetam',
                class: 'Antiepileptic',
                mechanism: 'Binds to synaptic vesicle protein SV2A, modulating neurotransmitter release',
                dosing: 'Adults: 500-1000mg BD (may increase to 3000mg/day). IV formulations available for acute seizures',
                contraindications: 'Hypersensitivity to levetiracetam',
                interactions: 'Minimal drug interactions (advantageous in polypharmacy)',
                monitoring: 'Renal dose adjustments (check CrCl), mood/behaviour for irritability',
                pregnancy: 'Use with caution; folate recommended pre-conception',
                sideEffects: 'Somnolence, dizziness, behavioural changes, irritability, rarely psychosis',
                pharmacokinetics: 'Renal excretion primarily unchanged; half-life ~6-8h (longer in elderly)',
                clinicalPearls: 'Favourable interaction profile; widely used for acute and chronic seizure control',
                indication: 'Focal and generalized seizures, status epilepticus adjunct'
            },
            'nitroglycerin': {
                name: 'Nitroglycerin (GTN)',
                class: 'Nitrate vasodilator',
                mechanism: 'Releases nitric oxide causing venodilation and coronary artery dilation',
                dosing: 'Sublingual: 400-600mcg (1-2 sprays or tablets) every 5 minutes up to 3 doses. IV infusion titrated in acute coronary syndromes/heart failure',
                contraindications: 'Hypotension, use with PDE5 inhibitors (sildenafil) within 24-48h, severe aortic stenosis',
                interactions: 'PDE5 inhibitors (severe hypotension), antihypertensives (additive hypotension)',
                monitoring: 'BP, heart rate, relief of chest pain, signs of headache or flushing',
                pregnancy: 'Use if clearly indicated; consult obstetrics',
                sideEffects: 'Headache, hypotension, flushing, reflex tachycardia',
                pharmacokinetics: 'Rapid onset sublingual; short half-life; hepatic metabolism for oral/IV forms',
                clinicalPearls: 'Sublingual GTN for acute angina; remove patch at night to reduce tolerance. Avoid with PDE5 inhibitors',
                indication: 'Acute angina, acute pulmonary oedema (IV), myocardial ischaemia'
            },
            'metronidazole': {
                name: 'Metronidazole',
                class: 'Nitroimidazole antibiotic',
                mechanism: 'Prodrug reduced by anaerobic organisms, causing DNA strand breakage',
                dosing: 'Anaerobic infections: 400-500mg TDS PO/IV. C. difficile: 400mg TDS IV (oral vancomycin preferred for severe disease)',
                contraindications: 'First trimester pregnancy (use when benefits outweigh risks), hypersensitivity',
                interactions: 'Alcohol (disulfiram-like reaction), warfarin (↑ INR), lithium (monitor)',
                monitoring: 'Neurological symptoms with prolonged use, LFTs for long courses',
                pregnancy: 'Avoid in first trimester unless necessary; generally considered safe later',
                sideEffects: 'GI upset, metallic taste, headache, peripheral neuropathy with prolonged use',
                pharmacokinetics: 'Well absorbed, hepatic metabolism, half-life ~8h',
                clinicalPearls: 'Avoid alcohol during and for 48h after treatment. Useful for anaerobic infections and certain protozoal infections',
                indication: 'Anaerobic infections, bacterial vaginosis, giardiasis, trichomoniasis'
            },
            'potassium-chloride': {
                name: 'Potassium Chloride (KCl)',
                class: 'Electrolyte replacement',
                mechanism: 'Provides potassium ions to correct hypokalaemia',
                dosing: 'Oral: 600mg (8mmol) BD-TDS or as prescribed. IV: individualised replacement guided by serum K+ (use diluted IV KCl not bolus) ',
                contraindications: 'Hyperkalaemia, severe renal impairment without monitoring, untreated Addison’s disease',
                interactions: 'ACE inhibitors/ARBs/spironolactone (↑ hyperkalaemia risk), trimethoprim, NSAIDs',
                monitoring: 'Serum potassium, renal function, ECG during IV replacement',
                pregnancy: 'Use if required with monitoring',
                sideEffects: 'GI upset, local pain at infusion site, hyperkalaemia if over-replaced',
                pharmacokinetics: 'Rapidly distributed in extracellular fluid; excreted renally',
                clinicalPearls: 'Never give concentrated IV KCl as bolus. Dilute and infuse slowly with cardiac monitoring for significant deficits',
                indication: 'Hypokalaemia replacement and prevention'
            },
            'clindamycin': {
                name: 'Clindamycin',
                class: 'Lincosamide antibiotic',
                mechanism: 'Inhibits 50S ribosomal subunit, preventing bacterial protein synthesis',
                dosing: 'Adults: 300-450mg TDS PO or 600-900mg IV in divided doses depending on infection severity',
                contraindications: 'History of C. difficile colitis associated with prior clindamycin use',
                interactions: 'Neuromuscular blockers (may potentiate blockade), erythromycin (antagonism)',
                monitoring: 'GI symptoms, signs of C. difficile infection, LFTs for prolonged therapy',
                pregnancy: 'Generally considered safe in pregnancy when needed',
                sideEffects: 'Diarrhoea, risk of C. difficile, rash, metallic taste',
                pharmacokinetics: 'Good tissue penetration including bone; hepatic metabolism',
                clinicalPearls: 'Good for skin/soft tissue infections and anaerobic coverage when beta-lactams cannot be used',
                indication: 'Skin/soft tissue infections, anaerobic infections, aspiration pneumonia (in combination)'
            }
            ,
            'cefuroxime': {
                name: 'Cefuroxime',
                class: 'Second-generation cephalosporin',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'IV: 750mg-1.5g BD depending on infection severity. PO (axetil): 250-500mg BD',
                contraindications: 'Severe β-lactam allergy',
                interactions: 'May affect warfarin (monitor INR), probenecid (↑ levels)',
                monitoring: 'Renal function for dose adjustment, signs of hypersensitivity',
                pregnancy: 'Generally considered safe in pregnancy when indicated',
                sideEffects: 'GI upset, rash, allergic reactions, C. difficile-associated diarrhoea',
                pharmacokinetics: 'Good oral absorption (axetil prodrug), renal excretion',
                clinicalPearls: 'Good for respiratory tract infections and some soft tissue infections; check local susceptibility',
                indication: 'Respiratory tract infections, pyelonephritis (IV), skin/soft tissue infections'
            },
            'dalteparin': {
                name: 'Dalteparin',
                class: 'Low molecular weight heparin (LMWH)',
                mechanism: 'Enhances antithrombin-mediated inhibition of factor Xa',
                dosing: 'Prophylaxis: 2500-5000 units SC once daily. Treatment dosing weight-based (e.g., 200 units/kg daily or 100 units/kg BD)',
                contraindications: 'Active bleeding, severe thrombocytopenia, history of heparin-induced thrombocytopenia (HIT)',
                interactions: 'Antiplatelet agents (↑ bleeding), other anticoagulants',
                monitoring: 'Platelet count (for HIT), renal function, signs of bleeding',
                pregnancy: 'Preferred anticoagulant in pregnancy when anticoagulation needed',
                sideEffects: 'Bleeding, injection site reactions, thrombocytopenia (rare), hyperkalaemia',
                pharmacokinetics: 'SC absorption with predictable dose-response; renal excretion',
                clinicalPearls: 'Use dose adjustment for renal impairment and obesity. Monitor anti-Xa in special populations',
                indication: 'VTE prophylaxis and treatment, bridging for high-risk patients'
            },
            'celecoxib': {
                name: 'Celecoxib',
                class: 'COX-2 selective NSAID',
                mechanism: 'Selective inhibition of cyclooxygenase-2 enzyme, reducing prostaglandin synthesis',
                dosing: '200mg once daily or 100mg BD depending on indication',
                contraindications: 'Established cardiovascular disease (caution), active peptic ulcer disease, severe renal impairment',
                interactions: 'Warfarin (↑ bleeding), ACEi/ARBs (↓ efficacy), lithium (↑ levels)',
                monitoring: 'Renal function, BP, signs of GI bleeding',
                pregnancy: 'Avoid in late pregnancy (risk of premature closure of ductus arteriosus)',
                sideEffects: 'GI upset, increased cardiovascular risk, renal impairment, hypertension',
                pharmacokinetics: 'Oral absorption, hepatic metabolism CYP2C9, half-life ~11h',
                clinicalPearls: 'Lower GI risk than non-selective NSAIDs but may increase CV risk. Use lowest effective dose for the shortest duration',
                indication: 'Osteoarthritis, acute pain where NSAID indicated and GI risk a concern'
            },
            'ketorolac': {
                name: 'Ketorolac',
                class: 'Non-selective NSAID',
                mechanism: 'Inhibits COX-1 and COX-2, reducing prostaglandin synthesis',
                dosing: 'IV/IM: 10-30mg single doses as required. PO: 10mg then 10mg every 4-6h (max 40mg/day) for short-term use',
                contraindications: 'Active peptic ulcer, significant renal impairment, bleeding diathesis, recent major surgery (esp. CABG)',
                interactions: 'Anticoagulants/antiplatelets (↑ bleeding), ACEi/ARBs (↓ efficacy)',
                monitoring: 'Renal function, signs of bleeding, pain relief',
                pregnancy: 'Avoid in late pregnancy; use caution earlier',
                sideEffects: 'GI bleeding, renal impairment, increased bleeding risk, bronchospasm in aspirin-sensitive asthma',
                pharmacokinetics: 'Good analgesic potency; short-term use only to limit adverse effects',
                clinicalPearls: 'Powerful analgesic for short-term use (≤5 days). Avoid with other NSAIDs and in renal impairment',
                indication: 'Moderate to severe acute pain (short-term postoperative pain)'
            },
            'moxifloxacin': {
                name: 'Moxifloxacin',
                class: 'Fluoroquinolone antibiotic',
                mechanism: 'Inhibits bacterial DNA gyrase and topoisomerase IV',
                dosing: '400mg once daily PO/IV',
                contraindications: 'Tendon disorders related to fluoroquinolones, pregnancy (avoid unless necessary), prolonged QT',
                interactions: 'Drugs that prolong QT (macrolides, some antipsychotics), antacids (↓ absorption)',
                monitoring: 'QT interval for at-risk patients, hepatic function in prolonged use',
                pregnancy: 'Generally avoided unless benefit outweighs risk',
                sideEffects: 'Tendonitis/tendon rupture, QT prolongation, nausea, CNS effects (confusion, hallucinations)',
                pharmacokinetics: 'Good tissue penetration, hepatic metabolism and renal excretion',
                clinicalPearls: 'Reserve for specific indications due to safety concerns and rising resistance',
                indication: 'Certain respiratory and intra-abdominal infections where indicated'
            },
            'oxytocin': {
                name: 'Oxytocin',
                class: 'Uterotonic',
                mechanism: 'Stimulates uterine smooth muscle contraction via oxytocin receptors',
                dosing: 'IV infusion titrated for labour induction/augmentation; IM 10 units for postpartum haemorrhage',
                contraindications: 'Uterine rupture risk, foetal distress when vaginal birth not advisable',
                interactions: 'Vasoconstrictors and ergometrine (use caution), tocolytics (antagonistic)',
                monitoring: 'Continuous CTG during labour, uterine tone, maternal vital signs',
                pregnancy: 'Used during labour and postpartum under obstetric supervision',
                sideEffects: 'Uterine hyperstimulation, hypotension, water retention with prolonged high-dose infusion',
                pharmacokinetics: 'Rapid onset; short half-life',
                clinicalPearls: 'Use with careful monitoring in labour wards and for PPH management',
                indication: 'Labour induction/augmentation, postpartum haemorrhage'
            },
            'clotrimazole': {
                name: 'Clotrimazole',
                class: 'Azole antifungal (topical)',
                mechanism: 'Inhibits ergosterol synthesis by blocking fungal CYP450 enzymes',
                dosing: 'Topical cream/ointment/vaginal pessary dosing varies by preparation; follow product instructions',
                contraindications: 'Hypersensitivity to imidazoles',
                interactions: 'Minimal for topical use; systemic formulations have more interactions (CYP450)',
                monitoring: 'Local skin reactions',
                pregnancy: 'Topical use generally considered safe in pregnancy for vulvovaginal candidiasis',
                sideEffects: 'Local irritation, burning, rash',
                pharmacokinetics: 'Poor systemic absorption when used topically',
                clinicalPearls: 'Useful topical antifungal; choose formulation based on site of infection',
                indication: 'Vaginal thrush, cutaneous fungal infections'
            }
            ,
            'linezolid': {
                name: 'Linezolid',
                class: 'Oxazolidinone antibiotic',
                mechanism: 'Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit and preventing formation of the initiation complex',
                dosing: 'Adults: 600mg IV/PO every 12 hours (usual duration depends on infection)',
                contraindications: 'Concurrent or recent (within 2 weeks) MAOI use, uncontrolled hypertension, untreated peripheral neuropathy',
                interactions: 'SSRIs/SNRIs/TCAs (risk of serotonin syndrome), tyramine-rich foods (hypertensive reactions), MAOIs',
                monitoring: 'Full blood count (weekly if >2 weeks), signs of neuropathy, blood pressure if hypertensive',
                pregnancy: 'Use only if clearly needed - limited data',
                sideEffects: 'Myelosuppression (thrombocytopenia, anaemia), peripheral and optic neuropathy with prolonged use, lactic acidosis (rare)',
                pharmacokinetics: 'Good oral bioavailability (~100%), wide tissue distribution, hepatic metabolism to inactive metabolites',
                clinicalPearls: 'Reserve for resistant Gram-positive infections including MRSA and VRE where appropriate. Limit duration where possible and monitor blood counts',
                indication: 'Serious Gram-positive infections including MRSA, VRE, complicated skin and soft tissue infections, some pneumonia'
            },
            'colistin': {
                name: 'Colistin (polymyxin E)',
                class: 'Polymyxin antibiotic',
                mechanism: 'Cationic detergent that disrupts bacterial cell membrane integrity (Gram-negative bacteria)',
                dosing: 'Dosing complex - use local guidance and consult pharmacy; typical IV dosing based on colistin base activity and renal function',
                contraindications: 'Hypersensitivity to polymyxins',
                interactions: 'Other nephrotoxic or neurotoxic agents (aminoglycosides, vancomycin, amphotericin)',
                monitoring: 'Renal function, respiratory status, neuromuscular blockade signs',
                pregnancy: 'Use only if no safer alternatives - limited data',
                sideEffects: 'Nephrotoxicity, neurotoxicity (paresthesia, dizziness, neuromuscular blockade), bronchospasm with inhaled forms',
                pharmacokinetics: 'Poor oral absorption; IV or inhaled administration. Renal clearance; dosing adjusted for renal impairment',
                clinicalPearls: 'Often used as a last-resort agent for multidrug-resistant Gram-negative infections; dosing regimens vary—consult infectious diseases/pharmacy',
                indication: 'Severe infections due to MDR Pseudomonas, Acinetobacter, Klebsiella species when other options exhausted'
            },
            'amikacin': {
                name: 'Amikacin',
                class: 'Aminoglycoside antibiotic',
                mechanism: 'Binds 30S ribosomal subunit inhibiting protein synthesis and causing bacterial cell death (concentration-dependent)',
                dosing: 'Typically 15mg/kg once daily IV/IM (adjust for renal function and therapeutic drug monitoring)',
                contraindications: 'Myasthenia gravis or other neuromuscular disorders (risk of paralysis), known hypersensitivity',
                interactions: 'Other nephrotoxic or ototoxic drugs (vancomycin, loop diuretics), neuromuscular blockers',
                monitoring: 'Renal function, trough/peak levels (TDM), audiology if prolonged therapy',
                pregnancy: 'Avoid unless benefit outweighs risk - risk of fetal ototoxicity',
                sideEffects: 'Nephrotoxicity, ototoxicity (vestibular and cochlear), neuromuscular blockade (rare)',
                pharmacokinetics: 'Poor oral absorption; IV/IM dosing. Renal excretion; half-life prolonged in renal impairment',
                clinicalPearls: 'Use TDM and once-daily dosing where possible. Adjust dose interval in renal impairment',
                indication: 'Serious Gram-negative infections, synergy for some Gram-positive infections in combination therapy'
            },
            'ertapenem': {
                name: 'Ertapenem',
                class: 'Carbapenem antibiotic',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: '1g IV/IM once daily',
                contraindications: 'Known hypersensitivity to carbapenems, history of seizures (use caution)',
                interactions: 'Valproate (↓ levels), probenecid (↓ clearance), other β-lactams (additive effects)',
                monitoring: 'Renal function, signs of C. difficile infection, seizure activity',
                pregnancy: 'Use if clearly needed - limited data',
                sideEffects: 'GI upset, rash, seizures (rare, especially with renal impairment), C. difficile colitis',
                pharmacokinetics: 'Once-daily dosing due to longer half-life than some carbapenems; primarily renal excretion',
                clinicalPearls: 'Does NOT reliably cover Pseudomonas or Acinetobacter (unlike meropenem). Useful for community severe infections and intra-abdominal sepsis in some protocols',
                indication: 'Intra-abdominal infections, complicated skin/soft tissue infections, community-acquired severe infections, some UTIs'
            },
            'cefepime': {
                name: 'Cefepime',
                class: 'Fourth-generation cephalosporin',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to PBPs; increased Gram-negative and Pseudomonas coverage',
                dosing: '1-2g IV every 8-12 hours (adjust for renal function)',
                contraindications: 'Cephalosporin hypersensitivity',
                interactions: 'Aminoglycosides (↑ nephrotoxicity risk), antacids (↓ absorption for oral forms - not applicable to IV)',
                monitoring: 'Renal function, signs of encephalopathy (rare with renal impairment)',
                pregnancy: 'Use if needed - limited data but often used in pregnancy when indicated',
                sideEffects: 'GI upset, allergic reactions, neurotoxicity (encephalopathy/seizures in renal impairment), C. difficile',
                pharmacokinetics: 'Good distribution including CSF in inflamed meninges; renal elimination',
                clinicalPearls: 'Strong anti-pseudomonal activity; dose adjust in renal impairment; watch for neurotoxicity in elderly/renal failure',
                indication: 'Serious Gram-negative infections including Pseudomonas, hospital-acquired pneumonia, febrile neutropenia'
            },
            'tigecycline': {
                name: 'Tigecycline',
                class: 'Glycylcycline antibiotic',
                mechanism: 'Binds 30S ribosomal subunit inhibiting protein synthesis',
                dosing: 'Loading 100mg IV, then 50mg IV every 12 hours (adjust per product guidance)',
                contraindications: 'Severe hepatic impairment (dose adjustment), hypersensitivity to tetracyclines/glycylcyclines',
                interactions: 'May reduce effectiveness of oral contraceptives; interactions similar to tetracyclines',
                monitoring: 'LFTs, clinical response, signs of pancreatitis (rare)',
                pregnancy: 'Contraindicated (tetracycline class effects on teeth/bone)',
                sideEffects: 'Nausea/vomiting (common), increased mortality signal in some studies when used for severe infections, photosensitivity',
                pharmacokinetics: 'Large volume of distribution (poor serum concentrations), hepatic metabolism',
                clinicalPearls: 'Not ideal for bloodstream infections due to low serum levels. Use for complicated intra-abdominal and skin infections where organisms resistant to other agents',
                indication: 'Complicated intra-abdominal infections, complicated skin/soft tissue infections, some MDR organisms when options limited'
            },
            'daptomycin': {
                name: 'Daptomycin',
                class: 'Lipopeptide antibiotic',
                mechanism: 'Causes rapid depolarization of bacterial cell membrane leading to cell death (concentration-dependent)',
                dosing: '4-8mg/kg IV once daily (higher doses for bacteraemia/endocarditis); adjust for renal function',
                contraindications: 'Pneumonia (inactivated by surfactant), hypersensitivity',
                interactions: 'Statins (↑ risk of myopathy/rhabdomyolysis), concurrent muscle-toxic drugs',
                monitoring: 'CK at baseline and weekly during therapy, renal function, signs of myopathy',
                pregnancy: 'Use only if clearly needed - limited data',
                sideEffects: 'Myopathy, elevated CK, peripheral neuropathy (rare), eosinophilic pneumonia (rare)',
                pharmacokinetics: 'IV only; renal excretion; poor lung penetration (not for pneumonia)',
                clinicalPearls: 'Excellent for Gram-positive bacteraemia and endocarditis including MRSA and VRE; monitor CK and avoid concurrent statin use if possible',
                indication: 'Serious Gram-positive infections including MRSA bacteraemia, right-sided endocarditis, complicated skin/soft tissue infections'
            },
            'teicoplanin': {
                name: 'Teicoplanin',
                class: 'Glycopeptide antibiotic',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to D-ala-D-ala termini',
                dosing: 'Loading: 6-12mg/kg IV every 12 hours for 3 doses then 6-12mg/kg once daily; adjust for renal function and product guidance',
                contraindications: 'Hypersensitivity to glycopeptides',
                interactions: 'Other nephrotoxic agents (↑ nephrotoxicity risk)',
                monitoring: 'Renal function, trough levels where available, signs of ototoxicity/nephrotoxicity',
                pregnancy: 'Use if clearly needed - limited data',
                sideEffects: 'Infusion-related reactions, rash, nephrotoxicity (less than vancomycin in some studies)',
                pharmacokinetics: 'Long half-life allowing once-daily dosing after loading; mainly renal excretion',
                clinicalPearls: 'Used similarly to vancomycin in some settings; local dosing/monitoring protocols vary',
                indication: 'Gram-positive infections including MRSA and serious staphylococcal infections'
            },
            'ticagrelor': {
                name: 'Ticagrelor',
                class: 'Antiplatelet - P2Y12 receptor antagonist (reversible)',
                mechanism: 'Direct-acting reversible P2Y12 ADP receptor antagonist, prevents platelet aggregation',
                dosing: 'Loading 180mg PO, then 90mg BD for maintenance (duration per ACS/PCI protocol)',
                contraindications: 'Active bleeding, history of intracranial haemorrhage, severe hepatic impairment',
                interactions: 'Strong CYP3A4 inhibitors/inducers, concomitant anticoagulants/antiplatelets (↑ bleeding)',
                monitoring: 'Signs of bleeding, haemoglobin, platelets',
                pregnancy: 'Use only if clearly needed',
                sideEffects: 'Dyspnoea (commonly reported), bleeding, bradyarrhythmias (rare)',
                pharmacokinetics: 'Rapid onset; hepatic metabolism via CYP3A4',
                clinicalPearls: 'Used in acute coronary syndromes and after PCI; do not give with ticlopidine/clopidogrel concurrently',
                indication: 'Acute coronary syndrome (with or without PCI) and secondary prevention when indicated'
            },
            /* --- High-yield omitted drugs (added) --- */
            'fentanyl': {
                name: 'Fentanyl',
                class: 'Opioid analgesic (synthetic)',
                mechanism: 'Potent μ-opioid receptor agonist',
                dosing: 'Analgesia: 25-100mcg IV bolus titrated to effect; intranasal 100-200mcg (device dependent) for prehospital/ED use. Reduce dose in elderly and renal impairment',
                contraindications: 'Respiratory depression, acute severe asthma, hypersensitivity',
                interactions: 'CNS depressants, MAOIs, CYP3A4 inhibitors',
                monitoring: 'Respiratory rate, oxygen saturation, sedation score, BP',
                pregnancy: 'Use with caution; neonatal respiratory depression possible with prolonged maternal use',
                sideEffects: 'Respiratory depression, bradycardia, nausea, constipation, chest wall rigidity with large rapid boluses',
                clinicalPearls: 'Short-acting and potent — useful for ED analgesia and procedural analgesia. Titrate slowly and monitor closely',
                indication: 'Severe acute pain, procedural sedation/analgesia, peri-intubation analgesia'
            },
            'buprenorphine': {
                name: 'Buprenorphine',
                class: 'Partial opioid agonist',
                mechanism: 'Partial μ-opioid receptor agonist, κ-antagonist',
                dosing: 'Analgesic patches: variable; OST (sublingual) doses per specialist protocol. Avoid giving full opioid agonists shortly after buprenorphine in opioid-dependent patients (precipitated withdrawal)',
                contraindications: 'Severe respiratory depression without monitoring',
                interactions: 'CNS depressants, CYP3A4 modulators',
                monitoring: 'Respiratory monitoring, signs of withdrawal in dependent patients',
                pregnancy: 'Use in pregnancy for opioid dependence only under specialist antenatal care',
                sideEffects: 'Sedation, constipation, nausea, precipitated withdrawal risk',
                clinicalPearls: 'Partial agonist: risk of precipitated withdrawal in opioid-tolerant patients. Used for opioid substitution and some pain formulations',
                indication: 'Opioid dependence (OST), chronic pain management under specialist guidance'
            },
            'methadone': {
                name: 'Methadone',
                class: 'Long-acting opioid agonist',
                mechanism: 'Full μ-opioid agonist; NMDA receptor antagonist properties',
                dosing: 'Specialist supervised dosing for OST; analgesic regimens individualised. Risk of accumulation — start low and titrate slowly',
                contraindications: 'Respiratory depression, severe asthma, uncontrolled QT prolongation',
                interactions: 'Many CYP interactions, QT-prolonging drugs',
                monitoring: 'ECG (QT), respiratory status, signs of accumulation',
                pregnancy: 'Used in pregnancy for OST under specialist care',
                sideEffects: 'Respiratory depression, sedation, QT prolongation, constipation',
                clinicalPearls: 'Long half-life and accumulation risk; specialist prescribing and community OST pathways apply',
                indication: 'Opioid substitution therapy, severe chronic pain under specialist supervision'
            },
            'thiamine': {
                name: 'Thiamine (B1) / Pabrinex',
                class: 'Vitamin / metabolic therapy',
                mechanism: 'Cofactor in carbohydrate metabolism (pyruvate dehydrogenase, transketolase)',
                dosing: 'Prevention: IV thiamine 200mg daily in at-risk alcohol-dependent patients; Treatment (suspected Wernicke): high-dose parenteral thiamine (e.g., Pabrinex or 500mg IV thiamine 3x daily) per local protocol',
                contraindications: 'None significant for thiamine itself; follow product guidance for Pabrinex components',
                interactions: 'None clinically important',
                monitoring: 'Clinical neurological signs, magnesium status (replete Mg if low)',
                pregnancy: 'Safe and indicated when required',
                sideEffects: 'Rare hypersensitivity (parenteral formulations)',
                clinicalPearls: 'Give thiamine prior to/during glucose administration in malnourished or alcohol-dependent patients to avoid precipitating Wernicke',
                indication: 'Prevention/treatment of Wernicke encephalopathy; thiamine deficiency'
            },
            'prasugrel': {
                name: 'Prasugrel',
                class: 'Antiplatelet - irreversible P2Y12 inhibitor',
                mechanism: 'Irreversible P2Y12 receptor antagonist',
                dosing: 'Loading 60mg, then 10mg daily (consider 5mg daily in elderly/low body weight per guidance); used per ACS/PCI protocols',
                contraindications: 'History of stroke/TIA, active pathological bleeding',
                interactions: 'Other antiplatelet/anticoagulant drugs (↑ bleeding)',
                monitoring: 'Signs of bleeding, Hb and platelets',
                pregnancy: 'Use only if benefit outweighs risk',
                sideEffects: 'Bleeding, bruising',
                clinicalPearls: 'Preferentially used in PCI populations; avoid in prior stroke/TIA',
                indication: 'ACS patients undergoing PCI (per cardiology guidance)'
            },
            'edoxaban': {
                name: 'Edoxaban',
                class: 'DOAC - factor Xa inhibitor',
                mechanism: 'Direct factor Xa inhibition',
                dosing: 'AF: 60mg once daily (reduce to 30mg with renal impairment, low body weight or P-gp inhibitors) — follow SmPC/local guidance',
                contraindications: 'Active bleeding, mechanical heart valves, severe hepatic impairment',
                interactions: 'P-gp inhibitors/inducers, other anticoagulants',
                monitoring: 'Renal function, signs of bleeding',
                pregnancy: 'Contraindicated',
                sideEffects: 'Bleeding, anaemia',
                clinicalPearls: 'Dose adjustments required in renal impairment and with interacting drugs — check SmPC',
                indication: 'AF stroke prevention, VTE treatment/prophylaxis'
            },
            'dabigatran': {
                name: 'Dabigatran',
                class: 'DOAC - direct thrombin (IIa) inhibitor',
                mechanism: 'Direct thrombin inhibition',
                dosing: 'AF: 150mg BD (110mg BD in selected patients/renal impairment per SmPC); VTE dosing per guideline',
                contraindications: 'Active bleeding, mechanical prosthetic valves, severe renal impairment (CrCl <30 mL/min for many indications)',
                interactions: 'P-gp modulators, other anticoagulants',
                monitoring: 'Renal function, bleeding signs; idarucizumab is antidote for dabigatran where indicated',
                pregnancy: 'Contraindicated',
                sideEffects: 'Bleeding, dyspepsia',
                clinicalPearls: 'Offer clear adherence counselling; consider reversal options in major bleeding',
                indication: 'AF stroke prevention, VTE treatment/prophylaxis'
            },
            'fondaparinux': {
                name: 'Fondaparinux',
                class: 'Synthetic pentasaccharide (indirect anti‑Xa)',
                mechanism: 'Antithrombin-mediated selective factor Xa inhibition',
                dosing: 'Weight-based dosing for VTE prophylaxis/treatment; see local guideline. Used in some ACS pathways per local protocol',
                contraindications: 'Severe renal impairment (CrCl <30 mL/min), active bleeding, bacterial endocarditis',
                interactions: 'Other anticoagulants (↑ bleeding risk)',
                monitoring: 'Renal function, platelet count',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Bleeding',
                clinicalPearls: 'Once-daily subcutaneous injection; check weight-based dose and renal function',
                indication: 'VTE prophylaxis/treatment, used in certain ACS pathways per protocol'
            },
            'valsartan': {
                name: 'Valsartan',
                class: 'Angiotensin receptor blocker (ARB)',
                mechanism: 'Selective AT1 receptor antagonist',
                dosing: 'Hypertension: 80-160mg daily; titrate per response',
                contraindications: 'Pregnancy, bilateral renal artery stenosis',
                interactions: 'NSAIDs, potassium supplements, lithium',
                monitoring: 'eGFR and potassium baseline and 1–2 weeks after initiation',
                pregnancy: 'Contraindicated',
                sideEffects: 'Dizziness, hyperkalaemia, renal impairment',
                clinicalPearls: 'Alternative to ACE inhibitors when cough/intolerance occurs',
                indication: 'Hypertension, heart failure (where indicated)'
            },
            'irbesartan': {
                name: 'Irbesartan',
                class: 'Angiotensin receptor blocker (ARB)',
                mechanism: 'Selective AT1 receptor antagonist',
                dosing: 'Hypertension: 150-300mg daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis',
                interactions: 'NSAIDs, potassium supplements, lithium',
                monitoring: 'eGFR and potassium baseline and 1–2 weeks after initiation',
                pregnancy: 'Contraindicated',
                sideEffects: 'Dizziness, hyperkalaemia',
                clinicalPearls: 'Common ARB for hypertension and nephropathy',
                indication: 'Hypertension, proteinuric CKD'
            },
            'perindopril': {
                name: 'Perindopril',
                class: 'ACE inhibitor',
                mechanism: 'ACE inhibition reducing angiotensin II and aldosterone',
                dosing: 'Hypertension: start 2-4mg daily and titrate as tolerated',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, history of ACEi-induced angioedema',
                interactions: 'NSAIDs, potassium-sparing diuretics, lithium',
                monitoring: 'eGFR and potassium baseline and 1–2 weeks after initiation',
                pregnancy: 'Contraindicated',
                sideEffects: 'Cough, hyperkalaemia, hypotension, angioedema',
                clinicalPearls: 'Used widely in UK cardiology/HTN pathways',
                indication: 'Hypertension, heart failure, post-MI'
            },
            'eplerenone': {
                name: 'Eplerenone',
                class: 'Mineralocorticoid receptor antagonist (MRA)',
                mechanism: 'Selective aldosterone receptor antagonist',
                dosing: 'Heart failure: 25mg daily, up-titrate to 50mg daily as tolerated',
                contraindications: 'Hyperkalaemia, severe renal impairment, pregnancy',
                interactions: 'Potassium supplements, ACEi/ARBs (↑ hyperkalaemia risk), CYP3A4 inhibitors',
                monitoring: 'U&Es frequently after initiation and dose changes (K+ monitoring)',
                pregnancy: 'Avoid',
                sideEffects: 'Hyperkalaemia, dizziness',
                clinicalPearls: 'Less anti-androgenic effects than spironolactone; used in heart failure with reduced ejection fraction',
                indication: 'Heart failure (HFrEF) as per guideline; alternative MRA'
            },
            'isosorbide-mononitrate': {
                name: 'Isosorbide mononitrate',
                class: 'Nitrate (long-acting)',
                mechanism: 'NO donor causing venodilation and reduced preload',
                dosing: 'Immediate/modified-release preparations vary; commonly 20-60mg daily for chronic angina; follow product guidance',
                contraindications: 'Concurrent PDE5 inhibitor use, hypotension, severe anemia',
                interactions: 'PDE5 inhibitors (profound hypotension)',
                monitoring: 'BP, symptomatic response',
                pregnancy: 'Use if essential',
                sideEffects: 'Headache, hypotension, reflex tachycardia',
                clinicalPearls: 'Use nitrate-free interval to avoid tolerance',
                indication: 'Chronic stable angina, heart failure symptom control in some patients'
            },
            'isosorbide-dinitrate': {
                name: 'Isosorbide dinitrate',
                class: 'Nitrate (shorter-acting)',
                mechanism: 'NO donor — venodilation and preload reduction',
                dosing: 'Typical dosing varies by formulation and indication; follow product guidance',
                contraindications: 'Concurrent PDE5 inhibitors, hypotension',
                interactions: 'PDE5 inhibitors',
                monitoring: 'BP',
                pregnancy: 'Use if essential',
                sideEffects: 'Headache, hypotension',
                clinicalPearls: 'Used less commonly than ISMN for chronic management',
                indication: 'Angina, acute heart failure symptom relief in some settings'
            },
            /* --- Additional high-yield drugs (respiratory, diabetes, antimicrobials, obstetrics, vitamin K) --- */
            'salbutamol': {
                name: 'Salbutamol (albuterol)',
                class: 'Short-acting β2-agonist (SABA)',
                mechanism: 'β2-adrenoceptor agonist causing bronchodilation',
                dosing: 'Inhaler 100mcg per puff (usual 1-2 puffs as needed); nebuliser 2.5–5mg for severe bronchospasm',
                contraindications: 'Tachyarrhythmia (relative)',
                interactions: 'β-blockers may antagonise effect; hypokalaemia risk with diuretics',
                monitoring: 'Respiratory status, HR, potassium in high-dose therapy',
                pregnancy: 'Considered safe for use in pregnancy when indicated',
                sideEffects: 'Tachycardia, tremor, hypokalaemia',
                clinicalPearls: 'First-line reliever inhaler for asthma and COPD exacerbations',
                indication: 'Relief of bronchospasm in asthma/COPD'
            },
            'ipratropium': {
                name: 'Ipratropium',
                class: 'Short-acting muscarinic antagonist (SAMA)',
                mechanism: 'Antagonises M3 receptors causing bronchodilation',
                dosing: 'Inhaler/nebuliser formulations — commonly added to salbutamol in severe exacerbations',
                contraindications: 'Hypersensitivity to atropine derivatives',
                interactions: 'Additive anticholinergic effects with other antimuscarinics',
                monitoring: 'Symptom response',
                pregnancy: 'Use if clinically needed',
                sideEffects: 'Dry mouth, blurred vision (if sprayed into eyes)',
                clinicalPearls: 'Useful adjunct in severe COPD/asthma exacerbations',
                indication: 'Bronchodilation in exacerbations, particularly COPD'
            },
            'salmeterol': {
                name: 'Salmeterol',
                class: 'Long-acting β2-agonist (LABA)',
                mechanism: 'Long-acting β2 agonist for maintenance bronchodilation',
                dosing: 'Inhaled via DPI/Breath-actuated; usually 50mcg BD (product-specific)',
                contraindications: 'Use without inhaled corticosteroid in asthma (increases risk of severe exacerbations)',
                interactions: 'β-blockers, CYP3A4 inhibitors may increase levels',
                monitoring: 'Asthma control and exacerbation frequency',
                pregnancy: 'Use with inhaled steroid as indicated',
                sideEffects: 'Tremor, palpitations',
                clinicalPearls: 'Always ensure concomitant inhaled corticosteroid for asthma',
                indication: 'Maintenance therapy for asthma/COPD'
            },
            'formoterol': {
                name: 'Formoterol',
                class: 'Long-acting β2-agonist (LABA)',
                mechanism: 'Rapid-onset LABA used for maintenance and sometimes as part of SMART regimens with budesonide',
                dosing: 'Typical dosing via inhaler; follow product labelling',
                contraindications: 'As for other LABAs — not monotherapy in asthma',
                interactions: 'β-blockers, CYP3A4 inhibitors',
                monitoring: 'Asthma control',
                pregnancy: 'Use with ICS when indicated',
                sideEffects: 'Tremor, palpitations',
                clinicalPearls: 'Used in combination inhalers and as reliever in some SMART strategies',
                indication: 'Maintenance therapy in asthma and COPD'
            },
            'budesonide-inhaled': {
                name: 'Budesonide (inhaled)',
                class: 'Inhaled corticosteroid (ICS)',
                mechanism: 'Anti-inflammatory glucocorticoid receptor agonist',
                dosing: 'Dose varies by device and indication; low-medium-high dosing tiers for asthma',
                contraindications: 'Acute severe asthma as sole therapy',
                interactions: 'Systemic corticosteroids interactions',
                monitoring: 'Clinical response, inhaler technique; consider oral candidiasis prevention',
                pregnancy: 'Preferred ICS in pregnancy when inhaled steroid is needed',
                sideEffects: 'Oral thrush (use spacer/rinse mouth), dysphonia',
                clinicalPearls: 'Mainstay of maintenance asthma therapy',
                indication: 'Maintenance anti-inflammatory therapy for asthma'
            },
            'fluticasone-inhaled': {
                name: 'Fluticasone (inhaled)',
                class: 'Inhaled corticosteroid (ICS)',
                mechanism: 'Anti-inflammatory corticosteroid',
                dosing: 'Device-specific dosing; used BD typically',
                contraindications: 'None specific',
                interactions: 'Systemic CYP3A4 inhibitors may increase systemic exposure',
                monitoring: 'Inhaler technique, thrush prevention',
                pregnancy: 'Use if indicated; discuss with obstetric team',
                sideEffects: 'Oral candidiasis, dysphonia',
                clinicalPearls: 'Often used in combination inhalers with LABA',
                indication: 'Maintenance asthma/COPD (as appropriate)'
            },
            'tiotropium': {
                name: 'Tiotropium',
                class: 'Long-acting muscarinic antagonist (LAMA)',
                mechanism: 'M3 receptor antagonist producing long-acting bronchodilation',
                dosing: 'Once-daily inhaler (18mcg via HandiHaler or 5mcg Respimat per product)',
                contraindications: 'Hypersensitivity to atropine derivatives',
                interactions: 'Additive anticholinergic effects',
                monitoring: 'Symptom response, anticholinergic side-effects',
                pregnancy: 'Use if necessary',
                sideEffects: 'Dry mouth, urinary retention, constipation',
                clinicalPearls: 'Mainstay maintenance bronchodilator in COPD and add-on in asthma',
                indication: 'COPD maintenance; some asthma indications as add-on'
            },
            'montelukast': {
                name: 'Montelukast',
                class: 'Leukotriene receptor antagonist',
                mechanism: 'Blocks CysLT1 receptors reducing leukotriene-mediated bronchoconstriction',
                dosing: '10mg daily (adults); paediatric dosing variable',
                contraindications: 'Hypersensitivity',
                interactions: 'Minimal',
                monitoring: 'Mood/behaviour changes (rare neuropsychiatric effects)',
                pregnancy: 'Use if clinically indicated',
                sideEffects: 'Rare neuropsychiatric effects, headache',
                clinicalPearls: 'Useful in aspirin-exacerbated respiratory disease and as adjunct in allergic asthma',
                indication: 'Adjunct asthma therapy, allergic rhinitis in some cases'
            },
            'empagliflozin': {
                name: 'Empagliflozin',
                class: 'SGLT2 inhibitor',
                mechanism: 'Inhibits SGLT2 in proximal renal tubule to promote glucosuria',
                dosing: '10-25mg once daily (depending on indication)',
                contraindications: 'Type 1 diabetes, active bladder cancer (caution), severe renal impairment',
                interactions: 'Diuretics (volume depletion), insulin/secretagogues (hypoglycaemia risk)',
                monitoring: 'Renal function, ketones if unwell, BP, genital infections',
                pregnancy: 'Avoid',
                sideEffects: 'Genital mycotic infections, volume depletion, rare euglycaemic DKA',
                clinicalPearls: 'Shown to reduce HF hospitalisations and renal outcomes in specific populations',
                indication: 'Type 2 diabetes; cardio-renal protective indications per guidance'
            },
            'dapagliflozin': {
                name: 'Dapagliflozin',
                class: 'SGLT2 inhibitor',
                mechanism: 'Promotes glucosuria by inhibiting renal SGLT2',
                dosing: '10mg once daily (typical)',
                contraindications: 'Type 1 diabetes, severe renal impairment',
                interactions: 'Diuretics (caution), insulin/secretagogues',
                monitoring: 'Renal function, signs of volume depletion and genital infections',
                pregnancy: 'Avoid',
                sideEffects: 'Genital infections, volume depletion, rare DKA',
                clinicalPearls: 'Cardiorenal benefit in selected patients',
                indication: 'Type 2 diabetes; heart failure/CKD indications per guidance'
            },
            'liraglutide': {
                name: 'Liraglutide',
                class: 'GLP-1 receptor agonist',
                mechanism: 'GLP-1 analogue increasing insulin secretion and reducing appetite',
                dosing: 'Titrated subcutaneously per product regimen; doses vary by indication',
                contraindications: 'Personal/family history of medullary thyroid carcinoma (MTC), MEN2',
                interactions: 'May delay gastric emptying affecting absorption of oral meds',
                monitoring: 'GI tolerance, weight, glycaemic control',
                pregnancy: 'Avoid',
                sideEffects: 'Nausea, vomiting, pancreatitis (rare)',
                clinicalPearls: 'Useful for weight loss and glycaemic control; specialist initiation often',
                indication: 'Type 2 diabetes; weight management in some licensed indications'
            },
            'semaglutide': {
                name: 'Semaglutide',
                class: 'GLP-1 receptor agonist',
                mechanism: 'GLP-1 analogue with potent glycaemic and weight loss effects',
                dosing: 'Subcutaneous or oral formulations per product; titration required',
                contraindications: 'MTC/MEN2 history',
                interactions: 'May delay absorption of oral drugs',
                monitoring: 'GI symptoms, glycaemic control',
                pregnancy: 'Avoid',
                sideEffects: 'Nausea, pancreatitis risk (rare)',
                clinicalPearls: 'Increasingly used for weight and glucose control; cost and access vary',
                indication: 'Type 2 diabetes; weight management in select settings'
            },
            'sitagliptin': {
                name: 'Sitagliptin',
                class: 'DPP-4 inhibitor',
                mechanism: 'Inhibits DPP-4 to increase endogenous incretins',
                dosing: '100mg once daily (adjust for renal impairment)',
                contraindications: 'Hypersensitivity',
                interactions: 'Minimal',
                monitoring: 'Renal function, glycaemic control',
                pregnancy: 'Avoid',
                sideEffects: 'Rare pancreatitis, joint pain',
                clinicalPearls: 'Generally weight neutral and well tolerated',
                indication: 'Type 2 diabetes adjunct therapy'
            },
            'insulin-aspart': {
                name: 'Insulin aspart',
                class: 'Rapid-acting insulin analogue',
                mechanism: 'Rapid-onset insulin for prandial glucose control',
                dosing: 'Doses individualized; given at mealtimes or by pump',
                contraindications: 'Hypoglycaemia',
                interactions: 'Drugs affecting glucose levels (steroids, beta-blockers)',
                monitoring: 'Blood glucose, signs of hypoglycaemia',
                pregnancy: 'Used in pregnancy when required (insulin of choice per obstetric guidance)',
                sideEffects: 'Hypoglycaemia, weight gain',
                clinicalPearls: 'Short-acting prandial insulin used in multiple regimens',
                indication: 'Prandial insulin therapy in type 1 and type 2 diabetes as required'
            },
            'insulin-glargine': {
                name: 'Insulin glargine',
                class: 'Long-acting insulin analogue',
                mechanism: 'Basal insulin replacement with relatively flat profile',
                dosing: 'Once daily dosing individualized',
                contraindications: 'Hypoglycaemia',
                interactions: 'As for other insulins',
                monitoring: 'BG monitoring, HbA1c, hypoglycaemia',
                pregnancy: 'Use with specialist/obstetric guidance',
                sideEffects: 'Hypoglycaemia, injection site reactions',
                clinicalPearls: 'Common basal insulin option; dose adjustments required during illness',
                indication: 'Basal insulin therapy'
            },
            'gentamicin': {
                name: 'Gentamicin',
                class: 'Aminoglycoside antibiotic',
                mechanism: 'Binds 30S ribosomal subunit causing misreading and inhibition of protein synthesis',
                dosing: 'IV dosing weight-based and indication-specific; use once-daily regimens where appropriate and monitor levels',
                contraindications: 'Myasthenia gravis (relative), hypersensitivity',
                interactions: 'Nephrotoxins (vancomycin, loop diuretics), neuromuscular blockers',
                monitoring: 'Renal function, gentamicin trough/peak levels per local protocol, hearing/vestibular symptoms',
                pregnancy: 'Use if essential with caution',
                sideEffects: 'Nephrotoxicity, ototoxicity (esp. high doses/rapid IV or coadministration with other ototoxins)',
                clinicalPearls: 'Dose and monitor levels closely; adjust for renal impairment',
                indication: 'Severe Gram-negative infections, synergistic therapy in endocarditis'
            },
            'vancomycin': {
                name: 'Vancomycin',
                class: 'Glycopeptide antibiotic',
                mechanism: 'Inhibits cell wall synthesis via D-Ala-D-Ala binding',
                dosing: 'IV dosing weight-based with therapeutic drug monitoring (trough/AUC-based per local policy); oral for C. difficile',
                contraindications: 'Hypersensitivity',
                interactions: 'Other nephrotoxins and ototoxins',
                monitoring: 'Renal function, vancomycin levels per local protocol, hearing',
                pregnancy: 'Use if essential',
                sideEffects: 'Nephrotoxicity, ototoxicity, Red man syndrome with rapid infusion',
                clinicalPearls: 'Infuse slowly to avoid infusion-related reactions; monitor levels in prolonged therapy',
                indication: 'Serious Gram-positive infections including MRSA; oral for C. difficile colitis'
            },
            'piperacillin-tazobactam': {
                name: 'Piperacillin-tazobactam',
                class: 'Extended-spectrum penicillin + β-lactamase inhibitor',
                mechanism: 'Inhibits cell wall synthesis; tazobactam inhibits β-lactamases',
                dosing: 'IV dosing per indication; adjust in renal impairment',
                contraindications: 'β-lactam allergy',
                interactions: 'May affect INR in warfarinised patients',
                monitoring: 'Renal function, clinical response',
                pregnancy: 'Use if clinically needed',
                sideEffects: 'Allergic reactions, diarrhoea, electrolyte disturbance with high-dose',
                clinicalPearls: 'Broad empirical cover for severe infections in hospital',
                indication: 'Severe polymicrobial/healthcare-associated infections'
            },
            'co-amoxiclav': {
                name: 'Co-amoxiclav (amoxicillin + clavulanic acid)',
                class: 'Aminopenicillin + β-lactamase inhibitor',
                mechanism: 'Inhibits cell wall synthesis with β-lactamase protection',
                dosing: 'Oral/IV formulations; adjust for severity and renal impairment',
                contraindications: 'History of cholestatic jaundice/hepatic dysfunction with prior co-amoxiclav',
                interactions: 'May affect oral contraceptives efficacy (rare)',
                monitoring: 'LFTs if prolonged therapy',
                pregnancy: 'Generally considered safe',
                sideEffects: 'Diarrhoea, hypersensitivity, cholestatic hepatitis (rare)',
                clinicalPearls: 'Common community/hospital antibiotic for mixed infections',
                indication: 'Respiratory, ENT, skin/soft tissue, intra-abdominal infections as indicated'
            },
            'ceftriaxone': {
                name: 'Ceftriaxone',
                class: 'Third-generation cephalosporin',
                mechanism: 'Inhibits bacterial cell wall synthesis',
                dosing: 'IV dosing once daily commonly; adjust in severe hepatic dysfunction',
                contraindications: 'Neonates with hyperbilirubinaemia (risk), calcium-containing IV products concurrently in neonates',
                interactions: 'May displace bilirubin in neonates',
                monitoring: 'LFTs if prolonged therapy',
                pregnancy: 'Use if necessary',
                sideEffects: 'Allergic reactions, diarrhoea',
                clinicalPearls: 'Useful for many severe community-acquired infections including meningitis (higher doses)',
                indication: 'Severe community infections, meningitis, gonorrhoea (depending on guidance)'
            },
            'ciprofloxacin': {
                name: 'Ciprofloxacin',
                class: 'Fluoroquinolone antibiotic',
                mechanism: 'Inhibits DNA gyrase/topoisomerase',
                dosing: 'Oral/IV dosing per indication; adjust for renal impairment',
                contraindications: 'Tendon disorders related to fluoroquinolones, pregnancy (avoid unless essential)',
                interactions: 'Chelation with divalent cations reduces absorption; QT-prolonging drugs',
                monitoring: 'Tendinopathy signs, QT risk in predisposed patients',
                pregnancy: 'Avoid unless essential',
                sideEffects: 'Tendonitis/tendon rupture, QT prolongation, CNS effects',
                clinicalPearls: 'Avoid in children/young adolescents unless benefits outweigh risks',
                indication: 'Serious Gram-negative infections when indicated'
            },
            'metronidazole': {
                name: 'Metronidazole',
                class: 'Nitroimidazole antibiotic/antiprotozoal',
                mechanism: 'Generates toxic free radicals in anaerobic organisms',
                dosing: 'Oral/IV dosing per indication; avoid alcohol during and for 48 hours after therapy',
                contraindications: 'First trimester pregnancy caution for some indications; check guidance',
                interactions: 'Alcohol (disulfiram-like reaction), warfarin (may potentiate)',
                monitoring: 'LFTs in prolonged therapy',
                pregnancy: 'Use in pregnancy when indicated (avoid in first trimester for some indications—follow local guidance)',
                sideEffects: 'Nausea, metallic taste, peripheral neuropathy with long-term use',
                clinicalPearls: 'Key anaerobic coverage; oral for C. difficile as second-line in some guidelines',
                indication: 'Anaerobic infections, bacterial vaginosis, protozoal infections'
            },
            'oxytocin': {
                name: 'Oxytocin',
                class: 'Uterotonic (peptide hormone)',
                mechanism: 'Stimulates uterine smooth muscle contraction',
                dosing: 'IV infusion or IM bolus as per obstetric protocols for labour augmentation or postpartum haemorrhage',
                contraindications: 'Active genital herpes, previous classical caesarean section (relative for induction)',
                interactions: 'Other uterotonics (additive effect)',
                monitoring: 'Maternal vitals, uterine tone, fetal monitoring in labour',
                pregnancy: 'Used in labour and postpartum as indicated',
                sideEffects: 'Tachysystole, hypotension with rapid IV bolus, water retention',
                clinicalPearls: 'Primary uterotonic for prevention and treatment of postpartum haemorrhage',
                indication: 'Induction/augmentation of labour; prevention/treatment of postpartum haemorrhage'
            },
            'ergometrine': {
                name: 'Ergometrine (ergonovine)',
                class: 'Ergot alkaloid uterotonic',
                mechanism: 'Stimulates uterine smooth muscle causing sustained contraction',
                dosing: 'IM/IV bolus for postpartum haemorrhage as per protocol; IV should be given slowly with monitoring',
                contraindications: 'Hypertension, pre-eclampsia, cardiac disease, sepsis, pregnancy for labour augmentation',
                interactions: 'Other vasoconstrictors, macrolides (may increase levels)',
                monitoring: 'BP, uterine tone, signs of ischemia',
                pregnancy: 'Used postpartum for PPH; contraindicated for induction of labour in hypertensive disease',
                sideEffects: 'Hypertension, coronary vasospasm (rare), nausea',
                clinicalPearls: 'Use with caution in cardiac disease; often second-line or adjunct to oxytocin',
                indication: 'Management of postpartum haemorrhage'
            },
            'misoprostol': {
                name: 'Misoprostol',
                class: 'Prostaglandin E1 analogue (uterotonic)',
                mechanism: 'Causes uterine contractions and cervical ripening',
                dosing: 'Vaginal/oral/rectal/PO forms used in obstetrics per protocol; doses depend on indication',
                contraindications: 'Previous uterine surgery with caution, hypersensitivity',
                interactions: 'Other uterotonics (additive)',
                monitoring: 'Uterine activity, maternal vitals',
                pregnancy: 'Used in obstetrics as indicated (often for PPH or induction depending on protocol)',
                sideEffects: 'Fever, diarrhoea, uterine hyperstimulation',
                clinicalPearls: 'Widely used in global obstetric protocols; dosing and route vary by setting',
                indication: 'Prevention/treatment of PPH, induction of labour in select contexts'
            },
            'vitamin-k': {
                name: 'Vitamin K (phytonadione)',
                class: 'Fat-soluble vitamin / antidote',
                mechanism: 'Required for γ-carboxylation of clotting factors II, VII, IX and X',
                dosing: 'IV/IM/SC/PO dosing varies by indication; IV should be given slowly to reduce anaphylactoid risk',
                contraindications: 'Hypersensitivity to phytonadione or excipients',
                interactions: 'Warfarin (antagonises effect)',
                monitoring: 'INR for reversal of warfarin anticoagulation',
                pregnancy: 'Use when indicated (neonatal prophylaxis given IM at birth in many systems)',
                sideEffects: 'Rare hypersensitivity with IV administration',
                clinicalPearls: 'Essential antidote for warfarin over-anticoagulation; route/dose depend on urgency',
                indication: 'Reversal of vitamin K antagonist (warfarin) effects, neonatal prophylaxis'
            },
            /* --- More high-yield drugs (reversal agents, antifungals, PPIs, laxatives, psychotropics, etc.) --- */
            'naloxone': {
                name: 'Naloxone',
                class: 'Opioid antagonist',
                mechanism: 'Competitive opioid receptor antagonist (μ-opioid receptors)',
                dosing: 'IV/IM/SC 0.4-2 mg bolus (titrate to effect) or intranasal 400mcg-2mg depending on formulation; may require infusion for long-acting opioids',
                contraindications: 'None absolute in opioid overdose',
                interactions: 'Precipitates withdrawal in opioid-dependent patients',
                monitoring: 'Respiratory rate, consciousness, recurrence of respiratory depression',
                pregnancy: 'Use when maternal respiratory depression due to opioids occurs',
                sideEffects: 'Acute withdrawal, agitation, vomiting',
                clinicalPearls: 'Short-acting—monitor for re-sedation after effect wears off',
                indication: 'Opioid overdose reversal'
            },
            'flumazenil': {
                name: 'Flumazenil',
                class: 'Benzodiazepine antagonist',
                mechanism: 'Competitive antagonist at benzodiazepine binding site on GABA-A receptor',
                dosing: 'IV bolus 0.2mg, repeat to max 1-3mg per local protocol',
                contraindications: 'Chronic benzodiazepine dependence, mixed overdose with proconvulsant agents or TCA overdose',
                interactions: 'May precipitate seizures in chronic benzodiazepine users',
                monitoring: 'Conscious level, seizure activity',
                pregnancy: 'Use only if benefits outweigh risks',
                sideEffects: 'Seizures (rare), agitation',
                clinicalPearls: 'Use cautiously; only where benzo reversal indicated and risk of seizures low',
                indication: 'Reversal of benzodiazepine sedation/overdose in selected patients'
            },
            'idrarucizumab': {
                name: 'Idarucizumab',
                class: 'Dabigatran reversal agent (monoclonal antibody fragment)',
                mechanism: 'Binds dabigatran and neutralises its anticoagulant effect',
                dosing: '5g IV (two 2.5g boluses) per SmPC',
                contraindications: 'Hypersensitivity',
                interactions: 'None clinically significant',
                monitoring: 'Bleeding, coagulation tests',
                pregnancy: 'Use only if necessary',
                sideEffects: 'Headache, hypokalemia (rare)',
                clinicalPearls: 'Used for emergency reversal of dabigatran-associated bleeding or urgent surgery',
                indication: 'Dabigatran reversal'
            },
            'prothrombin-concentrate': {
                name: 'Prothrombin complex concentrate (PCC)',
                class: 'Coagulation factor concentrate',
                mechanism: 'Contains factors II, VII, IX, X (and variable protein C/S) to rapidly reverse vitamin K antagonists',
                dosing: 'Dose based on INR and weight per local guideline',
                contraindications: 'Known allergy to product components',
                interactions: 'None specific',
                monitoring: 'INR, haemostasis',
                pregnancy: 'Specialist use only',
                sideEffects: 'Thrombosis risk',
                clinicalPearls: 'Used for rapid reversal of warfarin in major bleeding or emergency surgery',
                indication: 'Rapid warfarin reversal'
            },
            'n-acetylcysteine': {
                name: 'N-acetylcysteine (NAC)',
                class: 'Antidote / mucolytic',
                mechanism: 'Replenishes glutathione to detoxify NAPQI in paracetamol overdose',
                dosing: 'IV protocols vary (e.g., 150mg/kg over 1h, then 50mg/kg over 4h, then 100mg/kg over 16h) or oral 72h regimen',
                contraindications: 'Hypersensitivity to components',
                interactions: 'None significant',
                monitoring: 'LFTs, clinical status, anaphylactoid reactions during IV infusion',
                pregnancy: 'Use when indicated',
                sideEffects: 'Anaphylactoid reactions with rapid IV infusion',
                clinicalPearls: 'Start empirically if uncertain timing for paracetamol overdose and NAC is available',
                indication: 'Paracetamol overdose'
            },
            'fluconazole': {
                // Note: fluconazole was updated earlier; include another antifungal entry for broader coverage
                name: 'Fluconazole (antifungal)',
                class: 'Triazole antifungal',
                mechanism: 'Inhibits fungal ergosterol synthesis via 14α-demethylase inhibition',
                dosing: 'Oral/IV dosing varies by indication (e.g., single 150mg dose for vaginal candidiasis)',
                contraindications: 'Known QT prolongation, significant hepatic impairment',
                interactions: 'Many CYP-mediated interactions (CYP3A4, CYP2C9)',
                monitoring: 'LFTs for prolonged therapy',
                pregnancy: 'Avoid high/prolonged doses in pregnancy; single 150mg dose for thrush is unlikely to increase risk',
                sideEffects: 'Nausea, headache, hepatotoxicity (rare)',
                clinicalPearls: 'Consider local guidance for systemic vs topical therapy',
                indication: 'Candidiasis and other systemic fungal infections as indicated'
            },
            'amphotericin-b': {
                name: 'Amphotericin B',
                class: 'Polyenes (antifungal)',
                mechanism: 'Binds ergosterol and disrupts fungal cell membranes',
                dosing: 'IV formulations vary; lipid formulations reduce nephrotoxicity',
                contraindications: 'Hypersensitivity to amphotericin',
                interactions: 'Nephrotoxins increase toxicity risk',
                monitoring: 'Renal function, electrolytes (K+, Mg2+), infusion reactions',
                pregnancy: 'Use if necessary',
                sideEffects: 'Nephrotoxicity, infusion-related fevers, electrolyte disturbances',
                clinicalPearls: 'Reserved for serious systemic fungal infections',
                indication: 'Serious systemic fungal infections'
            },
            'omeprazole': {
                name: 'Omeprazole',
                class: 'Proton pump inhibitor (PPI)',
                mechanism: 'Inhibits H+/K+ ATPase in gastric parietal cells',
                dosing: '20-40mg once daily depending on indication',
                contraindications: 'Hypersensitivity',
                interactions: 'Clopidogrel activation may be reduced (CYP2C19 interaction for some PPIs)',
                monitoring: 'Symptom response, magnesium with long-term use',
                pregnancy: 'Use if clinically indicated',
                sideEffects: 'Headache, GI upset, long-term risk: B12 deficiency, hypomagnesaemia',
                clinicalPearls: 'Use for stress ulcer prophylaxis in selected critically ill patients',
                indication: 'GORD, peptic ulcer disease, PPI prophylaxis'
            },
            'lansoprazole': {
                name: 'Lansoprazole',
                class: 'Proton pump inhibitor (PPI)',
                mechanism: 'Inhibits gastric H+/K+ ATPase',
                dosing: '15-30mg once daily',
                contraindications: 'Hypersensitivity',
                interactions: 'Potential CYP interactions',
                monitoring: 'Symptom response',
                pregnancy: 'Use if necessary',
                sideEffects: 'GI upset, headache',
                clinicalPearls: 'Alternative PPI option',
                indication: 'GORD, ulcer disease'
            },
            'senna': {
                name: 'Senna',
                class: 'Stimulant laxative',
                mechanism: 'Increases colonic motility via mucosal irritation and fluid secretion',
                dosing: '7.5-15mg at night (adults), follow local dosing',
                contraindications: 'Obstructive bowel disease, acute surgical abdomen',
                interactions: 'None significant',
                monitoring: 'Electrolytes with prolonged use',
                pregnancy: 'Use with caution',
                sideEffects: 'Abdominal cramp, diarrhoea',
                clinicalPearls: 'Useful for opioid-induced constipation when combined with laxative regimens',
                indication: 'Constipation'
            },
            'lactulose': {
                name: 'Lactulose',
                class: 'Osmotic laxative',
                mechanism: 'Increases colonic osmotic load and softens stool',
                dosing: '15-30ml daily titrated to effect',
                contraindications: 'Galactosaemia (some formulations)',
                interactions: 'None clinically significant',
                monitoring: 'Electrolytes if used long-term',
                pregnancy: 'Considered safe when needed',
                sideEffects: 'Flatulence, bloating',
                clinicalPearls: 'Also used to reduce ammonia absorption in hepatic encephalopathy',
                indication: 'Constipation, hepatic encephalopathy'
            },
            'sertraline': {
                name: 'Sertraline',
                class: 'Selective serotonin reuptake inhibitor (SSRI)',
                mechanism: 'Inhibits serotonin reuptake increasing synaptic serotonin',
                dosing: '50mg daily (start low and titrate)',
                contraindications: 'Concomitant MAOI use, acute mania',
                interactions: 'Other serotonergic drugs (risk serotonin syndrome), anticoagulants (↑ bleeding)',
                monitoring: 'Mood, suicidality (esp. initiation), hyponatraemia in elderly',
                pregnancy: 'Assess risks/benefits with obstetrics',
                sideEffects: 'Nausea, sexual dysfunction, insomnia',
                clinicalPearls: 'Common first-line antidepressant',
                indication: 'Depression, anxiety disorders, OCD'
            },
            'mirtazapine': {
                name: 'Mirtazapine',
                class: 'Noradrenergic and specific serotonergic antidepressant (NaSSA)',
                mechanism: 'Antagonises central α2-adrenergic and certain 5-HT receptors',
                dosing: '15-45mg at night',
                contraindications: 'Concurrent MAOI use',
                interactions: 'Other serotonergic agents',
                monitoring: 'Mood and weight (appetite increases)',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Sedation, increased appetite, weight gain',
                clinicalPearls: 'Useful when insomnia and poor appetite are comorbid',
                indication: 'Depression (second-line/alternative)'
            },
            'haloperidol': {
                name: 'Haloperidol',
                class: 'Typical antipsychotic',
                mechanism: 'D2 receptor antagonist',
                dosing: 'Oral/IM formulations; acute agitation IM dosing varies (e.g., 2.5-10mg)',
                contraindications: 'Parkinson disease, severe CNS depression',
                interactions: 'QT-prolonging drugs, other sedatives',
                monitoring: 'EPS, QT interval if IV/rapid dosing, sedation',
                pregnancy: 'Use only if necessary',
                sideEffects: 'Extrapyramidal symptoms, QT prolongation, sedation',
                clinicalPearls: 'Effective for acute psychosis and agitation; use lowest effective dose',
                indication: 'Acute psychosis, agitation'
            },
            /* --- Batch added: Cardiovascular, Endocrine, Respiratory, ID, GI, Neuro/Psych, Analgesia, Obstetrics, Haem/Onc --- */
            /* Cardiovascular */
            'prasugrel': {
                name: 'Prasugrel',
                class: 'P2Y12 inhibitor (antiplatelet)',
                mechanism: 'Irreversible P2Y12 receptor blockade',
                dosing: 'Loading 60mg then 10mg daily (consider 5mg for elderly/low body weight per local guidance)',
                contraindications: 'History of stroke/TIA, active bleeding',
                interactions: 'Other antithrombotics (↑ bleeding)',
                monitoring: 'Signs of bleeding, FBC',
                pregnancy: 'Specialist decision',
                sideEffects: 'Bleeding, bruising',
                clinicalPearls: 'Avoid in prior stroke/TIA; used in ACS/PCI per cardiology guidance',
                indication: 'ACS with PCI'
            },
            'fondaparinux': {
                name: 'Fondaparinux',
                class: 'Indirect factor Xa inhibitor (synthetic pentasaccharide)',
                mechanism: 'Enhances antithrombin action against factor Xa',
                dosing: 'Weight-dependent dosing for VTE prophylaxis/treatment; see local guideline',
                contraindications: 'Severe renal impairment (CrCl <30 mL/min), active bleeding',
                interactions: 'Other anticoagulants (↑ bleeding risk)',
                monitoring: 'Renal function, bleeding signs',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Bleeding',
                clinicalPearls: 'Once-daily subcutaneous injection; check weight-based dosing',
                indication: 'VTE prophylaxis/treatment'
            },
            'edoxaban': {
                name: 'Edoxaban',
                class: 'DOAC - factor Xa inhibitor',
                mechanism: 'Direct inhibition of factor Xa',
                dosing: 'AF: 60mg once daily (reduce to 30mg with renal impairment, low body weight or P-gp inhibitors)',
                contraindications: 'Active bleeding, mechanical heart valves',
                interactions: 'P-gp inhibitors/inducers, other anticoagulants',
                monitoring: 'Renal function, bleeding',
                pregnancy: 'Avoid',
                sideEffects: 'Bleeding, anaemia',
                clinicalPearls: 'Dose adjustments required per SmPC',
                indication: 'AF stroke prevention, VTE'
            },
            'dabigatran': {
                name: 'Dabigatran',
                class: 'DOAC - direct thrombin inhibitor',
                mechanism: 'Direct inhibition of thrombin (factor IIa)',
                dosing: 'AF: 150mg BD (110mg BD for selected patients/renal impairment); VTE dosing per guideline',
                contraindications: 'Active bleeding, mechanical heart valves, severe renal impairment',
                interactions: 'P-gp modulators',
                monitoring: 'Renal function; idarucizumab is specific antidote',
                pregnancy: 'Avoid',
                sideEffects: 'Bleeding, dyspepsia',
                clinicalPearls: 'Observe renal dosing and adherence',
                indication: 'AF, VTE'
            },
            'eplerenone': {
                name: 'Eplerenone',
                class: 'Mineralocorticoid receptor antagonist (MRA)',
                mechanism: 'Selective aldosterone receptor antagonist',
                dosing: '25mg daily, titrate to 50mg as tolerated in heart failure',
                contraindications: 'Hyperkalaemia, severe renal impairment',
                interactions: 'ACEi/ARBs, potassium supplements (↑ hyperkalaemia risk), CYP3A4 inhibitors',
                monitoring: 'U&Es after initiation and dose changes',
                pregnancy: 'Avoid',
                sideEffects: 'Hyperkalaemia',
                clinicalPearls: 'Alternative to spironolactone with fewer endocrine side effects',
                indication: 'Heart failure with reduced EF'
            },
            'valsartan': {
                name: 'Valsartan',
                class: 'ARB',
                mechanism: 'Selective antagonist at AT1 receptor',
                dosing: '80-160mg daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis',
                interactions: 'NSAIDs, potassium supplements',
                monitoring: 'eGFR and potassium',
                pregnancy: 'Contraindicated',
                sideEffects: 'Dizziness, hyperkalaemia',
                clinicalPearls: 'Alternative to ACEi for cough intolerance',
                indication: 'Hypertension, HF'
            },
            'irbesartan': {
                name: 'Irbesartan',
                class: 'ARB',
                mechanism: 'AT1 receptor antagonist',
                dosing: '150-300mg daily',
                contraindications: 'Pregnancy',
                interactions: 'NSAIDs, lithium',
                monitoring: 'eGFR, K+',
                pregnancy: 'Contraindicated',
                sideEffects: 'Hyperkalaemia, hypotension',
                clinicalPearls: 'Used in HTN and diabetic nephropathy',
                indication: 'Hypertension, CKD'
            },
            'perindopril': {
                name: 'Perindopril',
                class: 'ACE inhibitor',
                mechanism: 'Inhibits ACE',
                dosing: 'Start 2-4mg daily and titrate',
                contraindications: 'Pregnancy, bilateral renal artery stenosis',
                interactions: 'NSAIDs, potassium supplements',
                monitoring: 'Renal function, potassium',
                pregnancy: 'Contraindicated',
                sideEffects: 'Cough, hyperkalaemia',
                clinicalPearls: 'Commonly used ACE inhibitor',
                indication: 'HTN, HF'
            },
            'isosorbide-mononitrate': {
                name: 'Isosorbide mononitrate',
                class: 'Nitrate',
                mechanism: 'NO donor causing venodilation',
                dosing: '20-60mg daily depending on formulation',
                contraindications: 'Concurrent PDE5 inhibitors, hypotension',
                interactions: 'PDE5 inhibitors',
                monitoring: 'BP',
                pregnancy: 'Use if essential',
                sideEffects: 'Headache, hypotension',
                clinicalPearls: 'Avoid tolerance with nitrate-free interval',
                indication: 'Angina'
            },
            'isosorbide-dinitrate': {
                name: 'Isosorbide dinitrate',
                class: 'Nitrate',
                mechanism: 'NO donor',
                dosing: 'Variable by formulation',
                contraindications: 'PDE5 inhibitors',
                interactions: 'PDE5 inhibitors',
                monitoring: 'BP',
                pregnancy: 'Use if essential',
                sideEffects: 'Headache, hypotension',
                clinicalPearls: 'Shorter acting than ISMN',
                indication: 'Angina'
            },
            /* End cardiovascular */

            /* Endocrine / Diabetes */
            'dapagliflozin': {
                name: 'Dapagliflozin',
                class: 'SGLT2 inhibitor',
                mechanism: 'Inhibits SGLT2 causing glucosuria',
                dosing: '10mg once daily',
                contraindications: 'Type 1 diabetes, severe renal impairment',
                interactions: 'Diuretics (volume depletion), insulin (hypoglycaemia risk)',
                monitoring: 'Renal function, ketones if unwell',
                pregnancy: 'Avoid',
                sideEffects: 'Genital mycotic infections, volume depletion, DKA (rare)',
                clinicalPearls: 'Cardio-renal benefit in selected patients',
                indication: 'T2DM, HF/CKD indications per guidance'
            },
            'canagliflozin': {
                name: 'Canagliflozin',
                class: 'SGLT2 inhibitor',
                mechanism: 'Inhibits SGLT2',
                dosing: '100-300mg daily',
                contraindications: 'Type 1 diabetes, severe renal impairment',
                interactions: 'Diuretics',
                monitoring: 'Renal function, foot checks (amputation signal in some studies)',
                pregnancy: 'Avoid',
                sideEffects: 'Genital infections, volume depletion, rare DKA',
                clinicalPearls: 'Watch for foot infections/amputation signal in older studies',
                indication: 'T2DM'
            },
            'ertugliflozin': {
                name: 'Ertugliflozin',
                class: 'SGLT2 inhibitor',
                mechanism: 'Inhibits SGLT2',
                dosing: '5-15mg once daily',
                contraindications: 'Type 1 diabetes, severe renal impairment',
                monitoring: 'Renal function',
                pregnancy: 'Avoid',
                sideEffects: 'Genital infections',
                clinicalPearls: 'One of the SGLT2 class; follow SmPC for indications',
                indication: 'T2DM'
            },
            'semaglutide': {
                name: 'Semaglutide',
                class: 'GLP-1 receptor agonist',
                mechanism: 'GLP-1 analogue',
                dosing: 'Subcutaneous or oral titration per product',
                contraindications: 'MTC/MEN2 history',
                monitoring: 'GI tolerance, glycaemic control',
                pregnancy: 'Avoid',
                sideEffects: 'Nausea, pancreatitis (rare)',
                clinicalPearls: 'Powerful weight and glycaemic effects; specialist initiation often',
                indication: 'T2DM, weight management in specific settings'
            },
            'liraglutide': {
                name: 'Liraglutide',
                class: 'GLP-1 receptor agonist',
                mechanism: 'GLP-1 analogue',
                dosing: 'Titrated SC per product',
                contraindications: 'MTC/MEN2',
                monitoring: 'GI tolerance',
                pregnancy: 'Avoid',
                sideEffects: 'Nausea',
                clinicalPearls: 'Used for glycaemic control and weight management',
                indication: 'T2DM'
            },
            'dulaglutide': {
                name: 'Dulaglutide',
                class: 'GLP-1 receptor agonist',
                mechanism: 'GLP-1 analogue',
                dosing: 'Once-weekly SC per product',
                contraindications: 'MTC/MEN2',
                monitoring: 'GI tolerance',
                sideEffects: 'Nausea',
                clinicalPearls: 'Once-weekly option',
                indication: 'T2DM'
            },
            'linagliptin': {
                name: 'Linagliptin',
                class: 'DPP-4 inhibitor',
                mechanism: 'Inhibits DPP-4 increasing incretins',
                dosing: '5mg once daily',
                contraindications: 'Hypersensitivity',
                monitoring: 'Renal function (dose adjustment not required for many patients)',
                pregnancy: 'Avoid',
                sideEffects: 'Pancreatitis (rare)',
                clinicalPearls: 'No dose adjustment usually required in renal impairment',
                indication: 'T2DM'
            },
            'saxagliptin': {
                name: 'Saxagliptin',
                class: 'DPP-4 inhibitor',
                mechanism: 'Inhibits DPP-4',
                dosing: '5mg once daily (adjust for renal impairment)',
                contraindications: 'Hypersensitivity',
                monitoring: 'Renal function',
                pregnancy: 'Avoid',
                sideEffects: 'Pancreatitis (rare)',
                clinicalPearls: 'Well-tolerated, weight neutral',
                indication: 'T2DM'
            },
            'insulin-degludec': {
                name: 'Insulin degludec',
                class: 'Ultra-long acting insulin analogue',
                mechanism: 'Basal insulin replacement with very long duration',
                dosing: 'Once daily individualized dosing',
                contraindications: 'Hypoglycaemia',
                monitoring: 'BG, HbA1c',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Hypoglycaemia',
                clinicalPearls: 'Very long-acting basal insulin',
                indication: 'Basal insulin therapy'
            },
            'insulin-detemir': {
                name: 'Insulin detemir',
                class: 'Long-acting insulin analogue',
                mechanism: 'Basal insulin',
                dosing: 'Once or twice daily individualized dosing',
                contraindications: 'Hypoglycaemia',
                monitoring: 'BG',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Hypoglycaemia',
                clinicalPearls: 'Basal insulin option',
                indication: 'Basal insulin therapy'
            },
            'insulin-glargine': {
                name: 'Insulin glargine',
                class: 'Long-acting insulin analogue',
                mechanism: 'Basal insulin with relatively flat profile',
                dosing: 'Once daily individualized',
                contraindications: 'Hypoglycaemia',
                monitoring: 'BG',
                pregnancy: 'Use with specialist/obstetric guidance',
                sideEffects: 'Hypoglycaemia',
                clinicalPearls: 'Common basal insulin',
                indication: 'Basal insulin therapy'
            },
            'insulin-aspart': {
                name: 'Insulin aspart',
                class: 'Rapid-acting insulin analogue',
                mechanism: 'Prandial insulin',
                dosing: 'Individualized at mealtimes',
                contraindications: 'Hypoglycaemia',
                monitoring: 'BG',
                pregnancy: 'Used in pregnancy when required',
                sideEffects: 'Hypoglycaemia',
                clinicalPearls: 'Prandial insulin option',
                indication: 'Prandial insulin'
            },
            'insulin-lispro': {
                name: 'Insulin lispro',
                class: 'Rapid-acting insulin analogue',
                mechanism: 'Prandial insulin',
                dosing: 'Individualized',
                contraindications: 'Hypoglycaemia',
                monitoring: 'BG',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Hypoglycaemia',
                clinicalPearls: 'Rapid onset prandial insulin',
                indication: 'Prandial insulin'
            },
            'propylthiouracil': {
                name: 'Propylthiouracil (PTU)',
                class: 'Antithyroid drug',
                mechanism: 'Inhibits thyroid peroxidase and peripheral conversion of T4 to T3',
                dosing: 'Thyroid storm: high-dose per endocrinology guidance; regular dosing individualized',
                contraindications: 'Severe liver disease',
                interactions: 'Other hepatotoxic drugs',
                monitoring: 'LFTs, FBC',
                pregnancy: 'Preferred in first trimester as alternative to carbimazole in some cases; specialist advice',
                sideEffects: 'Hepatotoxicity, agranulocytosis (rare)',
                clinicalPearls: 'Use specialist guidance for thyroid storm and pregnancy',
                indication: 'Hyperthyroidism, thyroid storm'
            },
            /* End endocrine */

            /* Respiratory */
            'fluticasone': {
                name: 'Fluticasone (inhaled)',
                class: 'Inhaled corticosteroid',
                mechanism: 'Anti-inflammatory corticosteroid',
                dosing: 'Device-specific dosing; typically BD',
                contraindications: 'Hypersensitivity',
                monitoring: 'Inhaler technique, oral thrush',
                pregnancy: 'Use with ICS as indicated',
                sideEffects: 'Oral candidiasis, dysphonia',
                clinicalPearls: 'Often combined with LABA',
                indication: 'Asthma maintenance'
            },
            'mometasone': {
                name: 'Mometasone (inhaled)',
                class: 'Inhaled corticosteroid',
                mechanism: 'Anti-inflammatory',
                dosing: 'Device-specific',
                contraindications: 'Hypersensitivity',
                monitoring: 'Inhaler technique',
                pregnancy: 'Use if needed',
                sideEffects: 'Oral thrush',
                clinicalPearls: 'Once-daily options exist',
                indication: 'Asthma'
            },
            'budesonide-formoterol': {
                name: 'Budesonide/formoterol',
                class: 'ICS/LABA combination',
                mechanism: 'Anti-inflammatory + bronchodilator',
                dosing: 'Device-specific; follow product guidance',
                contraindications: 'See individual components',
                monitoring: 'Asthma control',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'As for components',
                clinicalPearls: 'Used in maintenance and SMART regimens',
                indication: 'Asthma maintenance; COPD in select cases'
            },
            'fluticasone-salmeterol': {
                name: 'Fluticasone/salmeterol',
                class: 'ICS/LABA combination',
                mechanism: 'Anti-inflammatory + bronchodilator',
                dosing: 'Device-specific',
                contraindications: 'See components',
                monitoring: 'Asthma control',
                pregnancy: 'Use if needed',
                sideEffects: 'As for components',
                clinicalPearls: 'Common combination inhaler',
                indication: 'Asthma, COPD (as appropriate)'
            },
            'montelukast': {
                name: 'Montelukast',
                class: 'Leukotriene receptor antagonist',
                mechanism: 'Blocks CysLT1 receptor',
                dosing: '10mg daily (adults)',
                contraindications: 'Hypersensitivity',
                monitoring: 'Mood/behaviour changes',
                pregnancy: 'Use if needed',
                sideEffects: 'Rare neuropsychiatric effects',
                clinicalPearls: 'Useful in aspirin-exacerbated respiratory disease',
                indication: 'Adjunct asthma therapy'
            },
            /* End respiratory */

            /* Infectious Diseases */
            'rifampicin': {
                name: 'Rifampicin',
                class: 'Rifamycin antibiotic',
                mechanism: 'Inhibits DNA-dependent RNA polymerase',
                dosing: '600mg daily in TB regimens (adult)',
                contraindications: 'Severe hepatic impairment',
                interactions: 'Potent CYP inducer (many drug interactions)',
                monitoring: 'LFTs, drug interactions',
                pregnancy: 'Use if benefits outweigh risks',
                sideEffects: 'Hepatotoxicity, orange discoloration of bodily fluids',
                clinicalPearls: 'Powerful CYP inducer — review all meds',
                indication: 'TB (part of multi-drug regimens)'
            },
            'isoniazid': {
                name: 'Isoniazid',
                class: 'Antitubercular',
                mechanism: 'Inhibits mycolic acid synthesis',
                dosing: '300mg daily (adult) in TB regimens',
                contraindications: 'Acute liver disease',
                interactions: 'Inhibits CYP enzymes (some interactions)',
                monitoring: 'LFTs, pyridoxine supplementation (B6) to reduce neuropathy',
                pregnancy: 'Use if indicated with pyridoxine',
                sideEffects: 'Hepatotoxicity, peripheral neuropathy',
                clinicalPearls: 'Give pyridoxine to prevent neuropathy',
                indication: 'TB'
            },
            'pyrazinamide': {
                name: 'Pyrazinamide',
                class: 'Antitubercular',
                mechanism: 'Prodrug active in acidic environments',
                dosing: 'Weight-based dosing per TB regimen',
                contraindications: 'Severe liver disease, acute gout',
                interactions: 'May ↑ uric acid',
                monitoring: 'LFTs, uric acid',
                pregnancy: 'Use per specialist guidance',
                sideEffects: 'Hepatotoxicity, hyperuricaemia',
                clinicalPearls: 'Part of standard TB regimen',
                indication: 'TB'
            },
            'ethambutol': {
                name: 'Ethambutol',
                class: 'Antitubercular',
                mechanism: 'Inhibits arabinosyl transferase (cell wall synthesis)',
                dosing: 'Weight-based dosing per TB regimen',
                contraindications: 'Children unable to report vision changes',
                interactions: 'None major',
                monitoring: 'Visual acuity and colour vision',
                pregnancy: 'Use if necessary',
                sideEffects: 'Optic neuropathy (dose-related)',
                clinicalPearls: 'Monitor vision regularly',
                indication: 'TB'
            },
            'oseltamivir': {
                name: 'Oseltamivir',
                class: 'Neuraminidase inhibitor',
                mechanism: 'Inhibits influenza neuraminidase',
                dosing: '75mg BD for 5 days (treatment) or 75mg once daily for prophylaxis',
                contraindications: 'Hypersensitivity',
                interactions: 'None major',
                monitoring: 'Clinical response',
                pregnancy: 'Use if clinical need',
                sideEffects: 'Nausea, vomiting',
                clinicalPearls: 'Start within 48h of symptom onset for greatest benefit',
                indication: 'Influenza treatment/prophylaxis'
            },
            'chloramphenicol': {
                name: 'Chloramphenicol',
                class: 'Broad-spectrum antibiotic',
                mechanism: 'Inhibits 50S ribosomal subunit',
                dosing: 'Topical ophthalmic or systemic dosing varies — systemic use limited by toxicity',
                contraindications: 'Aplastic anaemia history',
                interactions: 'Bone marrow suppressing drugs',
                monitoring: 'FBC for aplastic anaemia with systemic use',
                pregnancy: 'Use with caution; topical ophthalmic use common',
                sideEffects: 'Bone marrow suppression, aplastic anaemia (rare)',
                clinicalPearls: 'Topical ophthalmic use for conjunctivitis; systemic use limited due to toxicity',
                indication: 'Ophthalmic infections, selected systemic infections'
            },
            'fosfomycin': {
                name: 'Fosfomycin',
                class: 'Cell wall synthesis inhibitor (phosphonic acid derivative)',
                mechanism: 'Inhibits early stage peptidoglycan synthesis',
                dosing: 'Single-dose oral 3g sachet for uncomplicated UTI (women)',
                contraindications: 'Hypersensitivity',
                interactions: 'None major',
                monitoring: 'Clinical response',
                pregnancy: 'Use if needed',
                sideEffects: 'GI upset, headache',
                clinicalPearls: 'Useful for resistant UTI pathogens where appropriate',
                indication: 'Uncomplicated UTI'
            },
            'voriconazole': {
                name: 'Voriconazole',
                class: 'Triazole antifungal',
                mechanism: 'Inhibits fungal 14α-demethylase',
                dosing: 'Weight and route dependent; IV/PO dosing per SmPC',
                contraindications: 'Concurrent terfenadine, astemizole, cisapride',
                interactions: 'Extensive CYP interactions',
                monitoring: 'LFTs, visual disturbances, drug levels in prolonged therapy',
                pregnancy: 'Avoid unless necessary',
                sideEffects: 'Visual disturbance, hepatotoxicity, photosensitivity',
                clinicalPearls: 'First-line for invasive aspergillosis in many settings',
                indication: 'Serious invasive fungal infections'
            },
            'posaconazole': {
                name: 'Posaconazole',
                class: 'Triazole antifungal',
                mechanism: 'Inhibits ergosterol synthesis',
                dosing: 'Oral/IV formulation dosing per product',
                contraindications: 'Contraindicated with certain medications',
                interactions: 'CYP3A4 interactions',
                monitoring: 'LFTs, drug levels',
                pregnancy: 'Avoid unless necessary',
                sideEffects: 'GI upset, hepatotoxicity',
                clinicalPearls: 'Used for prophylaxis in neutropenic patients and resistant infections',
                indication: 'Invasive fungal infections'
            },
            'caspofungin': {
                name: 'Caspofungin',
                class: 'Echinocandin antifungal',
                mechanism: 'Inhibits β-(1,3)-D-glucan synthesis in fungal cell wall',
                dosing: 'IV dosing per product',
                contraindications: 'Hypersensitivity',
                interactions: 'Cyclosporin may ↑ levels',
                monitoring: 'LFTs',
                pregnancy: 'Use if necessary',
                sideEffects: 'Infusion reactions, hepatotoxicity',
                clinicalPearls: 'Useful for invasive Candida and salvage therapy',
                indication: 'Invasive fungal infections'
            },
            'anidulafungin': {
                name: 'Anidulafungin',
                class: 'Echinocandin antifungal',
                mechanism: 'Inhibits β-(1,3)-D-glucan synthesis',
                dosing: 'IV per product',
                contraindications: 'Hypersensitivity',
                monitoring: 'LFTs',
                pregnancy: 'Use if necessary',
                sideEffects: 'Infusion reactions',
                clinicalPearls: 'Another echinocandin option for invasive fungal infections',
                indication: 'Invasive Candida'
            },
            'itraconazole': {
                name: 'Itraconazole',
                class: 'Triazole antifungal',
                mechanism: 'Inhibits fungal ergosterol synthesis',
                dosing: 'Oral dosing varies by indication',
                contraindications: 'Coadministration with certain CYP substrates',
                interactions: 'Extensive CYP interactions',
                monitoring: 'LFTs',
                pregnancy: 'Avoid',
                sideEffects: 'GI upset, hepatotoxicity',
                clinicalPearls: 'Used for certain systemic mycoses',
                indication: 'Systemic fungal infections'
            },
            /* GI / Hepatology */
            'macrogol': {
                name: 'Macrogol (polyethylene glycol)',
                class: 'Osmotic laxative',
                mechanism: 'Osmotic water retention in colon',
                dosing: 'Constipation: sachet daily; bowel prep doses higher per protocol',
                contraindications: 'Bowel obstruction',
                monitoring: 'Electrolytes if prolonged use',
                pregnancy: 'Use if necessary',
                sideEffects: 'Bloating, diarrhoea',
                clinicalPearls: 'First-line for chronic constipation',
                indication: 'Constipation'
            },
            'docusate': {
                name: 'Docusate (stool softener)',
                class: 'Stool softener',
                mechanism: 'Surfactant reducing stool surface tension',
                dosing: 'Per product directions',
                contraindications: 'Intestinal obstruction',
                monitoring: 'Clinical response',
                pregnancy: 'Use if needed',
                sideEffects: 'GI upset',
                clinicalPearls: 'Often combined with stimulant laxatives',
                indication: 'Constipation'
            },
            'sodium-picosulfate': {
                name: 'Sodium picosulfate',
                class: 'Stimulant laxative (prodrug)',
                mechanism: 'Converted by gut bacteria to active stimulant',
                dosing: 'Per bowel prep or constipation dosing',
                contraindications: 'Bowel obstruction',
                monitoring: 'Electrolytes if significant use',
                pregnancy: 'Use with caution',
                sideEffects: 'Abdominal cramp, diarrhoea',
                clinicalPearls: 'Common in bowel prep formulations',
                indication: 'Constipation, bowel prep'
            },
            'rabeprazole': {
                name: 'Rabeprazole',
                class: 'PPI',
                mechanism: 'Proton pump inhibitor',
                dosing: '20mg once daily',
                contraindications: 'Hypersensitivity',
                monitoring: 'Response, magnesium with long-term use',
                pregnancy: 'Use if necessary',
                sideEffects: 'GI upset, headache',
                clinicalPearls: 'Alternative PPI',
                indication: 'GORD, PUD'
            },
            'ursodeoxycholic-acid': {
                name: 'Ursodeoxycholic acid (UDCA)',
                class: 'Bile acid',
                mechanism: 'Decreases cholesterol absorption and bile toxicity',
                dosing: '10-15mg/kg daily divided',
                contraindications: 'Obstructive bile duct disease without decompression',
                monitoring: 'LFTs, response',
                pregnancy: 'Use if indicated',
                sideEffects: 'Diarrhoea',
                clinicalPearls: 'Used in cholestatic liver disease and gallstone dissolution in select cases',
                indication: 'Primary biliary cholangitis, cholestasis'
            },
            'misoprostol-gastro': {
                name: 'Misoprostol (GI use)',
                class: 'Prostaglandin E1 analogue',
                mechanism: 'Protects gastric mucosa and reduces acid secretion',
                dosing: 'Use per product indication',
                contraindications: 'Pregnancy for some indications (teratogenic/abortifacient risk)',
                monitoring: 'GI response',
                pregnancy: 'Avoid for non-obstetric indications',
                sideEffects: 'Diarrhoea, abdominal pain',
                clinicalPearls: 'Used for NSAID ulcer prevention in some contexts',
                indication: 'GI mucosal protection'
            },
            /* Neurology / Psychiatry */
            'sodium-valproate': {
                name: 'Sodium valproate',
                class: 'Antiepileptic',
                mechanism: 'Multiple mechanisms incl. GABAergic effects',
                dosing: 'Loading/maintenance dosing per indication',
                contraindications: 'Pregnancy (teratogenic), hepatic disease',
                interactions: 'Many CYP interactions, lamotrigine levels affected',
                monitoring: 'LFTs, FBC, plasma levels where indicated',
                pregnancy: 'Contraindicated in pregnancy for many indications (teratogenic risk) - specialist advice',
                sideEffects: 'Weight gain, tremor, hair loss, hepatotoxicity, teratogenicity',
                clinicalPearls: 'Avoid in women of childbearing potential if possible',
                indication: 'Epilepsy, bipolar disorder (some indications)'
            },
            'lamotrigine': {
                name: 'Lamotrigine',
                class: 'Antiepileptic',
                mechanism: 'Inhibits voltage-gated sodium channels, reduces glutamate release',
                dosing: 'Slow titration to reduce rash risk',
                contraindications: 'Hypersensitivity',
                interactions: 'Valproate increases lamotrigine levels',
                monitoring: 'Skin reactions, clinical efficacy',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Rash (SJS risk), dizziness, ataxia',
                clinicalPearls: 'Slow titration required',
                indication: 'Epilepsy, bipolar maintenance'
            },
            'levetiracetam': {
                name: 'Levetiracetam',
                class: 'Antiepileptic',
                mechanism: 'Binds synaptic vesicle protein SV2A',
                dosing: '500-1500mg BD; adjust in renal impairment',
                contraindications: 'Hypersensitivity',
                interactions: 'Few significant interactions',
                monitoring: 'Mood changes, renal function',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Irritability, mood changes, somnolence',
                clinicalPearls: 'Well tolerated and widely used',
                indication: 'Epilepsy'
            },
            'clozapine': {
                name: 'Clozapine',
                class: 'Atypical antipsychotic',
                mechanism: 'Multiple receptor actions incl. D2 partial, 5-HT2A antagonism',
                dosing: 'Specialist initiation only with monitoring',
                contraindications: 'Uncontrolled epilepsy, myocarditis',
                interactions: 'Many CYP interactions',
                monitoring: 'Mandatory blood monitoring for neutropenia (ANC), ECG, metabolic monitoring',
                pregnancy: 'Specialist decision',
                sideEffects: 'Agranulocytosis risk, weight gain, sedation, myocarditis',
                clinicalPearls: 'Reserved for treatment-resistant schizophrenia with strict monitoring',
                indication: 'Treatment-resistant schizophrenia'
            },
            'quetiapine': {
                name: 'Quetiapine',
                class: 'Atypical antipsychotic',
                mechanism: 'D2 and 5-HT2 receptor antagonism',
                dosing: 'Dose varies by indication',
                contraindications: 'Hypersensitivity',
                interactions: 'CYP3A4 inhibitors',
                monitoring: 'Metabolic parameters, sedation',
                pregnancy: 'Specialist advice',
                sideEffects: 'Sedation, weight gain, metabolic syndrome',
                clinicalPearls: 'Used for psychosis, bipolar disorder, adjunct in depression',
                indication: 'Schizophrenia, bipolar disorder'
            },
            'olanzapine': {
                name: 'Olanzapine',
                class: 'Atypical antipsychotic',
                mechanism: 'D2 and 5-HT2 receptor antagonism',
                dosing: 'Dose varies by indication',
                contraindications: 'Hypersensitivity',
                interactions: 'CYP1A2 inducers/inhibitors',
                monitoring: 'Metabolic parameters',
                pregnancy: 'Specialist advice',
                sideEffects: 'Weight gain, metabolic syndrome, sedation',
                clinicalPearls: 'High metabolic risk',
                indication: 'Schizophrenia, bipolar disorder'
            },
            'clonazepam': {
                name: 'Clonazepam',
                class: 'Benzodiazepine',
                mechanism: 'Enhances GABA-A receptor activity',
                dosing: '0.5-2mg daily in divided doses (depending on indication)',
                contraindications: 'Respiratory depression, severe hepatic impairment',
                interactions: 'CNS depressants',
                monitoring: 'Sedation, dependence',
                pregnancy: 'Use with caution',
                sideEffects: 'Sedation, dependence, withdrawal risk',
                clinicalPearls: 'Used for panic disorder, some seizure types',
                indication: 'Seizures, anxiety'
            },
            'sumatriptan': {
                name: 'Sumatriptan',
                class: 'Triptan (5-HT1 agonist)',
                mechanism: '5-HT1B/1D agonist causing cranial vasoconstriction and reduced trigeminal transmission',
                dosing: '50-100mg oral or 6mg SC; repeat per guidance',
                contraindications: 'IHD, uncontrolled hypertension, hemiplegic migraine',
                interactions: 'MAOIs, other triptans (avoid within 24h)',
                monitoring: 'Blood pressure in patients with CV risk',
                pregnancy: 'Use with caution',
                sideEffects: 'Chest tightness, paraesthesia, dizziness',
                clinicalPearls: 'Effective for acute migraine attack',
                indication: 'Acute migraine'
            },
            'topiramate': {
                name: 'Topiramate',
                class: 'Antiepileptic and migraine prophylactic',
                mechanism: 'Multiple mechanisms including sodium channel blockade and GABAergic effects',
                dosing: 'Titrate slowly up to typical prophylactic doses',
                contraindications: 'Pregnancy (cleft risk), severe hepatic impairment',
                interactions: 'CYP interactions',
                monitoring: 'Weight, mood, cognitive side effects',
                pregnancy: 'Avoid if possible',
                sideEffects: 'Cognitive impairment, weight loss, paresthesia',
                clinicalPearls: 'Useful for migraine prophylaxis and adjunct in epilepsy',
                indication: 'Migraine prophylaxis, epilepsy'
            },
            /* Analgesia / Anaesthesia */
            'fentanyl': {
                name: 'Fentanyl',
                class: 'Synthetic opioid agonist',
                mechanism: 'Potent μ-opioid receptor agonist',
                dosing: 'IV 25-100mcg titrated; intranasal and patch formulations per product',
                contraindications: 'Respiratory depression, severe asthma',
                interactions: 'CNS depressants, CYP3A4 inhibitors',
                monitoring: 'Respiratory rate, sedation',
                pregnancy: 'Use with caution',
                sideEffects: 'Respiratory depression, bradycardia, chest wall rigidity (rare)',
                clinicalPearls: 'Short-acting and potent; titrate carefully',
                indication: 'Severe pain, anaesthesia adjunct'
            },
            'buprenorphine': {
                name: 'Buprenorphine',
                class: 'Partial opioid agonist',
                mechanism: 'Partial μ-opioid receptor agonist',
                dosing: 'Sublingual or patch formulations per indication',
                contraindications: 'Acute severe respiratory depression',
                interactions: 'CNS depressants',
                monitoring: 'Respiratory rate',
                pregnancy: 'Use under specialist care for OST',
                sideEffects: 'Constipation, sedation',
                clinicalPearls: 'Risks of precipitated withdrawal in opioid-dependent patients',
                indication: 'OST, pain management'
            },
            'methadone': {
                name: 'Methadone',
                class: 'Long-acting opioid agonist',
                mechanism: 'Full μ-opioid receptor agonist',
                dosing: 'Specialist OST dosing; analgesic dosing individualized',
                contraindications: 'Respiratory depression, QT prolongation',
                interactions: 'Many CYP interactions',
                monitoring: 'ECG (QT), respiratory status',
                pregnancy: 'Used in pregnancy for OST',
                sideEffects: 'QT prolongation, sedation, dependence',
                clinicalPearls: 'Long half-life — risk of accumulation',
                indication: 'OST, chronic pain (specialist)'
            },
            'ketamine': {
                name: 'Ketamine',
                class: 'NMDA antagonist / dissociative anaesthetic',
                mechanism: 'NMDA receptor antagonist producing dissociative anaesthesia and analgesia',
                dosing: 'Analgesic/ED doses: 0.1-0.5mg/kg IV (subanaesthetic) or 0.25-0.5mg/kg IM for induction depending on use',
                contraindications: 'Severe hypertension, aneurysm, raised intracranial pressure (relative)',
                interactions: 'CNS stimulants/depressants',
                monitoring: 'BP, consciousness, psychotomimetic effects',
                pregnancy: 'Use with caution',
                sideEffects: 'Hypertension, tachycardia, emergence reactions',
                clinicalPearls: 'Useful for analgesia and procedural sedation; preserves airway reflexes',
                indication: 'Analgesia, induction of anaesthesia, procedural sedation'
            },
            'lidocaine-systemic': {
                name: 'Lidocaine (systemic)',
                class: 'Local anaesthetic / antiarrhythmic',
                mechanism: 'Blocks voltage-gated sodium channels',
                dosing: 'IV bolus for arrhythmia 1-1.5mg/kg; infusion per protocol. Toxic doses vary',
                contraindications: 'Severe heart block without pacemaker, severe SA node dysfunction',
                interactions: 'Other antiarrhythmics',
                monitoring: 'ECG, signs of local anaesthetic systemic toxicity (LAST)',
                pregnancy: 'Use if necessary',
                sideEffects: 'CNS toxicity (tremor, seizures), cardiac toxicity at high doses',
                clinicalPearls: 'Monitor levels with infusion; treat LAST with lipid emulsion therapy',
                indication: 'Arrhythmias (IV), analgesia (topical/infiltration)'
            },
            /* Antidotes */
            'naloxone': {
                name: 'Naloxone',
                class: 'Opioid antagonist',
                mechanism: 'Competitive opioid receptor antagonist',
                dosing: 'IV/IM 0.4-2mg titrated; intranasal options available',
                contraindications: 'None in overdose',
                interactions: 'Precipitates withdrawal',
                monitoring: 'Respiratory rate',
                pregnancy: 'Use if maternal opioid toxicity',
                sideEffects: 'Acute withdrawal symptoms',
                clinicalPearls: 'Short-acting — monitor for re-sedation',
                indication: 'Opioid overdose'
            },
            'flumazenil': {
                name: 'Flumazenil',
                class: 'Benzodiazepine antagonist',
                mechanism: 'GABA-A benzodiazepine site antagonist',
                dosing: 'IV bolus 0.2mg increments to effect',
                contraindications: 'Chronic benzodiazepine use, mixed overdose with proconvulsants',
                monitoring: 'Seizure activity',
                sideEffects: 'Seizures (rare)',
                clinicalPearls: 'Use cautiously',
                indication: 'Benzodiazepine reversal'
            },
            /* Obstetrics / Gynaecology */
            'carboprost': {
                name: 'Carboprost',
                class: 'Prostaglandin F2α analogue (uterotonic)',
                mechanism: 'Stimulates uterine contraction',
                dosing: 'IM 250mcg repeated per PPH protocols',
                contraindications: 'Asthma (relative), severe hypertension',
                interactions: 'Other uterotonics',
                monitoring: 'Uterine tone, BP, respiratory status in asthma',
                pregnancy: 'Used postpartum for PPH',
                sideEffects: 'Bronchospasm, fever, vomiting',
                clinicalPearls: 'Avoid in severe asthma',
                indication: 'PPH management'
            },
            'magnesium-sulfate': {
                name: 'Magnesium sulfate',
                class: 'Anticonvulsant / tocolytic adjunct',
                mechanism: 'Multiple mechanisms including NMDA antagonism and calcium channel modulation',
                dosing: 'Severe pre-eclampsia: 4g IV loading then 1g/hr infusion (local protocols vary)',
                contraindications: 'Myasthenia gravis',
                interactions: 'CNS depressants, neuromuscular blockers',
                monitoring: 'Reflexes, respiratory rate, urine output, magnesium levels',
                pregnancy: 'Indicated for eclampsia prophylaxis and treatment',
                sideEffects: 'Flushing, hypotension, respiratory depression at high levels',
                clinicalPearls: 'Monitor closely; calcium gluconate is antidote',
                indication: 'Eclampsia prophylaxis/treatment'
            },
            /* Haematology / Oncology */
            'hydroxycarbamide': {
                name: 'Hydroxycarbamide (hydroxyurea)',
                class: 'Antimetabolite / cytoreductive',
                mechanism: 'Inhibits ribonucleotide reductase',
                dosing: 'Dosing per indication (e.g., myeloproliferative disease)',
                contraindications: 'Pregnancy, severe bone marrow suppression',
                interactions: 'Cytotoxic drugs (additive marrow suppression)',
                monitoring: 'FBC, renal, hepatic function',
                pregnancy: 'Contraindicated',
                sideEffects: 'Myelosuppression, mucositis, teratogenicity',
                clinicalPearls: 'Used for myeloproliferative neoplasms and sickle cell to reduce crises',
                indication: 'Polycythaemia vera, essential thrombocythaemia, sickle cell disease'
            },
            'azathioprine': {
                name: 'Azathioprine',
                class: 'Immunosuppressant/antimetabolite',
                mechanism: 'Purine analogue inhibiting DNA synthesis',
                dosing: 'Dose per indication; TPMT testing recommended prior to use',
                contraindications: 'Pregnancy unless benefits outweigh risks (specialist advice)',
                interactions: 'Allopurinol (↑ azathioprine toxicity), other immunosuppressants',
                monitoring: 'FBC, LFTs, TPMT activity',
                pregnancy: 'Use only if necessary with specialist advice',
                sideEffects: 'Myelosuppression, hepatotoxicity',
                clinicalPearls: 'Check TPMT before prescribing',
                indication: 'Autoimmune diseases, transplant'
            },
            'methotrexate': {
                name: 'Methotrexate',
                class: 'Antimetabolite/antifolate',
                mechanism: 'Inhibits dihydrofolate reductase',
                dosing: 'Low-dose weekly regimens for rheumatologic use; higher doses in oncology',
                contraindications: 'Pregnancy, breastfeeding, severe hepatic/renal impairment',
                interactions: 'NSAIDs (may ↑ levels), folic acid supplementation recommended',
                monitoring: 'FBC, LFTs, renal function',
                pregnancy: 'Contraindicated',
                sideEffects: 'Myelosuppression, hepatotoxicity, mucositis',
                clinicalPearls: 'Weekly dosing for rheumatology; ensure folic acid cover',
                indication: 'Rheumatologic disease, oncology'
            },
            'filgrastim': {
                name: 'Filgrastim (G-CSF)',
                class: 'Hematopoietic growth factor',
                mechanism: 'Stimulates neutrophil production',
                dosing: 'Per protocol for chemotherapy-induced neutropenia or stem cell mobilisation',
                contraindications: 'Hypersensitivity',
                interactions: 'None major',
                monitoring: 'FBC',
                pregnancy: 'Use if necessary',
                sideEffects: 'Bone pain, leukocytosis',
                clinicalPearls: 'Used to reduce duration of neutropenia',
                indication: 'Chemotherapy-induced neutropenia'
            },
            'tamoxifen': {
                name: 'Tamoxifen',
                class: 'Selective oestrogen receptor modulator (SERM)',
                mechanism: 'Oestrogen receptor antagonist in breast tissue',
                dosing: '20mg once daily',
                contraindications: 'History of thromboembolism, pregnancy',
                interactions: 'CYP interactions',
                monitoring: 'LFTs, signs of VTE',
                pregnancy: 'Contraindicated',
                sideEffects: 'Hot flushes, VTE risk, endometrial changes',
                clinicalPearls: 'Used as adjuvant therapy in ER+ breast cancer',
                indication: 'Breast cancer'
            },
            'letrozole': {
                name: 'Letrozole',
                class: 'Aromatase inhibitor',
                mechanism: 'Inhibits peripheral conversion of androgens to oestrogens',
                dosing: '2.5mg once daily',
                contraindications: 'Pregnancy',
                interactions: 'CYP interactions',
                monitoring: 'Bone density, lipids',
                pregnancy: 'Contraindicated',
                sideEffects: 'Hot flushes, arthralgia, bone density loss',
                clinicalPearls: 'Used in postmenopausal ER+ breast cancer',
                indication: 'Breast cancer'
            },
            'anastrozole': {
                name: 'Anastrozole',
                class: 'Aromatase inhibitor',
                mechanism: 'Inhibits aromatase',
                dosing: '1mg once daily',
                contraindications: 'Pregnancy',
                monitoring: 'Bone density',
                pregnancy: 'Contraindicated',
                sideEffects: 'Arthralgia, osteoporosis risk',
                clinicalPearls: 'Postmenopausal breast cancer therapy',
                indication: 'Breast cancer'
            },
            /* Infectious prophylaxis / antidotes */
            'pabrinex': {
                name: 'Pabrinex (Multivitamin infusion)',
                class: 'Vitamin replacement',
                mechanism: 'High-dose parenteral vitamins including thiamine',
                dosing: 'Per local protocol (e.g., parenteral B vitamins in alcohol withdrawal/malnutrition)',
                contraindications: 'Hypersensitivity',
                monitoring: 'Allergic reactions, clinical response',
                pregnancy: 'Use if indicated',
                sideEffects: 'Rare hypersensitivity',
                clinicalPearls: 'Used in malnutrition and alcohol withdrawal; provides parenteral thiamine',
                indication: 'Vitamin replacement in deficiency'
            },
            'thiamine': {
                name: 'Thiamine (Vitamin B1)',
                class: 'Vitamin',
                mechanism: 'Cofactor for carbohydrate metabolism',
                dosing: 'Often 200mg IV daily or per local protocol for deficiency/Wernicke',
                contraindications: 'Hypersensitivity',
                monitoring: 'Clinical response, magnesium status',
                pregnancy: 'Safe when indicated',
                sideEffects: 'Rare hypersensitivity',
                clinicalPearls: 'Give prior to glucose in malnourished/alcohol-dependent patients',
                indication: 'Prevention/treatment of Wernicke encephalopathy'
            },
            'activated-charcoal': {
                name: 'Activated charcoal',
                class: 'Adsorbent (decontamination)',
                mechanism: 'Adsorbs many toxins in GI tract reducing absorption',
                dosing: '50-100g orally for adults (single dose) — follow toxicology guidance',
                contraindications: 'Unprotected airway, caustic ingestion',
                interactions: 'May adsorb orally administered antidotes/meds',
                monitoring: 'Airway protection, vomiting',
                pregnancy: 'Use if indicated',
                sideEffects: 'Vomiting, aspiration risk if airway not protected',
                clinicalPearls: 'Most effective when given early after ingestion',
                indication: 'Acute poisoning (selected cases)'
            },
            'metoprolol': {
                name: 'Metoprolol',
                class: 'Beta-blocker (β1 selective)',
                mechanism: 'Selective β1-adrenoceptor antagonist reducing heart rate and myocardial contractility',
                dosing: 'Hypertension/angina: 50-100mg daily (in divided doses or extended-release). IV for acute rate control per local protocol',
                contraindications: 'Uncompensated heart failure, severe bradycardia, cardiogenic shock, asthma with active bronchospasm (use cautiously)',
                interactions: 'Other rate-limiting drugs (CCBs, digoxin), insulin (masks hypoglycaemia), CYP2D6 inhibitors (increase levels)',
                monitoring: 'Heart rate, blood pressure, signs of heart failure, ECG as needed',
                pregnancy: 'Use with caution—can cause fetal bradycardia and growth restriction',
                sideEffects: 'Bradycardia, fatigue, cold extremities, sleep disturbance, impotence',
                pharmacokinetics: 'Hepatic metabolism (CYP2D6); variable bioavailability; half-life ~3-7h (longer for extended-release formulations)',
                clinicalPearls: 'Cardioselective at low doses; useful for rate control in AF/flutter and post-MI management',
                indication: 'Hypertension, angina, rate control in atrial fibrillation, secondary prevention post-MI'
            },
            'propranolol': {
                name: 'Propranolol',
                class: 'Non-selective beta-blocker',
                mechanism: 'Non-selective β1 and β2 antagonist reducing heart rate, myocardial contractility and peripheral vasodilation',
                dosing: 'Hypertension/angina: 40-320mg daily in divided doses or as extended-release; anxiety/thyrotoxicosis use lower doses as needed',
                contraindications: 'Asthma/COPD with active bronchospasm, severe peripheral vascular disease, uncontrolled heart failure',
                interactions: 'CCBs/antiarrhythmics (additive bradycardia), insulin (masks hypoglycaemia), CYP2D6 inhibitors',
                monitoring: 'HR, BP, signs of heart failure, respiratory status',
                pregnancy: 'Use with caution; fetal growth restriction reported with long-term use',
                sideEffects: 'Bradycardia, fatigue, bronchospasm, vivid dreams, impotence',
                pharmacokinetics: 'Hepatic metabolism; high first-pass effect; lipid soluble (crosses BBB)',
                clinicalPearls: 'Useful for migraine prophylaxis, essential tremor, thyrotoxicosis symptoms; avoid in reactive airways disease',
                indication: 'Hypertension, angina, arrhythmias, migraine prophylaxis, essential tremor'
            },
            'trametinib': {
                name: 'Trametinib',
                class: 'MEK inhibitor (targeted anticancer therapy)',
                mechanism: 'Inhibits MEK1 and MEK2, blocking MAPK pathway signalling in tumours with BRAF/MEK pathway activation',
                dosing: 'Oral 2mg once daily (usually in combination with other targeted agents); oncology dosing varies',
                contraindications: 'Known hypersensitivity; caution with cardiac disease and retinal disorders',
                interactions: 'CYP3A4 inducers/inhibitors may alter levels; many anticancer drug interactions possible',
                monitoring: 'LVEF, blood pressure, skin toxicity, ocular symptoms, LFTs',
                pregnancy: 'Contraindicated - teratogenic',
                sideEffects: 'Rash, diarrhoea, peripheral oedema, cardiomyopathy, ocular toxicity (retinal events)',
                pharmacokinetics: 'Oral agent with hepatic metabolism; refer to oncology guidance for specifics',
                clinicalPearls: 'Specialist oncology drug - use as part of targeted therapy in selected cancers; not a routine ward antimicrobial or cardiovascular drug',
                indication: 'Metastatic melanoma and other BRAF/MEK pathway-driven malignancies as per oncology guidance'
            },
            'pravastatin': {
                name: 'Pravastatin',
                class: 'Statin',
                mechanism: 'HMG-CoA reductase inhibitor reducing cholesterol synthesis',
                dosing: '10-40mg once daily (start 10-20mg and titrate)',
                contraindications: 'Active liver disease, pregnancy, breastfeeding',
                interactions: 'Fewer CYP interactions than many statins; caution with fibrates and cyclosporine',
                monitoring: 'LFTs at baseline and when clinically indicated, CK if muscle symptoms',
                pregnancy: 'Contraindicated',
                sideEffects: 'Myalgia, hepatotoxicity (rare), new-onset diabetes (small risk)',
                pharmacokinetics: 'Hydrophilic statin with less drug interaction via CYP system',
                clinicalPearls: 'Useful when drug interactions with CYP3A4-metabolised statins are a concern',
                indication: 'Hyperlipidaemia, cardiovascular risk reduction where appropriate'
            },
            'hydralazine': {
                name: 'Hydralazine',
                class: 'Vasodilator (direct arteriolar dilator)',
                mechanism: 'Direct relaxation of arteriolar smooth muscle reducing afterload',
                dosing: 'Start 25mg BD/TDS; titrate as needed (usual 50-200mg/day in divided doses)',
                contraindications: 'Coronary artery disease, mitral valve rheumatic disease (use with caution), severe tachycardia',
                interactions: 'Other antihypertensives (additive hypotension), MAOIs (sympathomimetic interactions)',
                monitoring: 'BP, HR, signs of lupus-like syndrome (long-term), renal function',
                pregnancy: 'Can be used in pregnancy for severe hypertension under specialist guidance',
                sideEffects: 'Tachycardia, fluid retention, headache, flushing, lupus-like syndrome with long-term use',
                pharmacokinetics: 'Hepatic acetylation (slow vs fast acetylators affect response and side effects)',
                clinicalPearls: 'Often used in combination with a β-blocker and diuretic to counter reflex tachycardia; consider in pregnancy with severe hypertension under guidance',
                indication: 'Severe hypertension (including in pregnancy under specialist care), refractory hypertension'
            }
}

// Make drugDatabase available globally
window.drugDatabase = drugDatabase;

